



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> G01N 33/567, 33/574, 33/48, A61K 38/06, 38/16, C07K 1/00, 5/00, 7/00, 14/00, 16/00, 17/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 97/37223 <b>(43) International Publication Date:</b> 9 October 1997 (09.10.97)
<b>(21) International Application Number:</b> PCT/US97/05547 <b>(22) International Filing Date:</b> 3 April 1997 (03.04.97)  <b>(30) Priority Data:</b> 08/630,916 3 April 1996 (03.04.96) US  <b>(71) Applicants:</b> CYTOGEN CORPORATION [US/US]; 600 College Road East, Princeton, NJ 08540 (US). UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; Office of Technology and Development, CB#4100, 302 Bynum Hall, Chapel Hill, NC 27599-4105 (US).  <b>(72) Inventors:</b> PIROZZI, Gregorio; 3 Stonehedge Drive, East Windsor, NJ 08520 (US). KAY, Brian, K.; 18 Wysteria Way, Chapel Hill, NC 27514 (US). FOWLKES, Dana, M.; 2013 Damascus Church Drive, Chapel Hill, NC 27516 (US).  <b>(74) Agents:</b> ANTLER, Adriane, M. et al.; Pennie & Edmonds L.L.P., 1155 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> IDENTIFICATION AND ISOLATION OF NOVEL POLYPEPTIDES HAVING WW DOMAINS AND METHODS OF USING SAME  <b>(57) Abstract</b>  Novel polypeptides having WW domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

IDENTIFICATION AND ISOLATION OF NOVEL POLYPEPTIDES HAVING  
WW DOMAINS AND METHODS OF USING SAME

1. FIELD OF THE INVENTION

5       The present invention is directed to the identification and isolation of polypeptides having WW domains or functional equivalents thereof. Various methods of use of these polypeptides are described including, but not limited to, targeted drug discovery. Also provided are various peptide  
10 recognition units that bind to WW domains.

2. BACKGROUND OF THE INVENTION

2.1. FUNCTIONAL DOMAINS IN PROTEINS

Many biological processes involve the specific binding of  
15 proteins to one another. Examples of such processes are signal transduction, transcription, DNA replication, cytoskeletal organization, membrane transport, etc. In many cases it has been shown that specific binding is mediated by small portions of the proteins involved and that these  
20 portions can function to a large extent independently of the rest of the proteins. Such independent portions of proteins, mediating specific recognition or binding of one protein by another, have come to be called "functional domains". A variety of functional domains have been characterized to a  
25 variety of levels of understanding. Some of these are described below.

Src homology 2 domains (SH2) domains are short (about 100 residues) amino acid sequences that were originally found in the non-membrane bound tyrosine kinase Src. Since then they  
30 have been shown to occur in about 20 other proteins. SH2 domains recognize certain phosphotyrosine-containing sites on proteins. Proteins containing SH2 domains participate in a variety of signalling pathways. For reviews discussing SH2 domains see Pawson, 1995, Nature 373:573-580; Cohen et al.,  
35 1995, Cell 80:237-248; Pawson and Gish, 1992, Cell 71:359-362; Koch et al., 1991, Science 252:668-674.

Src homology 3 (SH3) domains are another class of short amino acid sequences that were originally found by comparing the amino acid sequence of the Src protein with the sequences of Crk, Phospholipase C- $\gamma$ ,  $\alpha$ -Spectrin, Myosin IB, Cdc25, and Fus1 (Lehto et al., 1988, Nature 334:388; Mayer et al., 1988, Nature 332:272-275; Stahl et al., 1988, Nature 332:269-272; Rodaway et al., 1989, Nature 342:624). In addition to Src, almost 30 proteins are known to contain SH3 domains and these proteins perform a wide range of functions.

10 For reviews discussing SH3 domains see Pawson, 1995, Nature 373:573-580; Cohen et al., 1995, Cell 80:237-248; Pawson and Gish, 1992, Cell 71:359-362; Koch et al., 1991, Science 252:668-674.

SH3 domains have been shown to specifically bind certain  
15 proline-rich amino acid sequences (Chen et al., 1993, J. Am. Chem. Soc. 115:12591-12592; Ren et al., 1993, Science 259:1157-1161; Feng et al., 1994, Science 266:1241-1247; Yu et al., 1994, Cell 76:933-945; Sparks et al., 1994, J. Biol. Chem. 269:23853-23856; Sparks et al., 1996, Proc. Natl. Acad.  
20 Sci. USA 93:1540-1544). However, in general, the homology between different sequences that bind SH3 domains tends to be low.

This low homology would explain the specificity that has usually been observed for the interactions between SH3 domains  
25 and their natural ligands. Generally, a sequence that is identified by screening for binders to a particular SH3 domain will bind to that particular SH3 domain much more strongly than it binds to other SH3 domains. For example, Cicchetti et al., 1992, Science 257:803-806 probed a  $\lambda$ gt11 cDNA expression  
30 library with a glutathione S-transferase fusion protein containing the 55 amino acid SH3 region of Abl and isolated two clones that produced proteins capable of specifically binding the Abl SH3 domain. Analysis of one of the clones uncovered the region of the encoded protein responsible for  
35 binding to the SH3 domain. This region, as part of a glutathione S-transferase fusion protein, bound the SH3 domain



from Abl very strongly, the SH3 domain from Src less well, and the SH3 domains from Crk and neural Src very weakly.

Pleckstrin is the major substrate for Protein Kinase C in platelets. Two domains of about 100 amino acids in Pleckstrin have been found to have counterparts in a number of signal transduction and cytoskeletal proteins. These domains are known as Pleckstrin homology, or PH, domains (Haslam et al., 1993, Nature 363:309-310; Mayer et al., 1993, Cell 73:629-630). Although the sequence homology between PH domains from various proteins is low, structural studies have shown that PH domains fold into a similar conformation containing two antiparallel  $\beta$  sheets and a long C-terminal  $\alpha$  helix (Gibson et al., 1994, Trends Biochem. Sci. 19:349-353). Among the proteins that have been found to have PH domains are a number of proteins with important roles in signal transduction or cytoskeletal architecture, e.g., Spectrin, Dynamin, Phospholipase C- $\gamma$ , Btk, RasGAP, mSOS-1, Rac, Akt.

Leucine zippers consist of alpha helical regions of proteins in which a leucine residue appears at every seventh position along the helix. The leucines interdigitate with leucines from the leucine zipper of a different protein or another molecule of the same protein, leading to dimerization of the proteins containing the leucine zippers. Leucine zippers have been found in a number of proteins that are believed to function as transcription factors, e.g., C/EBP, Myc, Fos, Jun, GCN4. In many of these proteins, dimerization through leucine zippers has been shown to be necessary for the DNA binding activity of the transcription factor.

The binding of leucine zippers exhibits specificity in that some leucine zippers preferably bind to certain other leucine zippers. For example, the Jun-Fos heterodimer formed by the binding of the leucine zippers of Fos and Jun forms in preference to a Jun-Jun homodimer formed by the binding of the leucine zippers of two Jun proteins.

Fas/APO-1(CD95) is a member of a class of transmembrane receptors that have been shown to be involved in the phenomenon of programmed cell death or apoptosis (Itoh et al.,

1991, Cell 66:233-243). The tumor necrosis factor receptor 1 (TNFR-1) is also a member of this class (Baglioni, C., 1992, "The Molecules and Their Emerging Roles in Medicine," in Tumor Necrosis Factors, B. Beutler, ed. (New York: Raven Press).

5 Itoh, N. and Nagata, S., 1993, J. Biol. Chem. 268:10932-10937 have shown that certain amino acid sequences in the cytoplasmic domain of Fas/APO-1(CD95) are required for the programmed cell death response mediated by this receptor. Tartaglia et al., 1993, Cell 74:845-853 proposed that a  
10 similar region in TNFR-1 also is responsible for programmed cell death. This region of similarity between Fas/APO-1(CD95) and TNFR-1 has come to be called the cell death domain.

Three groups have used the yeast two-hybrid system to clone genes whose products specifically bind to the cell death  
15 domains of Fas/APO-1(CD95) and TNFR-1 (Hsu et al., 1995, Cell 81:495-504; Chinnaiyan, et al., 1995, Cell 81:505-512; Stanger et al., 1995, Cell 81:513-523). These genes were shown to induce apoptosis when overexpressed in certain cell types, a result which argues that they are intracellular transducers of  
20 death signals from Fas/APO-1(CD95) and TNFR-1.

#### 2.1.1. WW DOMAINS

The WW domain is a small functional domain found in a large number of proteins from a variety of species including  
25 humans, nematodes, and yeast. Its name is derived from the observation that two tryptophan residues, one in the amino terminal portion of the WW domain and one in the carboxyl terminal portion, are almost invariably conserved. At about 30 to 40 amino acids in length, it is quite small for a  
30 functional domain, most of which tend to be from 50 to 150 residues long. Often a WW domain will be flanked by stretches of amino acids rich in histidine or cysteine; these stretches might be metal-binding sites. The center of WW domains is quite hydrophobic; however, sprinkled throughout the rest of  
35 the domain are a high number of charged residues. These features are characteristic of functional domains involved in

protein-protein interactions (Bork and Sudol, 1994, Trends in Biochem. Sci. 19:531-533).

Based upon their study of various WW domains, André and Springael, 1994, Biochem. Biophys. Res. Comm. 205:1201-1205  
5 ("André and Springael") proposed the following consensus sequence for WW domains:

WX<sub>1</sub>G(K/R)X<sub>1</sub>(Y/F)(Y/F)X<sub>1</sub>(N/D)X<sub>2</sub>(T/S)(K/R)X<sub>1</sub>(T/S)(T/Q/S)WX<sub>2</sub>P  
(SEQ ID NO:2)

where X represents any amino acid and bold letters represent  
10 highly conserved amino acids. André and Springael's analysis of WW domains led them to conclude that WW domains lack  $\alpha$ -helical content, instead possessing a central  $\beta$ -strand region flanked by unstructured regions. Other studies predict a structure of  $\beta$ -strands containing charged residues flanking a  
15 hydrophobic core composed of four aromatic residues (Chen and Sudol, 1995, Proc. Natl. Acad. Sci. USA 92:7819-7823, and references cited therein).

The WW domain has been found in a wide variety of proteins of varying function. Despite this diversity of  
20 function, it appears that most proteins containing WW domains for which a function is known have something to do with either cell signalling and growth regulation or the organization of the cytoskeleton.

For example, the WW domain-containing protein dystrophin  
25 belongs to a family of cytoskeletal proteins that includes  $\alpha$ -actinin and  $\beta$ -spectrin. Mutations in dystrophin are responsible for Duchenne and Becker muscular dystrophies. The dystrophin gene gives rise to a family of alternatively spliced transcripts. The longest of these encodes a protein  
30 having four domains: (1) a globular, actin-binding region; (2) 24 spectrin-like repeats; (3) a cysteine-rich  $\text{Ca}^{2+}$  binding region; and (4) a carboxyl terminal globular region. A short stretch of the dystrophin protein, after the spectrin-like repeats and before the  $\text{Ca}^{2+}$  binding region, contains a WW  
35 domain. This WW domain is in an area that has been shown to bind  $\beta$ -dystroglycan. This suggests that WW domains may be

involved in protein-protein interactions (Bork and Sudol, 1994, Trends in Biochem. Sci. 19:531-533).

Utrophin, a protein having 70% sequence homology to dystrophin, and, like dystrophin, capable of forming tetramers  
5 via its spectrin-like repeats, also possesses a WW domain. Utrophin and dystrophin are believed to be involved in membrane stability and the transmission of contractile forces to the extracellular environment (Bork and Sudol, 1994, Trends in Biochem. Sci. 19:531-533).

10 YAP is a protein that was discovered by virtue of its binding to the SH3 domain of the proto-oncogene Yes (Sudol, 1994, Oncogene 9:2145-2152). Murine YAP was found to have two WW domains; interestingly, chicken and human YAP each have only a single WW domain (Sudol, et al., 1995, J. Biol. Chem.  
15 270:14733-14741). Chen and Sudol, 1995, Proc. Natl. Acad. Sci. USA 92:7819-7823 screened a cDNA expression library with bacterially produced glutathione S-transferase fusion proteins of the WW domain from YAP. They identified and isolated two  
20 proteins from the library (WBP-1 and WBP-2) that specifically bound the YAP WW domain. Comparison of the amino acid sequences of WBP-1 and WBP-2 revealed a homologous proline-rich region in each protein. The proline-rich regions contained the shared motif PPPPY (SEQ ID NO:3). Chen and Sudol then showed that as few as ten residues containing this  
25 motif conferred upon a fusion protein the ability to specifically bind the YAP WW domain. This binding was highly specific; the motif bound to the YAP WW domain but not to the WW domain from dystrophin or to a panel of SH3 domains.

Nedd-4 is a protein which possesses three WW domains. In  
30 mouse, Nedd-4 seems to play a role in embryonic development and the differentiation of the central nervous system (Kumar et al., 1992, Biochem. Biophys. Res. Comm. 185:115-1161).

RSP5 is a protein of yeast that is involved in the phenomenon of nitrogen catabolite inactivation whereby a  
35 number of permeases that import nitrogenous compounds into the cell are inactivated when yeast are exposed to a good nitrogen source such as  $\text{NH}_4^+$ . RSP5 probably interacts with the

transcription factor SPT3 since certain alleles of RSP5 can complement mutations in SPT3 (Eisenmann et al., 1992, Genes Dev. 6:1319-1331).

RSP5 contains three WW domains in its amino terminus.

- 5 RSP5 appears to be a homolog of the vertebrate protein Nedd-4. The 6 total WW domains of RSP5 and Nedd-4 share 30% amino acid sequence identity and 50% similarity. The carboxyl terminal domains of both RSP5 and Nedd-4 are homologous to the carboxyl terminal domain of E6-AP, a human ubiquitin-protein ligase
- 10 (André and Springael). A region of RSP5 known as HECT can form a high energy thioester bond with ubiquitin, arguing that RSP5 is a ubiquitin-protein ligase (Scheffner et al., 1995, Cell 75:495-505; Huibregste et al., 1995, Proc. Natl. Acad. Sci. USA 92:2563-2567).
- 15 Another yeast protein, *ess1*, contains a WW domain and is thought to be involved in cytokinesis and/or cell separation (Hanes et al., 1989, Yeast 5:55-72).

- A search of protein databases, using the WW domains of Nedd-4 and RSP5, identified two proteins of unknown function,
- 20 YKL012W from *Saccharomyces cerevesiae* and Z22176 from *Caenorhabditis elegans*, each containing two WW domains at their amino terminus (André and Springael).

- Among other proteins having WW domains, the rat transcription factor FE65 possesses an amino terminal
- 25 activation region that includes a WW domain (Bork and Sudol, 1994, Trends in Biochem. Sci. 19:531-533). The human protein *kiaa93* has 4 WW domains and shares other regions of sequence similarity with RSP5, and may be the human version of mouse Nedd-4 (Hoffman and Bucher, 1995, FEBS Lett. 358:153-157).
- 30 The human protein HUMORF1, although of unknown function, has a roughly 350 amino acid region which is homologous to GTPase-activating proteins (André and Springael).

- Citation of a reference hereinabove shall not be construed as an admission that such is prior art to the
- 35 present invention.

### 3. SUMMARY OF THE INVENTION

In general, the present invention is directed to a method of identifying an exhaustive set of compounds binding operationally defined ligands that are involved in binding  
5 interactions with WW domains.

More specifically, the present invention is directed to a method of identifying a polypeptide or family of polypeptides having a WW domain. The basic steps of the method comprise:  
(a) choosing a recognition unit or set of recognition units  
10 having a selective affinity for a WW domain in a target molecule of interest; (b) contacting the recognition unit with a plurality of polypeptides; and (c) identifying one or more polypeptides having a selective affinity for the WW domain of interest, which polypeptides include the WW domain of interest  
15 or a functional equivalent thereof.

In one particular embodiment of the invention, exhaustive screening of proteins having a desired WW domain involves an iterative process by which recognition units for WW domains identified in a first round of screening are used to detect WW  
20 domain-containing proteins in successive expression library screens.

More particularly, the method of the present invention includes choosing a recognition unit having a selective affinity for a WW domain of interest. With this recognition  
25 unit, it has been discovered that a plurality of polypeptides from various sources can be examined such that certain polypeptides having a selective affinity for the recognition unit can be identified. The polypeptides so identified have been shown to include a WW domain; that is, the WW domains  
30 found are working versions that are capable of displaying the same binding specificity (binding to the same recognition unit, particularly under the multivalent recognition unit screening conditions taught by the present invention) as the WW domain of interest. Hence, the polypeptides identified by  
35 the present method also possess those attributes of the WW domain of interest which allow these related polypeptides to exhibit the same, similar, or analogous (but functionally

equivalent) selective binding affinity characteristics as the WW domain of interest of the initial target molecule.

In specific embodiments of the present invention, the plurality of polypeptides is obtained from the proteins  
5 produced by a cDNA expression library. The binding specificity of the polypeptides which bear a WW domain or a functional equivalent thereof for various peptides or recognition units can subsequently be examined, allowing for a greater understanding of the physiological role of particular  
10 polypeptide/recognition unit interactions. Indeed, the present invention provides a method of targeted drug discovery based on the observed effects of a given drug candidate on the interaction between a recognition unit-polypeptide pair or a recognition unit and a "panel" of related polypeptides each  
15 with a copy or a functional equivalent of (e.g., capable of displaying the same binding specificity as) a WW domain.

The present invention also provides polypeptides comprising certain amino acid sequences. Moreover, the present invention also provides nucleic acids, including  
20 certain DNA constructs comprising certain coding sequences. Other compositions are likewise contemplated which are products of the methods of the present invention.

The present inventors have found, unexpectedly, that the valency (i.e., whether it is a monomer, dimer, tetramer, etc.)  
25 of the recognition unit that is used to screen an expression library or other source of polypeptides appears to have a marked effect upon the specificity of the recognition unit-WW domain interaction. The present inventors have discovered that recognition units in the form of small peptides, in  
30 multivalent form, have a specificity that is eased but not forfeited. In particular, biotinylated peptides bound to a multivalent (believed to be tetravalent) streptavidin-alkaline phosphatase complex have an unexpected generic specificity. This allows such peptides to be used to screen libraries to  
35 identify classes of polypeptides containing WW domains that are similar but not identical in sequence to the peptides' target WW domains.

The present invention also provides methods for identifying potential new drug candidates (and potential lead compounds) and determining the specificities thereof. For example, knowing that a polypeptide with a WW domain and a recognition unit, e.g., a binding peptide, exhibit a selective affinity for each other, one may attempt to identify a drug that can exert an effect on the polypeptide-recognition unit interaction, e.g., either as an agonist or as an antagonist (inhibitor) of the interaction. With this assay, then, one can screen a collection of candidate "drugs" for the one exhibiting the most desired characteristic, e.g., the most efficacious in disrupting the interaction or in competing with the recognition unit for binding to the polypeptide.

In addition, the present invention also provides certain assay kits and methods of using these assay kits for screening drug candidates. In a particular aspect of the present invention, the assay kit comprises: (a) a polypeptide containing a WW domain; and (b) a recognition unit having a selective affinity for the polypeptide. Yet another assay kit may comprise a plurality of polypeptides, each polypeptide containing a WW domain, preferably of a different sequence, and at least one recognition unit having a selective affinity for each of the plurality of polypeptides.

25

#### 4. DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of the general aspects of a method of identifying recognition units exhibiting a selective affinity for a target molecule containing a WW domain. In this illustration, the target molecule is a polypeptide having a WW domain, and the recognition units are peptides having a selective affinity for the WW domain that are expressed in a phage display library.

Figure 2 illustrates a strategy for exhaustively screening an expression library for WW domain-containing proteins. A peptide recognition unit is generated by screening a combinatorial peptide library for binders to a WW domain expressed bacterially as a GST fusion protein. This



peptide is then used to select a subset of the WW domain-containing proteins represented in a cDNA expression library. A combinatorial library is once again used to identify recognition units of WW domains identified in the first  
5 expression library screen; these recognition units identify overlapping sets of proteins from the expression library. With multiple iterations of this process, it should be possible to clone systematically all WW domains represented in a given cDNA expression library.

10 Figure 3 is a schematic representation of the general method of identifying polypeptides containing a WW domain by screening a plurality of polypeptides using a suitable recognition unit. In the illustration, the plurality of polypeptides is obtained from a cDNA expression library, and  
15 the recognition units are WW domain-binding peptides.

Figure 4 illustrates how a WW domain-binding peptide can be used to identify other WW domain-containing proteins. Shown is a schematic representation of the progression from initial selection of a target molecule containing a WW domain,  
20 choice of peptide recognition unit, and identification of polypeptides that have a selective affinity for the recognition unit and include the WW domain of the initial target molecule or a functional equivalent thereof.

Figure 5 shows an alignment of the twelve novel WW  
25 domains from the novel proteins WWP1, WWP2, WWP3, and WWP4 as well as WW domains from a variety of known proteins. This alignment illustrates the minimal primary sequence homology among various known WW domains. "pos" indicates, where known, the position of the first amino acid of the displayed sequence  
30 in the indicated proteins. "acc. no." indicates GenBank accession numbers. Residues in boldface are those that are conserved in greater than 75% of the sequences. A single amino acid gap has been introduced in the amino acid sequence of the third WW domain of WWP2 (WWP2-3) between positions 12  
35 and 13 in order to maximize homology with the other WW domains. In the consensus sequence:

X represents any amino acid;

h represents a hydrophobic amino acid; and  
t represents a polar amino acid.

Figure 6A is a schematic representation of a population of WW domains represented by the circles. "A" is a  
5 recognition unit specific to one circle only. B, on the other hand, recognizes three WW domains, while B1 and B2 recognize only two each.

Figure 6B illustrates an iterative method whereby new recognition units are chosen based on polypeptides uncovered  
10 with the first recognition unit(s). These new recognition units lead to the identification of other related polypeptides, etc., expanding the scope of the study to increasingly diverse members of the related population.

Figure 7 depicts the results of experiments in which  
15 peptide sequences from the indicated genes were synthesized and tested for their ability to bind to the novel WW domains described in Sections 6.1 and 6.1.1. Purified phage clones were applied to a bacterial lawn, grown for an appropriate time, and filter lifts were processed as in Section 6.1. A  
20 minus indicates no binding; a plus indicates binding, with the number of pluses indicating the strength of binding. For further details, see Section 6.3.

Figure 8 is a schematic depiction of 5 clones of the Nedd-4 gene isolated by screening a 16 day mouse embryo cDNA  
25 library with the QP peptide (SEQ ID NO:8). Black boxes indicate WW domains. See Section 6.1 for details.

Figure 9 is a schematic depiction of 2 clones of the YAP gene isolated by screening a 16 day mouse embryo cDNA library with a 1:1:1 mixture of the peptides TP, YP, and QP (SEQ ID  
30 NOs:6, 7, and 8). Black boxes indicate WW domains; // indicates regions still to be sequenced. See Section 6.1 for details.

Figure 10 is a schematic depiction of three clones of novel WW domain-containing genes isolated by screening human  
35 bone marrow and brain cDNA expression libraries with the peptides WBP-1, WBP-2A, and WBP-2B, and a fourth clone of a novel WW domain-containing gene isolated by screening a human

prostate cDNA expression library with ENaCB and ENaCy. Black boxes indicate WW domains; boxes with cross hatching indicate HECT domains; the empty box indicates a guanylate kinase-like domain. The box with dots indicates a C2 domain. Arrows  
 5 denote incomplete N and C-terminal coding sequences. See Sections 6.1 and 6.1.1 for details.

Figure 11 shows the sequences of the oligonucleotides used to construct the CW1 random peptide library. See Section 6.2 for details.

10 Figure 12 illustrates the peptide sequence encoded in the mBAX vector situated at the N-terminus of mature pIII protein. TCCTCGAGTATCGACATGCCTTAGACTGCTAGCACTATGTACAACATGCTTCATCGCAACGA GCCAGGTGGGAGGAAGTTGAGCCCCGCCGCCAACGACATGCCGCCGCCCTCCTGAAGAGGT CTAGA is SEQ ID NO:4. TASTMYNMLHRNEPGGRKLSPPANDMP  
 15 PALLKRSR is SEQ ID NO:5. SSIDMP is SEQ ID NO:51.

Figure 13 depicts the specificity continuum described in Section 5.2.1. "SA-AP peptide complex" represents the tetravalent complex of streptavidin-alkaline phosphatase and biotinylated peptide described in that section.

20 Figure 14 shows a comparison of the HECT domain sequences from WWP1 and WWP2 and the HECT domains of various proteins. See Section 6.1.1.

Figures 15 A, B, C and D show the results of a cross affinity mapping experiment wherein biotinylated peptides were  
 25 tested for their relative binding to individual WW domains expressed as GST fusion proteins. PPPPY and PPPPY-like motifs within the peptide sequences are underlined and specific alanine substitution variants of the WBP-1 and WBP-2A peptides are indicated in bold. Relative binding was assessed from  
 30 three independent determinations. All PPPPY motif peptides displayed no detectable binding to GST control protein or to BSA. See Section 6.3 for details.

Figure 16 depicts the nucleotide sequence of WWP1, a novel human gene (SEQ ID NO:45).

35 Figure 17 depicts the amino acid sequence of WWP1, a novel human gene (SEQ ID NO:46).

Figure 18A depicts the nucleotide sequence from position 1-1800 of WWP2, a novel human gene (a portion of SEQ ID NO:47).

Figure 18B depicts the nucleotide sequence from position 1800-3476 of WWP2, a novel human gene (a portion of SEQ ID NO:47).

Figure 19 depicts the amino acid sequence of WWP2, a novel human gene (SEQ ID NO:48).

Figure 20 depicts the nucleotide sequence of WWP3, a novel human gene (SEQ ID NO:49).

Figure 21 depicts the amino acid sequence of WWP3, a novel human gene (SEQ ID NO:50).

Figure 22 depicts the nucleotide sequence of WWP4, a novel human gene (SEQ ID NO:125).

Figure 23 depicts the amino acid sequence of WWP4, a novel human gene (SEQ ID NO:126). The three WW domains are underlined (these domains are identified as SEQ ID NOs:127-129, which identification corresponds to the respective order from the amino terminus). The HECT domain (SEQ ID NO:130) is contained in the last 300 amino acids of WWP4.

Figures 24A and B show the results of a cross affinity mapping experiment wherein PPPPY motif-containing peptides derived from the  $\alpha$ ,  $\beta$ , and  $\delta$  wild-type subunits of human ENaC and several variants were tested for their relative binding to WW-GST fusion proteins. ENaC $\beta$ P616L and ENaC $\beta$ -Y618H denote peptides containing specific missense substitutions found in Liddle Syndrome patients. Amino acid substitutions are indicated in bold.

Figure 25 shows a cross affinity mapping experiment wherein Biotinylated peptides (corresponding to the PPPPY-like motif of WWP2 (Peptide bWW061) (SEQ ID NO:3) and WWP4 (Peptide bWW059) were tested for their relative binding to individual WW domains expressed as GST fusion proteins (following methods as set forth in Section 6.1). PPPPY (SEQ ID NO:3) and PPPPY (SEQ ID NO:3)-like motifs are underlined and specific alanine substitution peptide variants of the PPPPY-like motif in the HECT domain of WWP2 and WWP4 (the variants are identified as

peptide bWW061 and bWW060, respectively) are indicated in bold.

Figure 26A depicts the Epithelial Na<sup>+</sup> Channel and Liddle syndrome associated mutations. The wild type epithelial Na<sup>+</sup> Channel protein consists of  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits. Each subunit contains a proline rich motif, i.e. a WW domain binding sequence. In Liddle syndrome the Epithelial Na<sup>+</sup> channel protein is mutated: either the  $\beta$  or  $\gamma$  subunits are truncated such that they lack the proline-rich motif or point mutations have been found in the  $\beta$  subunit that change the PPPNY motif to PPLNY (labeled P616L) or to PPPNH (Y618H).

Figure 26B depicts Nedd-4-like proteins containing WW domains binding to the wild type epithelial Na<sup>+</sup> channel protein, thereby bringing the HECT domain into the vicinity of the protein where it can mediate ubiquitin tagging of the protein. The ubiquitin tag signals that the protein is to be degraded. This allows for the natural turn-over of the channel protein. However, in Liddle syndrome, the WW Nedd-4 like protein cannot bind to the channel protein due to the missing or mutated proline-rich regions of the channel protein. The protein does not get tagged by ubiquitin and is not degraded. The results in an overexpression of the channel protein in Liddle syndrome patients.

Figure 27 shows the sequences of WW domain binding clones obtained by screening random or biased libraries with WWP1.1, WWP1.4 or WWP3 domains to obtain peptide recognition units ("ligands") for analyzing specificities of the WW domains.

##### 5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to polypeptides having a WW domain, methods of identifying and using these polypeptides and derivatives thereof, and nucleic acids encoding the foregoing. The detailed description that follows is provided to elucidate the invention further and to assist further those of ordinary skill who may be interested in practicing particular aspects of the invention.

First, certain definitions are in order. Accordingly, the term "polypeptide" refers to a molecule comprised of amino acid residues joined by peptide (i.e., amide) bonds and includes proteins and peptides. Hence, the polypeptides of the present invention may have single or multiple chains of covalently linked amino acids and may further contain intrachain or interchain linkages comprised of disulfide bonds. Some polypeptides may also form a subunit of a multiunit macromolecular complex. Naturally, the polypeptides can be expected to possess conformational preferences and to exhibit a three-dimensional structure. Both the conformational preferences and the three-dimensional structure will usually be defined by the polypeptide's primary (i.e., amino acid) sequence and/or the presence (or absence) of disulfide bonds or other covalent or non-covalent intrachain or interchain interactions.

The polypeptides of the present invention can be any size. As can be expected, the polypeptides can exhibit a wide variety of molecular weights, some exceeding 150 to 200 kilodaltons (kD). Typically, the polypeptides may have a molecular weight ranging from about 5,000 to about 100,000 daltons. Still others may fall in a narrower range, for example, about 10,000 to about 75,000 daltons, or about 20,000 to about 50,000 daltons.

WW domains tend to be modular in that such domains may occur one or more times in a given polypeptide (or target molecule) or may be found in a family of different polypeptides. When found more than once in a given polypeptide or in different polypeptides, the modular WW domain may possess substantially the same structure, in terms of primary sequence and/or three-dimensional conformation, or may contain slight or great variations or modifications among the different versions of the WW domain of interest.

What is important, however, is that these related WW domains retain at least one of the functional aspects of the WW domain of interest present in the target molecule. It is stressed that, indeed, it is this functional relationship

among two or more possible versions of a WW domain which may be identified, defined, and exploited by the methods of the present invention. In a preferred aspect, the function of interest is the ability to bind to a molecule (e.g., a peptide) of interest.

The present invention provides a general strategy by which recognition units that bind to a WW domain-containing protein can be used to screen expression libraries of genes (e.g., cDNA, genomic libraries) systematically for novel WW domain-containing proteins. In specific embodiments, the recognition units are prior isolated from a random peptide library, or are known peptide recognition units, or are recognition units that are identified by database searches for sequences having homology to a peptide recognition unit having the binding specificity of interest.

In the prior art, novel genes (and thus their encoded protein products) are most commonly identified from cDNA libraries. Generally, an appropriate cDNA library is screened with a probe that is either an oligonucleotide or an antibody. In either case, the probe must be specific enough for the gene that is to be identified to pick that gene out from a vast background of non-relevant genes in the library. It is this need for a specific probe that is the highest hurdle that must be overcome in the prior art identification of novel genes. Another method of identifying genes from cDNA libraries is through use of the polymerase chain reaction (PCR) to amplify a segment of a desired gene from the library. PCR requires that oligonucleotides having sequence similarity to the desired gene be available.

If the probe used in prior art methods is a nucleic acid, the cDNA library may be screened without the need for expressing any protein products that might be encoded by the cDNA clones. If the probe used in prior art methods is an antibody, then it is necessary to build the cDNA library into a suitable expression vector. For a comprehensive discussion of the art of identifying genes from cDNA libraries, see Sambrook, Fritsch, and Maniatis, "Construction and Analysis of

cDNA Libraries," Chapter 8 in Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989. See also Sambrook, Fritsch, and Maniatis, "Screening Expression Libraries with Antibodies and Oligonucleotides," Chapter 12 in  
5 Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989.

As an alternative to cDNA libraries, genomic libraries may be used. When genomic libraries are used in prior art methods, the probe is virtually always a nucleic acid probe.  
10 See Sambrook, Fritsch, and Maniatis, "Analysis and Cloning of Eukaryotic Genomic DNA," Chapter 9 in Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989.

In the prior art, nucleic acid probes used in screening libraries are often based upon the sequence of a known gene  
15 that is thought to be homologous to a gene that it is desired to isolate. The success of the procedure depends upon the degree of homology between the probe and the target gene being sufficiently high. Probes based upon the sequences of known WW domains had limited value because, while the sequences of  
20 the WW domains were similar enough to allow for their recognition as shared domains, the similarity was not so high that probes could be designed that could be used to screen cDNA or genomic libraries for genes containing the WW domains with a reasonable expectation of success. See Figure 5 for an  
25 illustration of the level of primary sequence homology among WW domains.

PCR may also be used to identify genes from genomic libraries. However, as in the case of using PCR to identify genes from cDNA libraries, this requires that oligonucleotides  
30 having sequence similarity to the desired gene be available.

Using the screening methods provided by the present invention, DNA encoding proteins having a desired WW domain can be identified by functional binding specificity to recognition units. By virtue of an ease in specificity of  
35 binding requirements conferred by the screening methods of the present invention, many novel, functionally homologous, WW domain-containing proteins can be identified. Although not



intending to be bound by any mechanistic explanation, this ease in binding specificity is believed to be the result of the use of a multivalent recognition unit used to screen the gene library, preferably of a valency greater than bivalent, 5 more preferably tetravalent or greater, and most preferably the streptavidin-biotinylated peptide recognition unit complex.

In one particular embodiment of the invention, exhaustive screening of proteins having a WW domain involves an iterative 10 process by which recognition units for WW domains identified in the first round of screening are used to detect WW domain-containing proteins in successive expression library screens (see Figures 2 and 6B). This strategy enables one to search "sequence space" in what might be thought of as ever-widening 15 circles with each successive cycle. This iterative strategy can be initiated even when only one WW domain-containing protein and recognition unit are available.

The present invention provides polypeptides comprising novel HECT domains and nucleic acids encoding those 20 polypeptides. In particular, the present invention provides a novel HECT domain having an amino acid sequence selected from the group consisting of SEQ ID NOS:115, 116, 124, and 130. Also provided are nucleic acids encoding those novel HECT domains. The novel HECT domains of the present invention can 25 be used to identify and isolate recognition units that can be used to identify and isolate additional HECT domain containing polypeptides.

#### 30 5.1. DISCOVERY OF NOVEL GENES AND POLYPEPTIDES CONTAINING WW DOMAINS

The present invention makes possible the identification of one or more polypeptides (in particular, a "family" of polypeptides, including the target molecule) that contain a WW domain that either corresponds to or is the functional 35 equivalent of a WW domain present in a predetermined target molecule.

The present invention provides a mechanism for the rapid identification of genes (e.g., cDNAs) encoding virtually any WW domain. By screening cDNA libraries or other sources of polypeptides for recognition unit binding rather than sequence  
5 similarity, the present invention circumvents the limitations of conventional DNA-based screening methods and allows for the identification of highly disparate protein sequences possessing equivalent functional activities. The ability to isolate entire repertoires of proteins containing particular  
10 modular WW domains will prove invaluable both in molecular biological investigations of the genome and in bringing new targets into drug discovery programs.

It should likewise be apparent that a wide range of polypeptides having a WW domain can be identified by the  
15 process of the invention, which process comprises:

- (a) contacting a multivalent recognition unit complex with a plurality of polypeptides; and
- (b) identifying a polypeptide having a selective binding affinity for said recognition unit complex, in which the  
20 recognition unit selectively binds a WW domain.

In a specific embodiment, the process comprises:

- (a) contacting a multivalent recognition unit complex with a plurality of polypeptides from which it is desired to identify a polypeptide having selective binding affinity for  
25 the recognition unit, in which the valency of the recognition unit in the complex is at least two, or at least four, in which the recognition unit selectively binds a WW domain; and
- (b) identifying, and preferably recovering, a polypeptide having a selective binding affinity for the  
30 recognition unit complex.

In another specific embodiment, the process comprises a method of identifying a polypeptide having a WW domain comprising:

- (a) contacting a multivalent recognition unit complex,  
35 which complex comprises (i) avidin or streptavidin, and (ii) biotinylated recognition units, with a plurality of polypeptides from a cDNA expression library, in which the

recognition unit is a peptide having in the range of 6 to 60 amino acid residues and which selectively binds a WW domain; and

- (b) identifying a polypeptide having a selective binding  
5 affinity for said recognition unit complex.

In another embodiment, the present invention includes a method of identifying one or more novel polypeptides having a WW domain, said method comprising:

- (a) identifying a recognition unit having a selective  
10 affinity for the WW domain by screening a peptide library with the WW domain;
- (b) producing said recognition unit;
- (c) contacting said recognition unit with a source of polypeptides; and
- 15 (d) identifying one or more novel polypeptides having a selective affinity for said recognition unit, which polypeptides comprise a WW domain.

In another specific embodiment, the process comprises a method of identifying a polypeptide having a WW domain of  
20 interest or a functional equivalent thereof comprising:

- (a) screening a random peptide library to identify a peptide that selectively binds a WW domain of interest; and
- (b) screening a cDNA or genomic expression library with said peptide or a binding portion thereof to identify a  
25 polypeptide that selectively binds said peptide.

In a specific embodiment of the above method, the screening step (b) is carried out by use of said peptide in the form of multiple antigen peptides (MAP) or by use of said peptide cross-linked to bovine serum albumin or keyhole limpet  
30 hemocyanin.

In another specific embodiment, the process comprises a method of identifying a polypeptide having a WW domain of interest or a functional equivalent thereof comprising:

- (a) screening a random peptide library to identify a  
35 plurality of peptides that selectively bind a WW domain of interest;

(b) determining at least part of the amino acid sequences of said peptides;

(c) determining a consensus sequence based upon the determined amino acid sequences of said peptides; and

5 (d) screening a cDNA or genomic expression library with a peptide comprising the consensus sequence to identify a polypeptide that selectively binds said peptide.

In another specific embodiment, the process comprises a method of identifying a polypeptide having a WW domain, which  
10 can be the WW domain of interest or a functional equivalent thereof, comprising:

(a) screening a random peptide library to identify a first peptide that selectively binds a WW domain of interest;

(b) determining at least part of the amino acid sequence  
15 of said first peptide;

(c) searching a database containing the amino acid sequences of a plurality of expressed natural proteins to identify a protein containing an amino acid sequence homologous to the amino acid sequence of said first peptide;

20 and

(d) screening a cDNA or genomic expression library with a second peptide comprising the sequence of said protein that is homologous to the amino acid sequence of said first peptide.

25 The polypeptide identified by the above-described methods thus should contain the WW domain of interest or a functional equivalent thereof (that is, have a WW domain that is identical, or have a WW domain that differs in sequence but is capable of binding to the same recognition unit). In a  
30 particular embodiment, the polypeptide identified is a novel polypeptide. In a preferred embodiment, the recognition unit that is used to form the multivalent recognition unit complex is isolated or identified from a random peptide library.

The present invention provides amino acid sequences of  
35 any DNA sequences encoding novel proteins containing WW domains. The WW domains vary in sequence but retain binding specificity to a WW domain recognition unit. Also provided

are fragments and derivatives of the novel proteins containing WW domains as well as DNA sequences encoding the same. It will be apparent to one of ordinary skill in the art that also provided are proteins that vary slightly in sequence from the  
5 novel proteins by virtue of conservative amino acid substitutions. It will also be apparent to one of ordinary skill in the art that the novel proteins may be expressed recombinantly by standard methods. The novel proteins may also be expressed as fusion proteins with a variety of other  
10 proteins, e.g., glutathione S-transferase.

The present invention provides a purified polypeptide comprising a WW domain, said WW domain having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 30-38, and 127-129. Also provided is a purified DNA encoding  
15 the polypeptide.

Also provided is a purified polypeptide comprising a WW domain, said polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 46, 48, 50, and 126. Also provided is a purified DNA encoding the  
20 polypeptide.

Also provided is a purified DNA encoding a WW domain, said DNA having a sequence selected from the group consisting of SEQ ID NOS: 45, 47, 49, and 125. Also provided is a nucleic acid vector comprising this purified DNA. Also  
25 provided is a recombinant cell containing this nucleic acid vector.

Also provided is a purified DNA encoding a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 46, 48, 50, and 126. Also provided  
30 is a nucleic acid vector comprising this purified DNA. Also provided is a recombinant cell containing this nucleic acid vector.

Also provided is a purified DNA encoding a polypeptide comprising an amino acid sequence selected from the group  
35 consisting of: SEQ ID NOS: 30-38 and 127-129. Also provided is a nucleic acid vector comprising this purified DNA. Also

provided is a recombinant cell containing this nucleic acid vector.

Also provided is a purified molecule comprising a WW domain of a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 46, 48, 50, and 126.

Also provided is a fusion protein comprising (a) an amino acid sequence comprising a WW domain of a polypeptide having the amino acid sequence of SEQ ID NO: 46, 48, 50, 126, 30-38, and 127-129, joined via a peptide bond to (b) an amino acid sequence of at least six, or ten, or twenty, amino acids from a different polypeptide. Also provided is a purified DNA encoding the fusion protein. Also provided is a nucleic acid vector comprising the purified DNA encoding the fusion protein. Also provided is a recombinant cell containing this nucleic acid vector. Also provided is a method of producing this fusion protein comprising culturing a recombinant cell containing a nucleic acid vector encoding said fusion protein such that said fusion protein is expressed, and recovering the expressed fusion protein.

The present invention also provides a purified nucleic acid hybridizable to a nucleic acid having a sequence selected from the group consisting of: SEQ ID NOS: 45, 47, 49, and 125.

The present invention also provides antibodies to a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 30-38, and 127-129.

The present invention also provides antibodies to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 46, 48, 50, and 126.

It has been demonstrated by way of example herein that recognition units that comprise WW domain ligands derived from combinatorial peptide libraries may be used in the methods of the present invention as probes for the rapid discovery of novel proteins containing WW functional domains. The methods of the present invention require no prior knowledge of the characteristics of a WW domain's natural cellular ligand to initiate the process of discovery. One needs only enough purified WW domain-containing protein (by way of example, 1-5

μg) to select peptides from a random peptide library. In addition, because the methods of the present invention identify novel proteins from cDNA expression libraries based only on their binding properties, low primary sequence identity between the target WW domain and the WW domains of the novel proteins discovered need not be a limitation, provided some functional similarity between these WW domains is conserved. Also, the methods of the present invention are rapid, require inexpensive reagents, and employ simple and well established laboratory techniques.

Using these methods, six different WW domain-containing proteins have been identified, of which four have not been previously described. These novel proteins are described more fully in Sections 6.1 and 6.1.1. The high incidence of novel proteins identified by the methods of the present invention indicates that a large number of WW domain-containing proteins remain to be discovered.

One of ordinary skill in the art would recognize that the above-described novel proteins need not be used in their entirety in the various applications of those proteins described herein. In many cases it will be sufficient to employ that portion of the novel protein that contains the WW domain. Such exemplary portions of WW domain-containing proteins are shown in Figure 5. Accordingly, the present invention provides derivatives (e.g., fragments and molecules comprising these fragments) of novel proteins that contain WW domains, e.g., as shown in Figure 5. Nucleic acids encoding these fragments or other derivatives are also provided.

#### 5.1.1. WW DOMAINS

WW domains of interest in the practice of the present invention can take many forms and may perform a variety of functions. For example, such WW domains may be involved in a number of cellular, biochemical, or physiological processes, such as cellular signal transduction, transcriptional regulation, protein ubiquitination, cell adhesion, cytoskeletal organization, and the like. In particular

embodiments of the present invention, the WW domains of interest may be found in such proteins as YAP, Nedd-4, RSP5, dystrophin, utrophin, ess1, FE65, HUMORF1, and many others.

In one embodiment of the invention, a suitable target molecule containing the chosen WW domain of interest is selected. A number of proteins may be selected as the target molecule, including but not limited to: YAP, Nedd-4, RSP5, dystrophin, utrophin, ess1, FE65, and HUMORF1. Alternatively, a portion of the above-mentioned proteins comprising the WW domain may be chosen as the target molecule.

#### 5.1.2. RECOGNITION UNITS

By the phrase "recognition unit," is meant any molecule having a selective affinity for the WW domain of the target molecule and, preferably, having a molecular weight of up to about 20,000 daltons. In a particular embodiment of the invention, the recognition unit has a molecular weight that ranges from about 100 to about 10,000 daltons.

Accordingly, preferred recognition units of the present invention possess a molecular weight of about 100 to about 5,000 daltons, preferably from about 100 to about 2,000 daltons, and most preferably from about 500 to about 1,500 daltons. As described further below, a recognition unit of the present invention can be a peptide, a carbohydrate, a nucleoside, an oligonucleotide, any small synthetic molecule, or a natural product. When the recognition unit is a peptide, the peptide preferably contains about 6 to about 50 amino acid residues.

When the recognition unit is a peptide, the peptide can have less than about 140 amino acid residues; preferably, the peptide has less than about 100 amino acid residues; preferably, the peptide has less than about 70 amino acid residues; preferably, the peptide has 20 to 50 amino acid residues; most preferably, the peptide has about 6 to 60 amino acid residues.

The peptide recognition units are preferably in the form of a multivalent peptide complex comprising avidin or



streptavidin (optionally conjugated to a label such as alkaline phosphatase or horseradish peroxidase) and biotinylated peptides.

According to the present invention, a recognition unit  
5 (preferably in the form of a multivalent recognition unit complex) is used to screen a plurality of expression products of gene sequences containing nucleic acid sequences that are present in native RNA or DNA (e.g., cDNA library, genomic library).

10 The step of choosing a recognition unit can be accomplished in a number of ways that are known to those of ordinary skill, including but not limited to screening cDNA libraries or random peptide libraries for a peptide that binds to the WW domain of interest. Essentially, screening cDNA  
15 libraries or random peptide libraries for a peptide that binds to a WW domain can be accomplished in the same manner as for screening cDNA libraries or random peptide libraries for a peptide that binds to an SH3 domain. See, e.g., Yu et al., 1994, Cell 76, 933-945; Sparks et al., 1994, J. Biol. Chem.  
20 269, 23853-23856; Sparks et al., 1996, Proc. Natl. Acad. Sci. USA 93:1540-1544 for screening of peptide libraries to discover peptides that bind to SH3 domains. Alternatively, a small molecule or drug may be known to those of ordinary skill to bind to a certain target molecule containing a WW domain.  
25 The recognition unit can even be synthesized from a lead compound, which again may be a peptide, carbohydrate, oligonucleotide, small drug molecule, or the like. The recognition unit can also be identified for use by doing searches (preferably via database) for molecules having  
30 homology for other, known recognition unit(s) having the ability to selectively bind to a WW domain.

In a specific embodiment, the step of selecting a recognition unit for use can be effected by, e.g., the use of diversity libraries, such as random or combinatorial peptide  
35 or nonpeptide libraries which can be screened for molecules that specifically bind to WW domains. Many libraries are known in the art that can be used, e.g., chemically

synthesized libraries, recombinant (e.g., phage display libraries), and *in vitro* translation-based libraries.

Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R.B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

*In vitro* translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, *Proc. Natl. Acad. Sci. USA* 91:11138-11142).

The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, *Bio/Technology* 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs,  $\beta$ -

mercaptoketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

5 Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful  
10 pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in a ways that create new shapes that depend on the order of the monomers. Among the  
15 monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the  $\alpha$  amino group rather than the  $\alpha$  carbon, form the basis of another version of non-peptide oligomer libraries. The first non-  
20 peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

Screening the libraries can be accomplished by any of a  
25 variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, Adv. Exp. Med. Biol. 251:215-218; Scott and Smith, 1990, Science 249:386-390; Fowlkes et al., 1992; BioTechniques 13:422-427; Oldenburg et al., 1992, Proc.  
30 Natl. Acad. Sci. USA 89:5393-5397; Yu et al., 1994, Cell 76:933-945; Staudt et al., 1988, Science 241:577-580; Bock et al., 1992, Nature 355:564-566; Tuerk et al., 1992, Proc. Natl. Acad. Sci. USA 89:6988-6992; Ellington et al., 1992, Nature 355:850-852; U.S. Patent No. 5,096,815, U.S. Patent No.  
35 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, Science 263:671-673; and PCT Publication No. WO 94/18318.

In a specific embodiment, screening to identify a recognition unit can be carried out by contacting the library members with a WW domain immobilized on a solid phase and harvesting those library members that bind to the WW domain.

5 Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, Gene 73:305-318; Fowlkes et al., 1992, BioTechniques 13:422-427; PCT Publication No. WO 94/18318; and in references cited hereinabove.

10 In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, Nature 340:245-246; Chien et al., 1991, Proc. Natl. Acad. Sci. USA 88:9578-9582) can be used to identify recognition units that specifically bind to WW domains.

15 Where the recognition unit is a peptide, the peptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated  
20 so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a  
25 particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only  
30 arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct  
35 comprising a lambda phage vector with a DNA insert.

As mentioned above, in the case of a recognition unit that is a peptide, the peptide may have about 6 to less than

about 60 amino acid residues, preferably about 6 to about 25 amino acid residues, and most preferably, about 6 to about 15 amino acids. In another embodiment, a peptide recognition unit has in the range of 20-100 amino acids, or 20-50 amino acids.

The selected recognition unit can be obtained by chemical synthesis or recombinant expression. Chemical synthesis may be accomplished using techniques known in the art.

By example, and not by way of limitation, peptides may be synthesized using a variation of standard solid phase Fmoc peptide chemistry (Knorr et al., 1989, Tetrahedron Lett. 30:1927-1930) on standard support resins, including but not limited to, polystyrene or TentaGel® (Tübingen, Germany). Product yield can be increased by varying DMSO (dimethylsulfoxide) solvent mixtures used in the synthesis. Specifically proline rich regions require the use of 50% DMSO as a co-solvent with DMF (N,N-dimethylformamide) or NMP (N-methylpyrrolidone) in order to obtain reasonable yields. Additionally, with respect to biotinylation, biotin is only marginally soluble in neat DMF or NMP, so this reagent was dissolved in DMSO and then diluted to 50% in NMP or DMF before coupling. Further, depending on the particular ligand, biotin sometimes requires a spacer moiety between it and the ligand. Although many spacers are commonly used in the synthesis of biotinyl peptides, it was found necessary to incorporate lysine in the spacer region in order to improve solubility in aqueous solvent systems. Specifically, in a typical 15-20mer proline rich peptide, it was found that solubility was best when the peptide contained three or more basic moieties, although two acidic moieties could substitute for any given basic moiety and preserve solubility.

The selected recognition units, whether obtained by chemical synthesis or recombinant expression, are preferably purified prior to use in screening a plurality of gene sequences.

### 5.1.3. SCREENING A SOURCE OF POLYPEPTIDES

After the recognition unit is chosen, the recognition unit is then contacted with a plurality of polypeptides, preferable containing a WW domain. In a particular embodiment of the invention, the plurality of polypeptides is obtained from a polypeptide expression library. The polypeptide expression library may be obtained, in turn, from cDNA, fragmented genomic DNA, and the like. In a specific embodiment, the library that is screened is a cDNA library of total poly A+ RNA of an organism, in general, or of a particular cell or tissue type or developmental stage or disease condition or stage. The expression library may utilize a number of expression vehicles known to those of ordinary skill, including but not limited to, recombinant bacteriophage, lambda phage, M13, a recombinant plasmid or cosmid, and the like.

The plurality of polypeptides or the DNA sequences encoding the same may be obtained from a variety of natural or unnatural sources, such as a procaryotic or a eucaryotic cell, either a wild type, recombinant, or mutant. In particular, the plurality of polypeptides may be endogenous to microorganisms, such as bacteria, yeast, or fungi, to a virus, to an animal (including mammals, invertebrates, reptiles, birds, and insects) or to a plant cell.

In addition, the plurality of polypeptides may be obtained from more specific sources, such as the surface coat of a virion particle, a particular cell lysate, a tissue extract, or they may be restricted to those polypeptides that are expressed on the surface of a cell membrane.

Moreover, the plurality of polypeptides may be obtained from a biological fluid, particularly from humans, including but not limited to blood, plasma, serum, urine, feces, mucus, semen, vaginal fluid, amniotic fluid, or cerebrospinal fluid. The plurality of polypeptides may even be obtained from a fermentation broth or a conditioned medium, including all the polypeptide products secreted or produced by the cells previously in the broth or medium.

The step of contacting the recognition unit with the plurality of polypeptides may be effected in a number of ways. For example, one may contemplate immobilizing the recognition unit on a solid support and bringing a solution of the plurality of polypeptides in contact with the immobilized recognition unit. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized recognition unit. The polypeptides having a selective affinity for the recognition unit can then be purified by affinity selection. The nature of the solid support, process for attachment of the recognition unit to the solid support, solvent, and conditions of the affinity isolation or selection procedure would depend on the type of recognition unit in use but would be largely conventional and well known to those of ordinary skill in the art. Moreover, the valency of the recognition unit in the recognition unit complex used to screen the polypeptides is believed to affect the specificity of the screening step, and thus the valency can be chosen as appropriate in view of the desired specificity (see Sections 5.2 and 5.2.1).

Alternatively, one may also separate the plurality of polypeptides into substantially separate fractions comprising individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface. Individual isolates can then be "probed" by the recognition unit, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the recognition unit and the individual clone. Prior to contacting the recognition unit with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience.

Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon.

In this manner, positive clones could be identified from a collection of transformed host cells of an expression  
5 library, which harbor a DNA construct encoding a polypeptide having a selective affinity for the recognition unit. The polypeptide produced by the positive clone includes the WW domain of interest or a functional equivalent thereof. Furthermore, the amino acid sequence of the polypeptide having  
10 a selective affinity for the recognition unit can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence.

15 If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

In certain situations, it may be desirable to wash away any unbound recognition unit from a mixture of the recognition  
20 unit and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction (i.e., the presence of a recognition unit that remains bound after the washing step). Such a wash step may be particularly desirable when the plurality of polypeptides  
25 is bound to a solid support.

As can be anticipated, the degree of selective affinities observed varies widely, generally falling in the range of about 1 nM to about 1 mM. In preferred embodiments of the present invention, the selective affinity falls on the order  
30 of about 10 nM to about 100  $\mu$ M, more preferably on the order of about 100 nM to about 10  $\mu$ M, and most preferably on the order of about 100 nM to about 1  $\mu$ M.<sup>7</sup>



### 5.2. SPECIFICITY OF RECOGNITION UNITS

A particular recognition unit may have fairly generic selectivity for several members (e.g., three or four or more) of a "panel" of polypeptides having a WW domain (the same WW domain or different versions of a WW domain or functional equivalents of a WW domain of interest) or a fairly specific selectivity for only one or two, or possibly three, of the polypeptides among a "panel" of same. Furthermore, multiple recognition units, each exhibiting a range of selectivities among a "panel" of polypeptides can be used to identify an increasingly comprehensive set of additional polypeptides that include a WW domain.

Hence, in a population of related polypeptides, the WW domains of each member may be schematically represented by a circle. See, by way of example, Figure 6A. The circle of one polypeptide may overlap with that of another polypeptide. Such overlaps may be few or numerous for each polypeptide. A particular recognition unit, A, may recognize or interact with a portion of the circle of a given polypeptide which does not overlap with any other circle. Such a recognition unit would be fairly specific to that polypeptide. On the other hand, a second recognition unit, B, may recognize a region of overlap between two or more polypeptides. Such a recognition unit would consequently be less specific than the recognition unit A and may be characterized as having a more generic specificity depending on the number of polypeptides that it recognizes or interacts with.

It should also be apparent to those of ordinary skill that any number of B-type recognition units ( $B_1$ ,  $B_2$ ,  $B_3$ , etc.) can be present, each recognizing different "panels" of polypeptides. Hence, the use of multiple recognition units provides an increasingly more exhaustive population of polypeptides, each of which exhibits a variation or evolution in the WW domain present in the initial target molecule. It should also be apparent to one that the present method can be applied in an iterative fashion, such that the identification of a particular polypeptide can lead to the choice of another

recognition unit. See, e.g., Figure 6B. Use of this new recognition unit will lead, in turn, to the identification of other polypeptides that contain WW domains that enhance the phenotypic and/or genotypic diversity of the population of  
5 "related" polypeptides.

Hence, with a given recognition unit, one may observe interaction with only one or two different polypeptides. With other recognition units, one may find three, four, or more selective interactions. In the situation in which only a  
10 single interaction is observed, it is likely, though not mandatory, that the selective affinity interaction is between the recognition unit and a replica of the initial target molecule (or a molecule very similar structurally and "functionally" to the initial target molecule).

15

**5.2.1. EFFECT OF THE PRESENTATION OF THE  
RECOGNITION UNIT ON THE SPECIFICITY OF  
THE RECOGNITION UNIT-WW DOMAIN INTERACTION**

The present inventors have found, unexpectedly, that the valency (i.e., whether it is a monomer, dimer, tetramer, etc.)  
20 of the recognition unit that is used to screen an expression library or other source of polypeptides apparently has a marked effect upon which genes or polypeptides are identified from the expression library or source of polypeptides. In particular, the specificity of the recognition unit-WW domain  
25 interaction appears to be affected by the valency of the recognition unit in the screening process. By this specificity is meant the selectivity in the WW domains to which the recognition unit will bind in the screening step.

As discussed above, in one embodiment, recognition units  
30 are obtained by screening a source of recognition units, e.g., a phage display library, for recognition units that bind to a particular target WW domain. Alternatively, database searches for recognition units with sequence homology to known recognition units can be employed. Of course, if a  
35 recognition unit for a particular target WW domain is already known, there is no need to screen a library or other source of

recognition units; one can merely synthesize that particular recognition unit. The recognition unit, however obtained, is then used to screen an expression library or other source of polypeptides to identify polypeptides that the recognition unit binds to. A recognition unit that identifies only its target WW domain is a recognition unit that is completely specific. A recognition unit that identifies one or two other polypeptides that do not contain identically the target WW domain, from among a plurality of polypeptides (e.g., of greater than  $10^4$ ,  $10^6$ , or  $10^8$  complexity), in addition to identifying a molecule comprising its target WW domain, is very or highly specific. A recognition unit that identifies most other polypeptides present that do not contain its target WW domain, in addition to identifying its target WW domain, is a non-specific recognition unit. In between very specific recognition units and non-specific recognition units, the present inventors have discovered that there are recognition units that recognize a small number of molecules having WW domains other than their target WW domains. These recognition units are said to have generic specificity.

Thus, there is a "specificity continuum", from completely and very specific through generic to non-specific, that a recognition unit may evince. See Figure 13 for a depiction of this specificity continuum. The Applicants have discovered that a major factor influencing the specificity exhibited by a recognition unit appears to be the valency of the recognition unit in the complex used to screen the expression library.

Usually, high specificity is considered to be desirable when screening a library. High specificity is exhibited, e.g., by affinity purified polyclonal antisera which, in general, are very specific. Monoclonal antibodies are also very specific. Small peptides in monovalent form, on the other hand, generally give very weak, non-specific signals when used to screen a library; thus, they are considered to be non-specific.

The present inventors have discovered that recognition units in the form of small peptides, in multivalent form, have

a specificity midway between the high specificity of antibodies and the low/non-specificity of monovalent peptides. Multivalency of the recognition unit of at least two, in a recognition unit complex used to screen the gene library, is preferred, with a multivalency of at least four more preferred, to obtain a screening wherein specificity is eased but not forfeited. In particular, a multivalent (believed to be tetravalent) recognition unit complex comprising streptavidin or avidin (preferably conjugated to a label, e.g., an enzyme such as alkaline phosphatase or horseradish peroxidase or a fluorogen such as green fluorescent protein) and biotinylated peptide recognition units have an unexpected generic specificity. This allows such peptides to be used to screen libraries to identify classes of polypeptides containing WW domains that are similar but not identical to the peptides' target WW domains. These classes of polypeptides are identified despite the low level of homology at the amino acid level of the WW domains of the members of the classes.

In another specific embodiment, multivalent peptide recognition units may be in the form of multiple antigen peptides (MAP) (Tam, 1989, J. Imm. Meth. 124:53-61; Tam, 1988, Proc. Natl. Acad. Sci. USA 85:5409-5413). In this form, the peptide recognition unit is synthesized on a branching lysyl matrix using solid-phase peptide synthesis methods. Recognition units in the form of MAP may be prepared by methods known in the art (Tam, 1989, J. Imm. Meth. 124:53-61; Tam, 1988, Proc. Natl. Acad. Sci. USA 85:5409-5413), or, for example, by a stepwise solid-phase procedure on MAP resins (Applied Biosystems), utilizing methodology established by the manufacturer. MAP peptides may be synthesized comprising (recognition unit peptide)<sub>2</sub>Lys<sub>1</sub>, (recognition unit peptide)<sub>4</sub>Lys<sub>3</sub>, (recognition unit peptide)<sub>8</sub>Lys<sub>6</sub> or more levels of branching.

The multivalent peptide recognition unit complexes may also be prepared by cross-linking the peptide to a carrier protein, e.g., bovine serum albumin (BSA), keyhole limpet

hemocyanin (KLH) by use of known cross-linking reagents. Such cross-linked peptide recognition units may be detected by, e.g., an antibody to the carrier protein or detection of the enzymatic activity of the carrier protein.

5 Furthermore, the present inventors have discovered what specificity is exhibited by various types of recognition units and their complexes, i.e., where these recognition units and their complexes fall in the specificity continuum. The present inventors have discovered a range of formats for  
10 presenting recognition units used to screen libraries. Monovalent peptides, for example, synthesized peptides themselves, are non-specific. A peptide in the form of a bivalent fusion protein with alkaline phosphatase is very specific. The same peptide in the form of a fusion protein  
15 with the pIII protein of an M13 derived bacteriophage, expressed on the phage surface, has somewhat less, though still high, specificity. That same peptide when biotinylated in the form of a tetravalent streptavidin-alkaline phosphatase complex has generic specificity. Use of such a generically  
20 specific peptide permits the identification of a wide range of proteins from expression libraries or other sources of polypeptides, each protein containing an example of a particular WW domain.

Accordingly, the present invention provides a method of  
25 modulating the specificity of a peptide such that the peptide can be used as a recognition unit to screen a plurality of polypeptides, thus identifying polypeptides that have a WW domain. In a specific embodiment, specificity is generic so as to provide for the identification of polypeptides having a  
30 WW domain that varies in sequence from that of the target WW domain known to bind the recognition unit under conditions of high specificity. In a particular embodiment, the method comprises forming a tetravalent complex of the biotinylated peptide and streptavidin-alkaline phosphatase prior to use for  
35 screening an expression library.

### 5.3. KITS

The present invention is also directed to an assay kit which can be useful in the screening of drug candidates. In a particular embodiment of the present invention, an assay kit  
5 is contemplated which comprises in one or more containers (a) a polypeptide containing a WW domain; and (b) a recognition unit having a selective affinity for the polypeptide. The kit optionally further comprises a detection means for determining the presence of a polypeptide-recognition unit interaction or  
10 the absence thereof.

In a specific embodiment, either the polypeptide containing the WW domain or the recognition unit is labeled. A wide range of labels can be used to advantage in the present invention, including but not limited to conjugating the  
15 recognition unit to biotin by conventional means. Alternatively, the label may comprise, e.g., a fluorogen, an enzyme, an epitope, a chromogen, or a radionuclide. Preferably, the biotin is conjugated by covalent attachment to either the polypeptide or the recognition unit. The  
20 polypeptide or, preferably, the recognition unit is immobilized on a solid support. The detection means employed to detect the label will depend on the nature of the label and can be any known in the art, e.g., film to detect a radionuclide; an enzyme substrate that gives rise to a  
25 detectable signal to detect the presence of an enzyme; antibody to detect the presence of an epitope, etc.

A further embodiment of the assay kit of the present invention includes the use of a plurality of polypeptides, each polypeptide containing a WW domain. The assay kit  
30 further comprises at least one recognition unit having a selective affinity for each of the plurality of polypeptides and a detection means for determining the presence of a polypeptide-recognition unit interaction or the absence thereof.

35 A kit is provided that comprises, in one or more containers, a first molecule comprising a WW domain and a second molecule that binds to the WW domain, i.e., a

recognition unit, where the WW domain is a novel WW domain identified by the methods of the present invention.

In the above assay kit, the polypeptide may comprise an amino acid sequence selected from the group consisting of SEQ  
5 ID NOs: 12-28 and 29. The polypeptide also may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 46, 48, 50, 126, 30-38, and 127-129.

In other embodiments of the above-described assay kit, the recognition unit may be a peptide. The recognition unit  
10 may be labeled with e.g., an enzyme, an epitope, a chromogen, or biotin.

The present invention also provides an assay kit comprising in one or more containers:

(a) a plurality of purified different polypeptides, each  
15 polypeptide in a separate container and each polypeptide containing a WW domain; and

(b) at least one peptide having a selective affinity for the WW domain in each of said plurality of polypeptides, which optionally, if present as more than one peptide, each peptide  
20 can also be in a separate container.

The present invention also provides a kit comprising a plurality of purified polypeptides comprising a WW domain, each polypeptide in a separate container, and each polypeptide having a WW domain of a different sequence but capable of  
25 displaying the same binding specificity (binding to the same molecule under appropriate conditions).

In the above-described kits, the polypeptides may have an amino acid sequence selected from the group consisting of: SEQ ID NOs: 12-28 and 29. The polypeptides also may have an amino  
30 acid sequence selected from the group consisting of: SEQ ID NOs: 46, 48, 50, 126, 30-38, and 127-129.

The molecular components of the kits are preferably purified.

The kits of the present invention may be used in the  
35 methods for identifying new drug candidates and determining the specificities thereof that are described in Section 5.4.

#### 5.4. ASSAYS FOR THE DISCOVERY OF POTENTIAL DRUG CANDIDATES AND DETERMINING THE SPECIFICITY THEREOF

The present invention also provides methods for identifying potential drug candidates (and lead compounds) and determining the specificities thereof. For example, knowing  
5 that a polypeptide containing a WW domain and a recognition unit, e.g., a binding peptide, exhibit a selective affinity for each other, one may attempt to identify a drug that can exert an effect on the polypeptide-recognition unit  
10 interaction, e.g., either as an agonist or as an antagonist (inhibitor) of the interaction. With this assay, then, one can screen a collection of candidate "drugs" for the one exhibiting the most desired characteristic, e.g., the most efficacious in disrupting the interaction or in competing with  
15 the recognition unit for binding to the polypeptide.

Alternatively, one may utilize the different selectivities that a particular recognition unit may exhibit for different polypeptides bearing the same, similar, or functionally equivalent WW domains. Thus, one may tailor the  
20 screen to identify drug candidates that exhibit more selective activities directed to specific polypeptide-recognition unit interactions, among the "panel" of possibilities. Thus, for example, a drug candidate may be screened to identify the presence or absence of an effect on particular binding  
25 interactions, potentially leading to undesirable side effects.

In one embodiment, the effect of the drug candidate upon multiple, different interacting polypeptide-recognition unit pairs is determined in which at least some of said  
30 polypeptides have a WW domain that differs in sequence but is capable of displaying the same binding specificity as the WW domain in another of said polypeptides.

In another embodiment, at least one of said at least one polypeptide or recognition unit contains a consensus WW domain and consensus recognition unit, respectively.

35 In another embodiment, the drug candidate is an inhibitor of the polypeptide-recognition unit interaction that is identified by detecting a decrease in the binding of



polypeptide to recognition unit in the presence of such inhibitor.

In another embodiment, said polypeptide is a polypeptide containing a WW domain produced by a method comprising:

- 5 (i) screening a peptide library with a WW domain to obtain one or more peptides that bind the WW domain;
- (ii) using one of the peptides from step (i) to screen a source of polypeptides to identify one or more polypeptides containing a WW domain;
- 10 (iii) determining the amino acid sequence of the polypeptides identified in step (ii); and
- (iv) producing the one or more novel polypeptides containing a WW domain.

In another embodiment, said polypeptide is a polypeptide 15 containing a WW domain produced by a method comprising:

- (i) screening a peptide library with a WW domain to obtain a plurality of peptides that bind the WW domain;
- (ii) determining a consensus sequence for the peptides obtained in step (i);
- 20 (iii) producing a peptide comprising the consensus sequence;
- (iv) using the peptide comprising the consensus sequence to screen a source of polypeptides to identify one or more polypeptides containing a WW domain;
- 25 (v) determining the amino acid sequence of the polypeptides identified in step (iv); and
- (vi) producing the one or more polypeptides containing a WW domain.

In a preferred embodiment, the effect of the drug 30 candidate upon multiple, different interacting polypeptide-recognition unit pairs is determined in which preferably at least some (e.g., at least 2, 3, 4, 5, 7, or 10) of said polypeptides have WW domains that vary in sequence yet are capable of displaying the same binding specificity, i.e., 35 binding to the same recognition unit. In another specific embodiment, at least one of said polypeptides and/or recognition units contains a consensus WW domain and

recognition unit, respectively (and thus are not known to be naturally expressed proteins). In another embodiment, the polypeptide is a novel polypeptide identified by the methods of the present invention. In a specific embodiment, an  
5 inhibitor of the polypeptide-recognition unit interaction is identified by detecting a decrease in the binding of polypeptide to recognition unit in the presence of such inhibitor.

A common problem in the development of new drugs is that  
10 of identifying a single, or a small number, of compounds that possess a desirable characteristic from among a background of a large number of compounds that lack that desired characteristic. This problem arises both in the testing of compounds that are natural products from plant, animal, or  
15 microbial sources and in the testing of man-made compounds. Typically, hundreds, or even thousands, of compounds are randomly screened by the use of *in vitro* assays such as those that monitor the compound's effect on some enzymatic activity, its ability to bind to a reference substance such as a  
20 receptor or other protein, or its ability to disrupt the binding between a receptor and its ligand.

The compounds which pass this original screening test are known as "lead" compounds. These lead compounds are then put through further testing, including, eventually, *in vivo*  
25 testing in animals and humans, from which the promise shown by the lead compounds in the original *in vitro* tests is either confirmed or refuted. See Remington's Pharmaceutical Sciences, 1990, A.R. Gennaro, ed., Chapter 8, pages 60-62, Mack Publishing Co., Easton, PA; Ecker and Crooke, 1995,  
30 *Bio/Technology* 13:351-360.

There is a continual need for new compounds to be tested in the *in vitro* assays that make up the first testing step described above. There is also a continual need for new assays by which the pharmacological activities of these  
35 compounds may be tested. It is an object of the present invention to provide such new assays to determine whether a candidate compound is capable of affecting the binding between

a polypeptide containing a WW domain and a recognition unit that binds to that WW domain. In particular, it is an object of the present invention to provide polypeptides, particularly novel ones, containing WW domains and their corresponding  
5 recognition units for use in the above-described assays. The use of these polypeptides greatly expands the number of assays that may be used to screen potential drug candidates for useful pharmacological activities (as well as to identify potential drug candidates that display adverse or undesirable  
10 pharmacological activities).

In one embodiment of the present invention, such polypeptides are identified by a method comprising: using a recognition unit that is capable of binding to a predetermined WW domain to screen a source of polypeptides, thus identifying  
15 novel polypeptides containing the WW domain or a similar WW domain.

In a particular embodiment of the above-described method, the novel polypeptide containing a WW domain is obtained by:

- (i) screening a peptide library with the WW domain to  
20 obtain one or more peptides that bind the WW domain;
- (ii) using one of the peptides from step (i), preferably in the form of a multivalent complex, to screen a source of polypeptides to identify one or more novel polypeptides containing WW domains;
- 25 (iii) determining the amino acid sequence of the polypeptides identified in step (ii); and
- (iv) producing the one or more novel polypeptides containing WW domains.

In another embodiment of the above-described method, the  
30 novel polypeptide containing a WW domain is obtained by:

- (i) screening a peptide library with the WW domain to obtain peptides that bind the WW domain;
- (ii) determining a consensus sequence for the peptides obtained in step (i);
- 35 (iii) producing a peptide comprising the consensus sequence;

(iv) using the peptide comprising the consensus sequence to screen a source of polypeptides to identify one or more novel polypeptides containing WW domains;

(v) determining the amino acid sequence of the novel  
5 polypeptides identified in step (iv); and

(vi) producing the one or more novel polypeptides containing WW domains.

One of ordinary skill in the art will recognize that it will not always be necessary to utilize the entire novel  
10 polypeptide containing the WW domain in the assays described herein. Often, a portion of the polypeptide that contains the WW domain will be sufficient, e.g., a glutathione S-transferase (GST)-WW domain fusion protein. See Figure 5 for a depiction of the portions of the exemplary novel  
15 polypeptides that contain WW domains.

A typical assay of the present invention consists of at least the following components: (1) a molecule (e.g., protein or polypeptide) comprising a WW domain; (2) a recognition unit that selectively binds to the WW domain; (3) a candidate  
20 compound, suspected of having the capacity to affect the binding between the protein containing the WW domain and the recognition unit. The assay components may further comprise (4) a means of detecting the binding of the protein comprising the WW domain and the recognition unit. Such means can be  
25 e.g., a detectable label affixed to the protein comprising the WW domain, the recognition unit, or the candidate compound. In a specific embodiment, the protein comprising the WW domain is a novel protein discovered by the methods of the present invention.

30 In another specific embodiment, the invention provides a method of identifying a compound that affects the binding of a molecule comprising a WW domain and a recognition unit that selectively binds to the WW domain comprising:

(a) contacting the molecule comprising the WW domain and  
35 the recognition unit under conditions conducive to binding in the presence of a candidate compound and measuring the amount of binding between the molecule and the recognition unit;

(b) comparing the amount of binding in step (a) with the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound, where a difference in the amount of  
5 binding between step (a) and the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound indicates that the candidate compound is a compound that affects the binding of the molecule comprising a WW domain and the recognition  
10 unit. In a specific embodiment, the compound is not a peptide.

In another specific embodiment, the invention provides a method of identifying a compound that affects the binding of a molecule comprising a WW domain and a recognition unit that  
15 selectively binds to the WW domain comprising:

(a) contacting the molecule comprising the WW domain and the recognition unit under conditions conducive to binding in the presence of a candidate compound and measuring the amount of binding between the molecule and the recognition unit in  
20 which the WW domain has an amino acid sequence selected from the group consisting of SEQ ID NOs:30-37 and 38;

(b) comparing the amount of binding in step (a) with the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the  
25 candidate compound, where a difference in the amount of binding between step (a) and the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound indicates that the candidate compound is a compound that affects the binding  
30 of the molecule comprising a WW domain and the recognition unit.

In one embodiment, the assay comprises allowing the polypeptide containing a WW domain to contact a recognition unit that selectively binds to the WW domain in the presence  
35 and in the absence of the candidate compound under conditions such that binding of the recognition unit to the polypeptide containing a WW domain will occur unless that binding is

disrupted or prevented by the candidate compound. By detecting the amount of binding of the recognition unit to the polypeptide containing a WW domain in the presence of the candidate compound and comparing that amount of binding to the amount of binding of the recognition unit to the polypeptide containing a WW domain in the absence of the candidate compound, it is possible to determine whether the candidate compound affects the binding and thus is a useful lead compound for the modulation of the activity of polypeptides containing the WW domain. The effect of the candidate compound may be to either increase or decrease the binding.

One version of an assay suitable for use in the present invention comprises binding the polypeptide containing a WW domain to a solid support such as the wells of a microtiter plate. The wells contain a suitable buffer and other substances to ensure that conditions in the wells permit the binding of the polypeptide containing a WW domain to its recognition unit. The recognition unit and a candidate compound are then added to the wells. The recognition unit is preferably labeled, e.g., it might be biotinylated or labeled with a radioactive moiety, or it might be linked to an enzyme, e.g., alkaline phosphatase. After a suitable period of incubation, the wells are washed to remove any unbound recognition unit and compound. If the candidate compound does not interfere with the binding of the polypeptide containing a WW domain to the labeled recognition unit, the labeled recognition unit will bind to the polypeptide containing a WW domain in the well. This binding can then be detected. If the candidate compound interferes with the binding of the polypeptide containing a WW domain and the labeled recognition unit, label will not be present in the wells, or will be present to a lesser degree than is the case when compared to control wells that contain the polypeptide containing a WW domain and the labeled recognition unit but to which no candidate compound is added. Of course, it is possible that the presence of the candidate compound will increase the binding between the polypeptide containing a WW domain and the

labeled recognition unit. Alternatively, the recognition unit can be affixed to a solid substrate during the assay.

In a specific embodiment of the above-described method, the polypeptide containing a WW domain is a novel polypeptide containing a WW domain that has been identified by the methods of the present invention.

**5.5. USE OF POLYPEPTIDES CONTAINING WW DOMAINS  
TO DISCOVER POLYPEPTIDES INVOLVED IN  
PHARMACOLOGICAL ACTIVITIES**

Using the methods of the present invention, it is possible to identify and isolate large numbers of polypeptides containing WW domains. Using these polypeptides, one can construct a matrix relating the polypeptides to an array of candidate drug compounds. For example, Table 1 shows such a matrix.

TABLE 1

	A	B	C	D	E	F	G	H	I	J
1										
20 2		X		X				X		
3										
4										
5						X				
25 6										
7			X					X		
8										
9	X									
30 10										

In Table 1, the columns headed by letters at the top of the table represent different polypeptides containing WW domains (preferably novel polypeptides identified by the methods of the invention). The rows numbered along the left side of the table represent recognition units with various specificity to WW domains. For each candidate drug compound,

a table such as Table 1 is generated from the results of binding assays. An X placed at the intersection of a particular numbered row and lettered column represents a positive assay for binding, i.e., the candidate drug compound affected the binding of the recognition unit of that particular row to the WW domain of that particular column.

Such data as that illustrated above is used to determine whether novel polypeptides or other molecules display or are at risk of displaying desirable or undesirable physiological or pharmacological activities. For example, in Table 1, the drug compound inhibits the binding of recognition unit 2 to the WW domains of polypeptides B, D, and H; the compound inhibits the binding of recognition unit 5 to the WW domain of polypeptide F; the compound inhibits the binding of recognition unit 7 to the WW domains of polypeptides C and H; and the compound inhibits the binding of recognition unit 9 to the WW domain of polypeptide A.

If interaction with polypeptide H leads to the desirable physiological or pharmacological activity, then this drug candidate might be a good lead. However, interaction with polypeptides A, B, C, D, and F would need to be evaluated for potential side effects.

As the maps are generated and pharmacological effects observed, the maps will allow strategic assessment of the specificity necessary to obtain the desired pharmacological effect. For example, if compounds 2 and 7 are able to affect some pharmacological activity, while compounds 5 and 9 do not affect that activity, then polypeptide H is likely to be involved in that pharmacological activity. For example, if compounds 2 and 7 were both able to inhibit mast cell degranulation, while compounds 5 and 9 did not, it is likely that polypeptide H is involved in mast cell degranulation.

Accordingly, the present invention provides a method of utilizing the polypeptides comprising WW domains of the present invention in an assay to determine the participation of those polypeptides in pharmacological activities.

In one embodiment, the method comprises:



(a) contacting a drug candidate with a molecule comprising a WW domain under conditions conducive to binding, and detecting or measuring any specific binding that occurs; and

- 5 (b) repeating step (a) with a plurality of different molecules, each comprising a different WW domain but capable of binding to a single predetermined recognition unit under appropriate conditions.

Preferably, at least one of said molecules is a novel  
10 polypeptide identified by the methods of the present invention.

The present invention also provides a method of determining the potential pharmacological activities of a molecule comprising:

- 15 (a) contacting the molecule with a compound comprising a WW domain under conditions conducive to binding;

(b) detecting or measuring any specific binding that occurs; and

- (c) repeating steps (a) and (b) with a plurality of  
20 different compounds, each compound comprising a WW domain of different sequence but capable of displaying the same binding specificity.

#### 5.6. USE OF MORE THAN ONE RECOGNITION UNIT SIMULTANEOUSLY

- 25 When screening a source of polypeptides with a recognition unit, it is possible to use more than one recognition unit at the same time. In a particular aspect, as many as five different recognition units may be used simultaneously to screen a source of polypeptides.

- 30 In particular, when the recognition units are biotinylated peptides and the source of polypeptides is a cDNA expression library, the steps of pre-conjugation of the biotinylated peptides to streptavidin-alkaline phosphatase as well as the steps involved in screening the cDNA expression  
35 library may be carried out in essentially the same manner as is done when a single biotinylated peptide is used as a recognition unit. See Section 6.1 for details. The key

difference when using more than one biotinylated peptide at a time is that the peptides are combined either before or at the step where they are placed in contact with the polypeptides from which selection occurs.

5 In an embodiment employing a bacteriophage expression library to express the polypeptides, when the positive clones are worked up to the level of isolated plaques, the clonal bacteriophage from the isolated plaques may be tested against each of the biotinylated peptides individually, in order to  
10 determine to which of the several peptides that were used as recognition units in the primary screen the phage are actually binding.

#### 5.7. USE OF RECOGNITION UNITS FROM 15 KNOWN AMINO ACID SEQUENCES

In many cases it may not be necessary to screen a collection of substances, e.g., a peptide library, in order to obtain a recognition unit for a given WW domain. In the case of peptide recognition units, for example, it is sometimes  
20 possible to identify a recognition unit by inspection of known amino acid sequences. Stretches of these amino acid sequences that resemble known binding sequences for the WW domain can be synthesized and screened against a source of polypeptides in order to obtain a plurality of polypeptides comprising the  
25 given WW domain. In one embodiment of the present invention, peptides from the proteins WBP-1 and WBP-2 (known to bind to the WW domain-containing protein YAP (Chen and Sudol, 1995, Proc. Natl. Acad. Sci. USA 92:7819-7823)) were used as recognition units.

30 Prior to the disclosure of the present invention of methods of preparing recognition units having generic specificity, it would have been thought fruitless to pursue this approach. The expectation would have been that a recognition unit, chosen from published amino acid sequences  
35 as described above, would have been useful, at best, to identify a single protein containing a WW domain and would

likely not have provided enough signal strength to differentiate positive binding from background.

**5.8. ISOLATION AND EXPRESSION OF NUCLEIC ACIDS  
ENCODING POLYPEPTIDES COMPRISING A WW DOMAIN**

5 In particular aspects, the invention provides amino acid sequences of polypeptides comprising WW domains, preferably human polypeptides, and fragments and derivatives thereof which comprise an antigenic determinant (i.e., can be  
10 recognized by an antibody) or which are functionally active, as well as nucleic acid sequences encoding the foregoing. "Functionally active" material as used herein refers to that material displaying one or more functional activities, e.g., a biological activity, antigenicity (capable of binding to an  
15 antibody) immunogenicity, or comprising a WW domain that is capable of specific binding to a recognition unit. In specific embodiments, the invention provides fragments of polypeptides comprising a WW domain consisting of at least 40 amino acids, or of at least 75 amino acids. Nucleic acids  
20 encoding the foregoing are provided.

In other specific embodiments, the invention provides nucleotide sequences and subsequences encoding polypeptides comprising a WW domain, preferably human polypeptides, consisting of at least 25 nucleotides, at least 50  
25 nucleotides, or at least 150 nucleotides. Nucleic acids encoding fragments of the polypeptides comprising a WW domain are provided, as well as nucleic acids complementary to and capable of hybridizing to such nucleic acids. In one embodiment, such a complementary sequence may be complementary  
30 to a cDNA sequence encoding a polypeptide comprising a WW domain of at least 25 nucleotides, or of at least 100 nucleotides. In a preferred aspect, the invention utilizes cDNA sequences encoding human polypeptides comprising a WW domain or a portion thereof.

35 Any eukaryotic cell can potentially serve as the nucleic acid source for the molecular cloning of polypeptides comprising a WW domain. The DNA may be obtained by standard

procedures known in the art (e.g., a DNA "library") by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 5 Cold Spring Harbor Laboratory, 2d. Ed., Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from 10 cDNA will contain only exon sequences. Whatever the source, the gene encoding a polypeptide comprising a WW domain should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from genomic DNA, 15 DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The 20 linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once a gene encoding a particular polypeptide comprising 25 a WW domain has been isolated from a first species, it is a routine matter to isolate the corresponding gene from another species. Identification of the specific DNA fragment from another species containing the desired gene may be accomplished in a number of ways. For example, if an amount 30 of a portion of a gene or its specific RNA from the first species, or a fragment thereof e.g., the WW domain, is available and can be purified and labeled, the generated DNA fragments from another species may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 35 1977, Science 196, 180; Grunstein, M. And Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72, 3961). Those DNA fragments with substantial homology to the probe will hybridize. In a

preferred embodiment, PCR using primers that hybridize to a known sequence of a gene of one species can be used to amplify the homolog of such gene in a different species. The amplified fragment can then be isolated and inserted into an expression or cloning vector. It is also possible to identify the appropriate fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection can be carried out on the basis of the properties of the gene. Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, *in vitro* aggregation activity ("adhesiveness") or antigenic properties as known for the particular polypeptide comprising a WW domain from the first species. If an antibody to that particular polypeptide is available, the corresponding polypeptide from another species may be identified by binding of labeled antibody to the putative polypeptide synthesizing clones in an ELISA (enzyme-linked immunosorbent assay)-type procedure.

Genes encoding polypeptides comprising a WW domain can also be identified by mRNA selection by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified DNA of genes encoding polypeptides comprising a WW domain of a first species. Immunoprecipitation analysis or functional assays (e.g., ability to bind to a recognition unit) of the *in vitro* translation products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies

specifically directed against polypeptides comprising a WW domain. A radiolabelled cDNA of a gene encoding a polypeptide comprising a WW domain can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The

5 radiolabelled mRNA or cDNA may then be used as a probe to identify the DNA fragments that represent the gene encoding the polypeptide comprising a WW domain of another species from among other genomic DNA fragments. In a specific embodiment, human homologs of mouse genes are obtained by methods

10 described above. In various embodiments, the human homolog is hybridizable to the mouse homolog under conditions of low, moderate, or high stringency. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl.

15 Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with

20 the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC,

25 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions

30 of low stringency which may be used are well known in the art (e.g., as employed for cross-species hybridizations).

By way of example and not limitation, procedures using conditions of high stringency are as follows:

Prehybridization of filters containing DNA is carried out for

35 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are

hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% 5 Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art.

The identified and isolated gene encoding a polypeptide 10 comprising a WW domain can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell 15 used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary 20 cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; 25 these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via 30 transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the 35 desired gene, for example, by size fractionization, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained  
5 in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleic acid coding for a polypeptide comprising a WW  
10 domain of the invention can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native gene  
15 encoding the polypeptide and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with  
20 virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized,  
25 any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of  
30 appropriate transcriptional/translational control signals operably linked to the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a protein or  
35 peptide fragment may be regulated by a second nucleic acid sequence so that the protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example,



expression of a protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control gene expression include, but are not limited to, the SV40 early promoter region (Benoist and  
5 Chambon, 1981, Nature 290, 304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22, 787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 1441-1445), the regulatory sequences of the  
10 metallothionein gene (Brinster et al., 1982, Nature 296, 39-42); prokaryotic expression vectors such as the  $\beta$ -lactamase promoter (Villa-Komaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75, 3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80, 21-25); see also  
15 "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242, 74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., Nature 303, 209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner, et al., 1981, Nucl.  
20 Acids Res. 9, 2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310, 115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase)  
25 promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38, 639-646; Ornitz et  
30 al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50, 399-409; MacDonald, 1987, Hepatology 7, 425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315, 115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984,  
35 Cell 38, 647-658; Adames et al., 1985, Nature 318, 533-538; Alexander et al., 1987, Mol. Cell. Biol. 7, 1436-1444), mouse mammary tumor virus control region which is active in

testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45, 485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1, 268-276), alpha-fetoprotein gene control region which is  
5 active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5, 1639-1648; Hammer et al., 1987, Science 235, 53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1, 161-171), beta-globin gene control region which is active in myeloid cells  
10 (Mogram et al., 1985, Nature 315, 338-340; Kollias et al., 1986, Cell 46, 89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48, 703-712); myosin light chain-2 gene control region which is active in skeletal muscle  
15 (Sani, 1985, Nature 314, 283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234, 1372-1378).

Expression vectors containing inserts of genes encoding polypeptides comprising a WW domain can be identified by three  
20 general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes  
25 comprising sequences that are homologous to the inserted gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype,  
30 occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the gene encoding a polypeptide comprising a WW domain is inserted within the marker gene sequence of the vector, recombinants containing the gene can be identified by the absence of the  
35 marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be

based, for example, on the physical or functional properties of the gene product in vitro assay systems, e.g., ability to bind to recognition units.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents.

In other specific embodiments, polypeptides comprising a WW domain, or fragments, analogs, or derivatives thereof may be expressed as a fusion, or chimeric protein product (comprising the polypeptide, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence

(of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper reading frame, and  
5 expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer.

10                   **5.8.1. IDENTIFICATION AND PURIFICATION  
                    OF THE EXPRESSED GENE PRODUCTS**

Once a recombinant which expresses the gene sequence encoding a polypeptide comprising a WW domain is identified, the gene product may be analyzed. This can be achieved by  
15 assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis.

Once the polypeptide comprising a WW domain is identified, it may be isolated and purified by standard  
20 methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay, including, but not  
25 limited to, binding to a recognition unit.

**5.9. DERIVATIVES AND ANALOGS OF  
      POLYPEPTIDES COMPRISING A WW DOMAIN**

The invention further provides derivatives (including but not limited to fragments) and analogs of polypeptides  
30 comprising a WW domain. In a specific embodiment, the derivative or analog is functionally active, i.e., capable of exhibiting one or more functional activities associated with a full-length, wild-type polypeptide, e.g., binding to a recognition unit. As one example, such derivatives or analogs  
35 may have the antigenicity of the full-length polypeptide.

In particular, derivatives can be made by altering gene sequences encoding polypeptides comprising a WW domain by substitutions, additions, or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a gene encoding a polypeptide comprising a WW domain may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of such genes which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a polypeptide comprising a WW domain including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence, resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Derivatives or analogs of genes encoding polypeptides comprising a WW domain include but are not limited to those polypeptides which are substantially homologous to the genes or fragments thereof, or whose encoding nucleic acid is capable of hybridizing to a nucleic acid sequence of the genes.

The derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned gene  
5 sequence can be modified by any of numerous strategies known in the art (Maniatis, T., 1989, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed  
10 by further enzymatic modification if desired, isolated, and ligated *in vitro*. PCR primers can be constructed so as to introduce desired sequence changes during PCR amplification of a nucleic acid encoding the desired polypeptide. In the production of the gene encoding a derivative or analog, care  
15 should be taken to ensure that the modified gene remains within the same translational reading frame, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the sequence of the genes encoding  
20 polypeptides comprising a WW domain can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro*  
25 modification. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., 1978, J. Biol. Chem 253:6551), use of TAB® linkers (Pharmacia, Piscataway, NJ), etc.

30 Manipulations of the sequence may also be made at the protein level. Included within the scope of the invention are protein fragments or other derivatives or analogs which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation,  
35 derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications

may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,  $\text{NaBH}_4$ ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

In addition, analogs and derivatives can be chemically synthesized. For example, a peptide corresponding to a portion of a polypeptide comprising a WW domain can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, designer amino acids such as  $\beta$ -methyl amino acids,  $\text{C}\alpha$ -methyl amino acids, and  $\text{N}\alpha$ -methyl amino acids.

#### 20 5.10. ANTIBODIES TO POLYPEPTIDES COMPRISING A WW DOMAIN

According to one embodiment, the invention provides antibodies and fragments containing the binding domain thereof, directed against polypeptides comprising a WW domain. Accordingly, polypeptides comprising a WW domain, fragments, analogs, or derivatives thereof, in particular, may be used as immunogens to generate antibodies against such polypeptides, fragments, analogs, or derivatives. Such antibodies can be polyclonal, monoclonal, chimeric, single chain, Fab fragments, or from an Fab expression library. In a specific embodiment, antibodies specific to the WW domain of a polypeptide comprising a WW domain may be prepared.

Various procedures known in the art may be used for the production of polyclonal antibodies. In a particular embodiment, rabbit polyclonal antibodies to an epitope of a polypeptide comprising a WW domain, or a subsequence thereof, can be obtained. For the production of antibody, various host animals can be immunized by injection with the native

polypeptide comprising a WW domain, or a synthetic version, or fragment thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.

For preparation of monoclonal antibodies, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256, 495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4, 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) may be used.

Antibody fragments which contain the idiotype (binding domain) of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the  $F(ab')_2$  fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay).



## 6. EXAMPLES

### 6.1. IDENTIFICATION OF GENES FROM cDNA EXPRESSION LIBRARIES USING RECOGNITION UNITS DERIVED FROM WBP-1, WBP-2, ENaCB, and ENaCy

5 A study was initiated to determine whether peptide  
recognition units could recognize WW domains that are the same  
as or similar to their target WW domain but that are contained  
in proteins other than the protein containing their target WW  
domain. Such "functional" screens, using recognition units of  
relatively small size, were not previously known and are  
10 difficult to develop because of the low degree of sequence  
homology among WW domain-containing proteins. Thus, for  
example, an oligonucleotide probe could not be designed with  
any degree of confidence based on the low degree of homology  
of primary sequences of WW domains.

15 A 16 day mouse embryo cDNA expression library from  
Novagen (Madison, WI) was screened using as a recognition unit  
synthetic peptides based upon the sequences of the YAP WW  
domain binding proteins WBP-1 and WBP-2 (Chen and Sudol, 1995,  
Proc. Natl. Acad. Sci. USA 92:7819-7823). The YAP peptides  
20 were chosen as a result of a search of the Swiss-Protein  
database for sequences that resembled the PPPPY (SEQ ID NO:3)  
consensus motif for WW binding peptides. The 16 day mouse  
embryo cDNA expression library was screened with these  
recognition units and clones were isolated that expressed  
25 mouse Nedd-4 and mouse YAP.

The peptide recognition units that were used were:

TP = biotin-HPGTPPPPYTVGP (SEQ ID NO:6)

YP = biotin-PGYPPPPPEFY (SEQ ID NO:7)

QP = biotin-YVQPPPPYPGPM (SEQ ID NO:8)

30 Screening of the library, including biotinylation of the  
peptide recognition units and their complexation with  
streptavidin-alkaline phosphatase, was as follows.

The 16 day mouse embryo cDNA expression library was  
diluted 1:1000 in SM solution (100 mM NaCl, 8 mM MgSO<sub>4</sub>, 50 mM  
35 Tris HCl pH 7.5, 0.01% gelatin). To a sterile test tube, 2  $\mu$ l  
of diluted mouse embryo library, 100  $\mu$ l of 10 mM CaCl<sub>2</sub>, 100  $\mu$ l

- of 10 mM  $MgCl_2$  and 100  $\mu$ l of BL21(DE3)pLysE bacterial cells (grown overnight) were added and incubated for 30 minutes at 37°C. The contents of the tube were mixed with 3 ml of 0.6% top agarose, containing 25 mg/ml chloramphenicol, and poured  
5 onto a 2xYT plate (90 mm diameter). For a large primary screen, 10-20 plates were prepared with  $3 \times 10^4$  pfu per plate. After 6 hours incubation at 37°C, a nitrocellulose filter soaked in 10 mM isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) was overlaid on each plate and incubated 3-6 hours at 37°C.
- 10 Before the filters were removed from the plates, they were marked asymmetrically with India ink in a 18 gauge syringe needle. The plates were stored at 4°C until ready for the secondary screen. The filters were washed with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM  $Na_2HPO_4$ , 1.4 mM  $KH_2PO_4$ )-0.05% Triton  
15 X-100 three times at room temperature, 15 minutes each wash, and then placed in a plastic bag containing non-specific blocking solution (PBS-2% BSA) for one hour. In the meantime, 1 ml of 1 mM biotinylated peptide in PBS-0.1% Tween 20 was added to 20 ml of 1 mg/ml streptavidin-alkaline phosphatase  
20 (SA-AP) in PBS-0.1% Tween 20 and incubated at 4°C for 30 minutes. As an alternative method of forming multivalent complexes, 50 pmol biotinylated peptide could have been incubated with 2  $\mu$ g SA-AP (for a biotin:biotin-binding site ratio of 1:1). Excess biotin-binding sites would then be  
25 blocked by addition of 500 pmol biotin. As a further alternative, 31.2  $\mu$ l of 1 mg/ml SA-AP could have been incubated with 15  $\mu$ l of 0.1 mM biotinylated peptide for 30 min at 4 °C. Ten  $\mu$ l of 0.1 mM biotin would then be added, and the solution incubated for an additional 15 min.
- 30 The preconjugated peptide recognition unit was introduced into the plastic bag containing the nitrocellulose filters and incubated overnight at room temperature. After three washes with PBS-0.1% Tween 20, the filters were incubated in 50 ml of 50 mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP), 100 ml  
35 of 50 mg/ml of dimethylformamide (DMF), and 15 ml of alkaline phosphatase buffer (0.1 M Tris-HCl, pH 9.4, 0.1 M NaCl, 50 mM  $MgCl_2$ ). Strong positive signals were evident in 5-10 minutes.

Positive plaques were cored with a Pasteur pipet from the petri plates that had been spread with the full cDNA library and left in 500  $\mu$ l of SM for 1 hour at room temperature or overnight at 4°C with a drop of chloroform present. Five microliters of a 1:100 dilution of the eluted phage were plated out for rescreening, with the intention of reducing the number of plaque forming units (pfu) by a factor of 10 (i.e.  $3 \times 10^4$  in the primary screen,  $3 \times 10^3$  in the secondary, etc.), until all the plaques were positive when screened.

10 After three rounds of screening, isolated positive plaques were obtained. The pEXlox plasmid was recovered from the recombinant lambda genomes of the isolated phage by cre-mediated excision in BM25.8 E. coli cells. For each lambda clone, 5  $\mu$ l of diluted phage (1:100 in SM) were added to a  
15 sterile test tube containing 100  $\mu$ l SM and 100  $\mu$ l of an overnight culture of BM25.8 cells. After 30 minutes incubation at 37°C, this mixture was spread on an 2xYT petri plate containing 100 mg/ml ampicillin and incubated overnight at 37°C. A single colony was picked from the plate,  
20 inoculated into 3 ml of 2xYT broth containing 100 mg/ml ampicillin and incubated overnight at 37°C. Plasmid DNA was isolated using a miniprep kit (Qiagen, Chatsworth, CA) and transformed into chemically competent DH5 $\alpha$ F' cells. At least two colonies were selected from each transformation, and grown  
25 in 3 ml of 2xYT broth containing 100 mg/ml ampicillin overnight. DNA was prepared as described above. To evaluate the size of the cDNA inserts in each plasmid, approximately 1/20 of each purified DNA sample was digested with EcoRI and HindIII to release the insert and resolved by agarose gel  
30 electrophoresis. DNA was sequenced by the dideoxy method with the T7 gene 10 oligonucleotide primer.

Five clones were identified and isolated when the cDNA library was screened with the peptide QP. The cDNA inserts of these clones were sequenced in order to identify them. A  
35 schematic diagram of these clones is shown in Figure 8. As can be seen in Figure 8, the screen with the QP peptide

identified 5 clones containing portions of the mouse Nedd-4 gene.

The cDNA library was also screened with a 1:1:1 mixture of the peptides TP, YP, and QP (SEQ ID NOS:6-8). Figure 9 shows that this screen identified 2 clones containing portions of the mouse YAP gene.

The method described above was also carried out using as recognition units the following synthetic peptides based upon sequences of the YAP WW domain-binding proteins WBP-1 and WBP-10 2:

WBP-1        biotin-SGSGPGTPPPPYTVGPGY (SEQ ID NO:9)

WBP-2A       biotin-SGSGYVQPPPPYPGPM (SEQ ID NO:10)

WBP-2B       biotin-SGSGPGTPYPPPPPEFY (SEQ ID NO:11)

The three peptides were biotinylated and complexed with 15 streptavidin-alkaline phosphatase as described above except for the WBP-1 peptide which was complexed with streptavidin-horseradish peroxidase. Detection of the bound peptides was as described above except for WBP-1, which was detected with the IBI enzygraphic™ Web (Kodak, New Haven, CT) as described 20 by the manufacturer. See Section 6.5. Alternatively, the TSA tyramide signal amplification system (DuPont, Wilmington, DE) could be used.

These three peptides were used as a mix to screen human bone marrow and brain cDNA libraries (Clontech, Palo Alto, 25 CA). Thirteen cDNA clones were identified and isolated. These clones represented three novel human genes, called WWP1, WWP2, and WWP3. WWP1 and WWP2 were isolated from both the brain and the bone marrow library; WWP3 was isolated from the brain library. Altogether, these three novel genes possessed 30 nine novel WW domains. Figure 10 shows a schematic diagram of these three novel WW domain-containing genes. The nucleotide and corresponding amino acid sequences of the inserts of the cDNA clones containing these novel genes were obtained. DNA was sequenced on both strands using PRISM DyeDeoxy Terminator 35 Cycle chemistry (Perkin/Elmer, Foster City, CA). These DNA sequences, as well as the corresponding amino acid sequences, are shown in Figures 16-21.

The method described above was also applied to screen a cDNA expression library generated from the LNCap Prostate Cancer Cell line using ENaC $\beta$  and ENaC $\gamma$  as recognition units. These recognition units are synthetic peptides that are based upon sequences of WW binding domains of the  $\alpha$  and  $\gamma$  subunits of Epithelial Na<sup>+</sup> Channel Protein.

ENaC $\beta$             biotin - PGTPPPNYDSLRL (SEQ ID NO:59)

ENaC $\gamma$            biotin - PGTPPPKYNTLRL (SEQ ID NO:60)

The two peptides were biotinylated and complexed with streptavidin-alkaline phosphatase as described above.

Detection of the band peptides was also as described above.

These two peptides were used as a mix to screen the human prostate library. This screen identified WWP1, described above, and a novel gene called WWP4, possessing three novel WW domains. Figure 10 shows a schematic diagram of this novel WW domain containing gene. The nucleotide and corresponding amino acid sequences of cDNA clones containing this novel gene were obtained. DNA was sequenced on both strands using PRISM DyeDeoxy Terminator Cycle chemistry (Perkin/Elmer, foster City, Ca). These DNA sequences, as well as the corresponding amino acid sequences, are shown in Figures 22 and 23, respectively.

From the cross affinity mapping data shown in Figures 15A and 15B, it can be seen that two or more WW domains in each of the proteins WWP1, WWP2, and WWP4 specifically bind to recognition units WBP-1, WBP-2A and WBP-2C but that none of the WW domains of these proteins specifically bind to WBP-2B. WWP3 specifically binds to recognition unit WBP-2A but not to WBP-1 or WBP-2B.

Based upon their possession of a HECT domain (See Figure 10 and Figure 14), three of the new genes (WWP1, WWP2, and WWP4) appear to be members of a family of proteins, including RSP5 and Nedd-4, that have ubiquitin-ligase activity. Two of the three genes, WWP1 and WWP2, possess four WW domains each. The third gene, WWP4, possesses three WW domains. The remaining novel gene, WWP3, possesses a single WW domain and

the N-terminal portion of a second, truncated WW domain. WWP3 also possesses a guanylate kinase-like region.

**6.1.1. NUCLEOTIDE AND CORRESPONDING AMINO ACID  
SEQUENCES OF NOVEL GENES IDENTIFIED FROM  
CDNA EXPRESSION LIBRARIES**

The nucleotide sequences of WWP1, WWP2, WWP3, and WWP4 are shown in Figures 16, 18A and 18B, and 20 and 22, respectively. The amino acid sequences of WWP1, WWP2, WWP3, and WWP4 are shown in Figures 17, 19, 21, and 23, respectively.

Figure 5 shows a comparison of the amino acid sequences of the four WW domains from WWP1, the four WW domains from WWP2, the three WW domains from WWP4 and the WW domain from WWP3, with the amino acid sequences of WW domains from a variety of known proteins. Alignment of the twelve novel WW domain sequences with several previously identified WW domains reveals two significant blocks of homology flanking the core of the domain. These blocks include an N-terminal tryptophan and a C-terminal proline residue that are absolutely conserved in all WW domains known to date. Also depicted is a consensus sequence based upon the various WW domain sequences shown. A single amino acid gap has been introduced in the amino acid sequence of the third WW domain of WWP2 (WWP2-3 in Figure 5) between positions 12 and 13 in order to maximize homology with the other WW domains.

In addition to the WW domains, primary sequence analysis of the novel clones revealed several other interesting structural features. Clones WWP2 and WWP4, contain a complete C-terminal HECT domain, and WWP1 contains a partial HECT domain at the carboxy terminus (Figure 10, Figure 14, and Figure 23). This domain has been shown to have *in vitro* E3 ubiquitin-protein ligase activity in the yeast Rsp5 and human papilloma virus E6-AP proteins and encodes a conserved cysteine residue within the last 40 amino acids that is the likely site for ubiquitin thioester formation (Huibregste et al., 1995, Proc. Natl. Acad. Sci. USA 92: 2563-2567). This is

noteworthy since structurally and functionally related E3 ubiquitin-protein ligases are thought to serve a major role in defining the substrate specificity of the ubiquitin degradation system (Ciechanover, 1994, Cell 79:13-21). In fact, Rsp5 was recently shown to be involved in the induced degradation of several nitrogen permeases in yeast (Hein et al, 1995, Mol. Microbiol. 18:77-87). WWP2 also encodes an N-terminal C2-like domain characteristic of a large family of proteins including protein kinase C (Kaibuchi et al., 1989, J. Biol. Chem. 264:13489-13496) and synaptotagmins (Sutton et al., 1995, Cell 80:929-938). The C2 domain has been shown to bind membrane phospholipids in a calcium-dependent manner, and is thought to function in the intracellular compartmentalization of proteins (Davletov and Südhof, 1993, J. Biol. Chem. 268:26386-26390). Although the various domains present within WWP1, WWP2, and WWP4 are highly homologous to those found in Nedd-4 and Rsp5, there is no significant homology among these proteins in regions flanking these domains, indicating they may have related but specific functions. Also of interest is the presence in clone WWP3 of an N-terminal guanylate kinase-like domain similar to those involved in GMP binding in several membrane-associated proteins including human erythrocyte membrane protein p55 (Ruff et al., 1991, Proc. Natl. Acad. Sci. USA 88:6595-6599) and rat presynaptic density protein (PSD-95) (Cho et al., 1992, Neuron 9:929-942).

#### **6.2. IDENTIFICATION OF RECOGNITION UNITS THAT BIND THE WW DOMAIN OF DYSTROPHIN AND SCREENING OF cDNA LIBRARY**

The WW domain of dystrophin was chosen as a target WW domain. Using this WW domain as a probe, a random peptide phage display library was screened in order to identify and isolate peptides that functioned as recognition units of the dystrophin WW domain. These recognition unit peptides were synthesized, biotinylated and used to screen a  $\lambda$ EXlox mouse 16

day embryo cDNA expression library (obtained from Novagen, Madison, WI).

The WW domain is located at the end of the central rod region of dystrophin, close to the cysteine-rich domain. A glutathione S-transferase (GST)-fusion protein containing this WW domain was prepared as follows. Two oligonucleotide primers were designed to flank the dystrophin WW domain: 5'-CTGTGCGGATCCAAGACCTGAACACCAGATGGA-3' (SEQ ID NO:40) and 5'-CTGTGCGAATTCCAAAGTCTCGAACAT-3' (SEQ ID NO:41).

- 10 Bam HI and Eco RI sites are underlined. The dystrophin WW domain was amplified through 24 cycles of the polymerase chain reaction (PCR). The 220 bp amplified fragment was purified with GeneClean (Bio 101, San Diego, CA) after agarose gel electrophoresis, digested with Bam HI and Eco RI, phenol-  
15 chloroform extracted, ethanol precipitated, and ligated into Bam HI and Eco RI digested pGEX-2T vector DNA (Pharmacia, Piscataway, NJ). E. coli (DH5 $\alpha$ F') cells were transformed with the ligated DNA and ampicillin resistant transformants were selected. Recombinants were verified by DNA sequencing.
- 20 Colonies of E. coli carrying the GST-dystrophin WW domain fusion protein were used to inoculate 50 ml of 2xYT medium containing 2% glucose and 100 mg/ml ampicillin. After growth overnight at 37°C, a 500 ml culture flask was inoculated with the cells; the cells were grown with vigorous aeration until  
25 the optical absorbance (590 nm) reached 0.6 to 0.8 optical units. To induce expression of the fusion protein, isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) was added to the culture to a final concentration of 0.1 mM. After 4-6 hours, the cells were transferred to centrifuge bottles, centrifuged at 7,700xg  
30 for 10 minutes at 4°C, and the pellet was resuspended in 25 ml of ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>). The cell suspension was then disrupted with sonication. Sonication was accomplished with short bursts, as over sonication leads to poorer yields. Triton X-100  
35 detergent was added to a final concentration of 1%, the lysate was mixed gently for 30 minutes at 4°C and then centrifuged at 12,000xg for 10 minutes. Two ml of glutathione Sepharose 4B



(Pharmacia, Piscataway, NJ), 50% slurry with PBS, was added to each 100 ml of the supernatant of the sonicated cell lysate. The mixture was incubated with gentle agitation at room temperature for 30 minutes. The mixture was then centrifuged at 500xg for 5 minutes to sediment the matrix and the supernatant was discarded. The pellet was washed with 10 volumes of PBS three times, centrifuged, and the bound GST-dystrophin WW domain fusion protein eluted with 1 ml of glutathione elution buffer (3.07 mg/ml glutathione, 100 mM NaCl, 50 mM Tris, pH 8.0) per ml volume of Sepharose. The fusion protein was partitioned from the beads by centrifugation at 500xg for 5 minutes. The amount of fusion protein recovered was estimated by the Bradford protein assay, and its purity was evaluated by 10% SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining.

The purified GST-dystrophin WW domain fusion protein was used to screen a random peptide phage display library. The library, termed CW1, was prepared as follows. Two oligonucleotides (see Figure 11) were synthesized, annealed, and converted into double-stranded DNA with Sequenase (US Biochemical Corp., Cleveland, OH) and deoxynucleotides according to published protocols (Kay et al., 1993, Gene 128:59-65). The oligonucleotides encoded random peptides with the codons NNS; N represents an equimolar mixture of A, C, G, and T; S corresponds to an equimolar mixture of C and G. The NNS coding scheme utilizes 32 codons to encode 20 amino acids; the number of codons for the amino acids is either one (C, D, E, F, H, I, K, L, M, N, Q, W, Y), two (A, G, P, V, T), or three (L, R, S). The assembled oligonucleotides were cleaved with the restriction enzymes XhoI and XbaI and ligated into a bacteriophage M13 vector, mBAX. The ligated DNA was introduced into E. coli JS5 by electroporation to generate a library of approximately  $10^9$  recombinants. The random peptides were displayed at the N terminus of mature pIII, in 3-5 copies per phage particle. Each phage particle of the CW1 library displays the sequence S(S/R) $X_{12}$ SRPT (SEQ ID NO:42) at

the N-terminus of mature pIII, where X represents any of the 20 amino acids.

The mBAX vector was created by generating cloning sites in gene III of the M13mp18 vector (Messing, J., 1991, Gene 100:3-12) in the manner of Fowlkes et al., 1992, Biotechniques 13:422-427. The mBAX vector displays a peptide sequence at the N-terminus of the mature pIII protein that encodes the epitope for the mouse monoclonal antibody 7E11 (see Figure 12); it includes the stop codon TAG in the coding region, which is suppressed in *E. coli* carrying suppressor tRNA gene mutations known as supE or supF. There are no other stop codons in the mBAX genome. The mBAX vector also carries a segment of the alpha fragment of  $\beta$ -galactosidase; bacterial cells expressing the omega fragment of  $\beta$ -galactosidase that are infected by a bacteriophage that expresses the alpha fragment convert the clear X-Gal substrate into an insoluble blue precipitate. Thus, plaques of such bacteriophage on such cells appear blue.

Recombinant mBAX molecules can be distinguished easily from non-recombinant molecules due to the TAG codon in the XhoI-XbaI segment in gene III of mBAX. When recombinants are generated by replacing the XhoI-XbaI fragment with oligonucleotides encoding random peptides, the recombinants can be grown in bacteria with (e.g., DH5 $\alpha$ F') or without (e.g., JS5) suppressor tRNA mutant genes. On the other hand, the non-recombinant mBAX molecules fail to produce plaques on bacterial lawns where the bacteria (e.g., JS5) lack such suppressor genes. This is because in JS5, the TAG codon serves as a stop codon to yield a truncated pIII molecule during translation; since pIII is an essential protein component of viable M13 viral particles, no plaques will form.

The GST-dystrophin WW domain fusion protein (3-10  $\mu$ g) was immobilized on the surface of a microtiter dish with 100  $\mu$ l of 100 mM NaHCO<sub>3</sub> (pH 8.5) for 1-3 hours at 25°C or overnight at 4°C. To minimize evaporation, the wells were sealed with Scotch tape. Next, the non-specific binding sites on the well surfaces were blocked with the addition of 150  $\mu$ l of 1.0%

bovine serum albumin (BSA) in 100 mM NaHCO<sub>3</sub> for 1-3 hours at 25°C or overnight at 4°C. The solution was discarded by inverting the plate and shaking out its contents; the residual liquid was removed by slapping the inverted plate on a mat of paper towels several times. The wells were washed several times with PBS-0.1% Tween 20 to remove unbound protein. Approximately 10<sup>12</sup> pfu of CW1 phage particles were added to 150 µl PBS-0.1% Tween 20 in each well and incubated at 25°C for 1-3 hours. The non-binding phage were washed away with excess PBS-0.1% Tween 20. Bound phage were eluted by adding 50 µl of 50 mM glycine-HCl (pH 2.0) to each well and incubating 5 minutes at 65°C. The solution was transferred to a new well containing 50 µl of 200 mM NaPO<sub>4</sub> buffer (pH 7.5) to neutralize the pH. This protocol represents one round of affinity selection, also termed "panning".

Before the next rounds of affinity selection, the phage recovered in the first round were amplified. To amplify the recovered phage, they were added to 200 µl of an overnight culture of F' E. coli (e.g. DH5αF'), and the mixture transferred to 5 ml of 2xYT. After incubation 6-8 hours at 37°C, the tubes were centrifuged and the supernatant transferred to a new tube. This supernatant was used in succeeding rounds of selection. To minimize proteolytic degradation of displayed peptides, the cultures were not incubated longer than 8 hours.

For rounds two and three, the target GST-dystrophin WW domain fusion protein was immobilized on microtiter wells as described above for the first round and 100 µl of culture supernatant (i.e., 10<sup>11</sup> - 10<sup>12</sup> pfu) was added to each well. The plate was incubated for 1-3 hours at 25°C. The non-binding phage were washed away and the bound phage were eluted and pH neutralized as described above. The recovered phage were used directly for a third round of screening.

To obtain individual plaques from the affinity selection experiments, the final solution containing recovered phage was serially diluted across a microtiter plate and pronged onto a bacterial lawn. The wells of a sterile microtiter plate were

individually filled with 80  $\mu$ l of PBS using a 12-channel multipipetter. Twenty microliters of recovered phage were added to the wells in column #1, mixed, and 20  $\mu$ l transferred to the adjacent wells in column #2. The serial dilutions were repeated five additional times. In this way, one may perform 6 separate 10-fold dilution series. A petri plate was prepared by adding 3 ml liquefied 1.2% top agar and 200  $\mu$ l of DH5 $\alpha$ F' cells from an overnight culture, 25  $\mu$ l of 20 mg/ml IPTG and 25  $\mu$ l of 20 mg/ml X-gal, and pouring over a 2xYT agar plate. After the surface of the plate hardened, a flame-sterilized 48-pronger was placed into the microtiter plate dilution series, and carefully rested onto the petri plate. The plaques were incubated overnight at 37°C. Individual plaques were cored and used to generate clonal phage stocks.

The inserts of the dystrophin WW domain-binding phage were sequenced via standard DNA sequencing techniques and the corresponding amino acid sequences of the inserts determined. Six of these peptides corresponding to the determined sequences were synthesized and biotinylated. The sequences of these peptides are shown below.

SLQWMDGVGWYME (SEQ ID NO:64)

RWAWDDGWMFGSV (SEQ ID NO:65)

SGLEGWYWERG WV (SEQ ID NO:66)

SIWEMGXDWARP (SEQ ID NO:67)

RMSWWEWEFGLG (SEQ ID NO:68)

SWGLDGWLVDGWS (SEQ ID NO:69)

These biotinylated peptides were complexed with streptavidin and used to screen a  $\lambda$ EXlox mouse 16 day embryo cDNA expression library (obtained from Novagen, Madison, WI) according to the methods of Section 6.1. In this way, cDNA clones expressing proteins capable of binding to these peptides were identified and isolated.

### 6.3. CROSS AFFINITY MAPPING

To determine the ligand preferences of the novel WW domain-containing clones described in Sections 6.1 and 6.1.1, as well as addressing the issue of whether peptides containing PPPPY (SEQ ID NO:3)-like motifs derived from a variety of proteins could also serve as recognition units and bind to these clones, a cross affinity mapping experiment was performed (Figures 15A-D). The peptides shown in Figures 15A-D were synthesized, biotinylated, complexed with streptavidin-alkaline phosphatase, and tested in an ELISA based assay for their ability to bind to the twelve individual novel WW domains of WWP1, WWP2, WWP3 and WWP4 which were expressed as GST fusion proteins. The ELISA based cross-affinity experiments were performed essentially as described by Sparks et al. (1996, Proc. Natl. Acad. Sci. 93:1540-1544) with the following modifications. Briefly, microtiter wells were coated with 1-5  $\mu$ g of fusion protein in 100 mM NaHCO<sub>3</sub>, blocked with SuperBlock TBS (Pierce) and washed four times with PBS, 0.05% Tween 20. Specific peptide-streptavidin/alkaline phosphatase complexes were added as above and unbound complexes washed five times with PBS, 0.05% Tween 20. Following addition of PNP substrate (p-nitrophenyl phosphate, Kirkegard & Perry Labs), peptide binding was quantitated after 30 min. at O.D. 405 nm. Relative binding measurements from three independent determinations were assigned to a scale as follows: O.D. units 0-0.5=(-), 0.5-1.0=(+), 1.0-2.0=(++), 2.0-3.0=(+++), >3.0=(++++). Peptide binding to human Fyn and Lyn SH3 and SH2 domains was assessed by a filter binding assay (see Section 6.1 and Sparks et al., 1996, Proc. Natl. Acad. Sci 93:1540-1544). Peptide sequences used in cross-affinity experiments correspond to segments of the following genes: RasGap (Database accession # P20936), AP-2 (P05549), p53BP-2 (U09582), IL-6R $\alpha$  (P22272), voltage-gated chloride channel CLCN5 (X91906), IL-2R $\gamma$  (D111086), RSV (D10652), HTLV-1 (D13784),  $\beta$ -dystroglycan (L19711), Formin (X53599), amiloride-sensitive epithelial Na<sup>+</sup> channel ENaC $\alpha$  (P37089), ENaC $\beta$  (X87159) and ENaC $\gamma$  (X87160), muscarinic acetylcholine receptor

M4 AChR (P08173), and c-Abl (P00522). Src and Crk SH3 binding peptide sequences were derived from a phage display random peptide library screen (Section 6.1 and Sparks et al., 1996, Proc. Natl. Acad. Sci. 93:1540-1544). Protein sequence  
5 homology searches were performed using BLAST (Altschul et al., 1990, J. Mol. Biol. 215:403-410) and PROFILES (Gribskov et al., 1987, Proc. Natl. Acad. Sci. 84:4355-4358) programs.

The results shown in Figures 15A and B demonstrate that the WBP-1, WBP-2A, and WBP-2C recognition unit peptides bound  
10 to several individual WW domains to varying degrees. However, only the WBP-2A recognition unit peptide bound to the WWP3 WW domain, suggesting that this domain may require additional determinants outside of the core PPPPY (SEQ ID NO:3) motif for peptide ligand binding. In addition, the WBP-2B peptide  
15 containing an N-terminal tyrosine residue, relative to the run of prolines, had no binding activity, indicating the necessity for a C-terminal tyrosine in the PPPPY (SEQ ID NO:3) motif. The relative importance of individual proline residues within the PPPPY (SEQ ID NO:3) motif for WW domain binding was  
20 assessed by alanine substitution variants for both the WBP-1 and WBP-2A peptides. All of the variants with the exception of the substitution at the third proline position (WBP-1-Pro3) in the PPPPY (SEQ ID NO:3) motif-retained binding activity to the WW domains present in clones WWP1 and WWP2, suggesting a  
25 critical role for the third proline residue. Additionally, substitution of the second proline residue of WBP-1 (WBP-1-Pro2) resulted in a loss of binding activity to the WW domains present in clone WWP4. Interestingly, substitution of the second proline residue (WBP-1-Pro2) did not abolish binding to  
30 WW domains WWP1.2 and WWP2.3. This was unanticipated in light of the results obtained for the binding of WBP-1 to the YAP WW domain in which both the second and third proline residues are crucial for binding (Chen and Sudol, 1995, Proc. Natl. Acad. Sci. USA 92:7819-7823). This finding suggests that WW domains  
35 WWP1.1 and WWP2.3 possess a more promiscuous binding specificity than the WW domains of WWP4 and the YAP WW domain.

Proline substitutions of the WBP-2A peptide indicate that the third proline residue (WBP-2A-Pro4) is absolutely essential for binding to WW domains in WWP1, WWP2, WWP3 and WWP4, whereas substitution of the second proline (WBP-2A-Pro3) is not.

Figures 15A-D and Figures 24A and B show that peptides containing PPPPY (SEQ ID NO:3) and PPPPY (SEQ ID NO:3)-like motifs found in a variety of regulatory proteins, including RasGap; AP-2 transcription factor; p53 binding protein-2 (p53BP-2); the renal chloride channel CLCN5; the interleukin receptors IL-2R, IL-6R, and IL-7R; dystrophin interacting molecule  $\beta$ -dystroglycan ( $\beta$ -dystroglycan-1 and  $\beta$  dystroglycan-2); the retroviral Gag proteins from HTLV-1 and RSV-1; EGR2; FIBNECT; MEL.AG; and Inscuteable; bound to WW domains from one or more of the four novel clones. A peptide from the  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits of the ENaC amiloride-sensitive Epithelial Na<sup>+</sup> channel also bound to WW domains from the novel clones (see Figures 24A and 24B). For descriptions of the proteins RasGap, AP-2, p53BP-2, IL-6R $\alpha$ , and the CLCN5 chloride channel, see Williams et al., 1988, Genes Dev. 2:1557-1569; Cho et al., 1992, Neuron 9:929-942; Iwabuchi et al., 1994, Proc. Natl. Acad. Sci. USA 91:6098-6102; Sugita et al., 1990, J. Exp. Med. 171:2001-2009; Trahey et al., 1988, Science 242:1697-1700; Helps, et al., 1995, FEBS Lett. 377:295-300; Lloyd et al., 1996, Nature 379:445-449. Interestingly, although all of these peptides displayed an ability to bind WW domains in general, differences in the specificity and relative binding were evident. In particular, of all the peptides tested, only the CLCN5 peptide showed appreciable binding to the WWP1.4 and WWP2.4 domains. The observation that PPPPY (SEQ ID NO:3) motif-containing peptides from several other proteins did not bind to any WW domain indicates that these interactions are specific and potentially biologically relevant.

Given the small size and high degree of sequence conservation of the WW domain, it is extraordinary that exquisite ligand selectivity is observed. The crystal structure of the human YAP WW domain and its peptide ligand

reveals that the hydrophobic residues Y188, L190 and W199 (see Figure 5) form a binding site in contact with the ligand (Macias et al., 1991, Nature: 382:646-649). In light of this data it is interesting to note that domains WWP1.4 and WWP2.4 which contain a C-terminal phenylalanine residue instead of a tryptophan display a more restrictive ligand binding preference. In addition, the presence of valine or isoleucine residues instead of L190 may also play a role in determining the distinct ligand specificity of the novel WW domains. The presence of multiple WW domains with distinct ligand specificities in WWP1, WWP2, and WWP4 suggests these proteins may bind to a broad range of cellular targets. Alternatively, multiple WW domains may confer additive binding affinity with target molecules that contain multiple PPPPY ligand motifs.

Of particular note is the demonstration that the HTLV-1 and RSV-1 peptides derived from Gag protein proline-rich "L domain" bind to several WW domains. L domain regions are highly conserved in retroviruses and have been shown to function in a positionally independent manner essential for retroviral budding (Parent et al., 1995, J. Virol. 69:5455-5460). Our results, coupled with a recent report demonstrating the interaction of the YAP WW domain to the L domain of RSV (Garnier et al., 1996, Nature 381:744-745), suggests a direct role for a WW domain(s)-Gag protein interaction in this process. The interaction of a  $\beta$ -dystroglycan peptide with several WW domains is also of interest.  $\beta$ -dystroglycan, which contains a C-terminal PPPPY (SEQ ID NO:3) motif, was previously shown to interact with the single WW domain present in dystrophin (Einbold et al., 1996, FEBS Lett. 384:1-8). Our results suggest that perhaps several different WW domain-containing proteins can interact with the  $\beta$ -dystroglycan C-terminal PPPPY (SEQ ID NO:3) motif.

Recently, a 12 amino acid proline-rich region of formin, a protein encoded by the mouse *limb deformity* locus (Woychik et al., 1985, Nature 318:36-40), was shown to bind to both SH3 and several novel WW domain-containing proteins (Chan et al. 1996, EMBO J. 15:1045-1054). Significantly, a peptide



encompassing the same proline-rich region of formin did not bind to any of our novel WW domains (Figures 15A, 15B, and 15D). Since this peptide does not contain a PPPPY (SEQ ID NO:3) motif, this suggests that the novel WW domains herein  
5 described, unlike those present in the formin-binding proteins, require PPPPY (SEQ ID NO:3) or a PPPPY (SEQ ID NO:3)-like motif for binding.

Taken together, the above observations suggest that interactions between the regulatory proteins discussed above  
10 and WW domain-containing proteins may play a role in the former's regulation *in vivo*. For example, given the likelihood that WWP1, WWP2, and WWP4 function as E3 ubiquitin-protein ligases, one could invoke a simple model whereby initial substrate specific recognition occurs via WW  
15 domain-substrate interaction followed by ubiquitin transfer and subsequent proteolysis.

The positive interaction of peptides containing PPPPY (SEQ ID NO:3)-like motifs derived from the  $\beta$  and  $\gamma$  subunits of the Epithelial Na<sup>+</sup> channel with WW domains found in clones  
20 WWP1, WWP2, WWP3 and WWP4 (See Figures 24A and 24B) is of particular medical interest. Recently, a number of mutations in both the  $\beta$  and  $\gamma$  subunits of the Epithelial Na<sup>+</sup> channel (ENaC) have been demonstrated in patients with an autosomal dominant form of hypertension characterized by elevated renal  
25 Na<sup>+</sup> reabsorption termed Liddle syndrome (Shimkets et al., 1994, Cell 79:407-414). Specifically, several nonsense mutations leading to the truncation of the cytoplasmic domain of both subunits. Additionally, two missense mutations in the  $\beta$  subunit which change the PPPNY motif to PPLNY (labeled  
30 P616L) or to PPPNH (Y618H) in codons 616 and 618 of the  $\beta$  subunit contained within a conserved proline-rich segment of the cytoplasmic domain have been identified (Schild et al., 1995, Proc. Natl. Acad. Sci. 92:5699-5703; Hansson et al., 1995, Proc. Natl. Acad. Sci., 92:11495-11499; and Tamura et  
35 al., 1996, Clin. Invest. 97:1780-1784). These mutations result in a 3 to 8-fold increase in Na<sup>+</sup> channel activity, reflected in an increase in the total number of active

channels. These results suggest that cytoplasmic segments of the  $\beta$  and  $\gamma$  subunits are involved in the normal negative regulation of channel activity via interactions with modulatory protein(s). In fact, Nedd-4 was recently  
5 identified as a binding partner to the C-terminus of the rat ENaC $\beta$  subunit using the two yeast hybrid system (Staub et al., 1996, EMBO J. 15:2371-2380; and Schild et al., 1996, EMBO J. 15:2381-2387). In addition, as discussed infra, using peptides corresponding to ENaC $\beta$  and ENaC  $\delta$  subunits we have  
10 isolated WWP1 and WWP4.

Our observation that mutant peptides (ENaC $\beta$ -P616L and ENaC $\beta$ -Y618H) containing missense substitutions found in Liddle syndrome patients do not bind to the WW domains in clones WWP1, WWP2 and WWP4 (See Figures 24A and 24B) is consistent  
15 with the above hypothesis. This result also confirms the observation that the third proline residue and the tyrosine within the PPPPY (SEQ ID NO:3) motif is critical for binding to the WW domain. Other substitutions of the  $\beta$  subunit PPPPY (SEQ ID NO:3) motif and flanking sequences were also shown to  
20 diminish binding to specific WW domains. Thus substitution of the second proline residue of the core PPPPY (SEQ ID NO:3) motif completely abrogated WW domain binding. In addition, mutation of specific residues flanking the C-terminus of the PPPPY (SEQ ID NO:3) motif also led to diminished WW domain  
25 binding. These results directly correlate with the activity of various ENaC $\beta$  mutants measured by a functional assay in *Xenopus* oocytes (Snyder et al., 1995, Cell 83:969-978). A PPPPY (SEQ ID NO:3) motif containing peptide from the cytoplasmic domain of the  $\alpha$  subunit of ENaC (ENaC $\alpha$ -WT) was  
30 also shown to bind to several WW domains suggesting that this subunit may also be regulated by a WW domain-mediated interaction(s). Taken together, the above observations suggest a direct mechanism whereby a WW domain-mediated interaction(s) of a Nedd-4 family member(s) leads to the  
35 eventual ubiquitin mediated degradation and negative regulation of the Na<sup>+</sup> channel and may lead to an understanding of the molecular pathology of Liddle Syndrome.

Figures 26A and 26B present a schematic model of the mechanism by which WW domain mediated interactions of a Nedd-4 family member may lead to negative regulation of the Na<sup>+</sup> channel and how mutations associated with Liddle's Syndrome result in a loss of this negative regulation, thereby increasing the number of active Na<sup>+</sup> channels in the affected individual when compared to normal individuals. According to this model, Nedd-4 like proteins containing WW domains bind to the wild type Epithelial Na<sup>+</sup> channel protein, thereby bringing the HECT domain into the vicinity of the protein where it can mediate ubiquitin tagging of the protein. The ubiquitin tag signals that the protein is to be degraded. This allows for the natural turn-over of the channel protein. However, in Liddle syndrome, the WW Nedd-4 like protein cannot bind to the channel protein due to the missing or mutated proline-rich regions of the channel protein. The protein does not get tagged by ubiquitin and is not degraded. This results in an overexpression of the channel protein in Liddle syndrome patients.

The specificity of individual WW domains for a PPPPY (SEQ ID NO:3)-like motif sequence is demonstrated by the ability to discriminate between peptides containing SH3 domain consensus PXXP (SEQ ID NO:44) ligand sequences (Figure 15, Src and Crk entries) as well as generally proline-rich peptides control peptides derived from several proteins including the muscarinic acetylcholine receptor (M4 AChR) and c-Abl. In addition, none of the PPPPY (SEQ ID NO:3)-like motif peptides bound to either Fyn or Lyn, which contain both SH3 and SH2 domains. Taken together, these results suggest that the PPPPY (SEQ ID NO:3) motif represents a distinct binding sequence for WW modular protein domains.

To examine the ligand preferences of the PPPPY (SEQ ID NO:3)-like motif contained in the HECT domain of WWP2 and WWP4, methods as set forth in Section 6.1 *infra* were followed to biotinylate and assay peptides corresponding to these motifs. Peptides corresponding to the wild-type PPPPY-like domain of WWP2 and WWP4 were designated bWW061 and bWW059,

respectively. Alanine substitution peptide variants of the tyrosine residue of the PPPPY-like domains of WWP2 and WWP4 were designated bWW062 and bWW060, respectively. The results shown in Figure 25 demonstrate that the peptides corresponding 5 to the PPPPY-like motif in the HECT domains of both WWP4 and WWP2 bind to individual WW domains in WWP1, WWP2 and WWP4. Noticeably, the peptide corresponding to the PPPPY-like motif in the WWP4 HECT domain binds to the individual WW domains of WWP1.1, WWP1.4, WWP2.1, WWP2.2, WW2.4 (O.D. after 30 minutes 10 at 405 nm was 3.0), WWP4.1, WWP4.2, and WWP4.3. The observation that alanine substitution of the tyrosine in the HECT domain PPPPY-like motifs of both WWP2 and WWP4 abolished binding activity to the WW domains of WWP1, WWP2, and WWP4, suggests that this tyrosine plays a critical role in the 15 binding interaction between the HECT domain PPPPY-like motif and the WW domains.

The presence of a critical tyrosine residue in the PPPPY (SEQ ID NO:3) motif raises the question of whether tyrosine phosphorylation can modulate WW domain binding. Although it 20 is not known whether PPPPY (SEQ ID NO:3) motifs are phosphorylated *in vivo*, the present inventors have observed that the presence of a phosphotyrosine residue in the pWBP-1 peptide (indicated by a lower case "p" in Figures 15A and 15B) abolishes binding to WWP1, WWP2 and WWP4. Moreover, binding 25 of the pWBP-1 peptide could be restored by removal of the phosphate moiety either with prior treatment of the free peptide or peptide bound to a streptavidin-HRP conjugate with alkaline phosphatase. These results demonstrate a potential regulatory role for tyrosine phosphorylation in modulating WW 30 domain-ligand interactions.

The interaction of peptides containing PPPPY (SEQ ID NO:3) and PPPPY (SEQ ID NO:3)-like motifs from several proteins with the WW domains in clones WWP1 and WWP2 suggests a role for ubiquitin-mediated degradation of these proteins. 35 In this respect, it is noteworthy that several cell membrane proteins including the PDGF receptor and yeast  $\alpha$  factor receptor Ste2p, are subject to ubiquitination and eventual

degradation upon ligand binding (Mori et al., 1992, J. Biol. Chem. 267:6429-6434; Hicke and Riezman, 1996, Cell 84:277-287).

To further define the binding preferences of the WW domains of the newly identified proteins WWP1, WWP2, and WWP3, the present inventors inspected a number of published amino acid sequences and identified proline-rich stretches of amino acids that resembled consensus WW domain binding sequences. See Chen and Sudol, 1995, Proc. Natl. Acad. Sci. USA 92:7819-7823 for a discussion of consensus WW domain binding sequences. Peptides comprising these proline-rich sequences were synthesized and tested by the methods of the present invention for their ability to specifically bind to the novel WW domains described in Sections 6.1 and 6.1.1. The results are shown in Figure 7. As can be seen, in many cases the synthesized peptides were able to bind to the novel WW domains. This indicates that those synthesized peptides could have been used to identify those novel WW domains from sources of polypeptides.

In further attempts to define the binding preference of the newly identified WW domains, biased phage display libraries (identified in Figure 27 as cw, pp and xy) were screened to identify peptide sequences that functioned as recognition units of the WW domains; WWP1.1, WWP1.4 and WWP3. These individual domains were expressed as GST fusion proteins and assayed for binding activity according to the methods set forth herein (see, e.g., Sections 6.1, 6.1.1 and 6.2). Figure 27 presents the recognition unit peptides identified by each of these respective screens and the relative binding affinity of each of these recognition units for the tested WW domain, which was determined using techniques described infra.

#### **6.4. MATERIALS USED IN SECTION 6 AND ITS SUBSECTIONS**

##### **2xYT media (1L)**

35 Bacto tryptone	16 g
Yeast Extract	10 g
NaCl	5 g

**2xYT agar plates**

2xYT + 15 g agar/L

**5 2xYT top agarose (8%)**

2xYT + 8 g agarose/L

**SDS/DTT loading buffer**

(10 mL of 5x solution)

	.5 M Tris base	0.61 g
	8.5% SDS	0.85 g
<b>10</b>	27.5% sucrose	2.75 g
	100 mM DTT	0.154 g
	.03% Bromophenol Blue	3.0 mg

**Overnight cell cultures:**

- 15** Inoculate media with one isolated colony of appropriate cell type and incubate 37°C O/N with shaking

**BL21 (DE3) pLysE**

2xYT media

	maltose	0.2%
<b>20</b>	MgSO <sub>4</sub>	10mM
	Chloramphenicol	34 µg/ml
	Kanamycin	50 µg/ml

**6.5. BIOTINYLATED PEPTIDE DETECTION  
USING TYRAMIDE AMPLIFICATION SYSTEM**

- 25** The following protocol is an alternative to the methods described herein that utilize alkaline phosphatase to detect the binding of recognition units and WW domains. It permits the use of recognition units that are phosphopeptides.

**Materials:**

- 30** TSA-Tyramide Signal Amplification System (Dupont NEL-700); Streptavidin-Peroxidase, SA-P, conjugate 1mg/ml H<sub>2</sub>O (Sigma S-5512); Streptavidin-Alkaline Phosphatase, SA-AP, conjugate 1mg/ml H<sub>2</sub>O (Sigma S-2890); Dulbecco's PBS (Sigma D1408); PBS+0.05% Triton-X100, PBS/Tr; PBS/Tr + 20%DMSO;
- 35** SuperBlock™ Blocking Buffer in TBS (Pierce 37535); d-Biotin 0.1 mM; Biotinylated Peptide probe 0.1mM; Plaque lifts on Nitrocellulose (Schleicher & Schuell BA85, 0.45µm, 85mm);

SIGMA FAST™ BCIP/NBT Buffered Substrate Tablets (Sigma B-5655)

**Method:**

1. Wash Plaque lifts in PBS/Tr 3x 5-10min at Room Temperature (RT) with agitation.
2. Block filters in 50-75ml SuperBlock at RT for 60-90 min or store at 4° C until needed.
3. Prepare SA-P/biotinylated peptide probe complex while filters are in block.
  - 10 Mix 93.6µl SA-P 1mg/ml and 45µl 0.1mM Biotinylated Peptide probe.  
Incubate 30min at 4° C.  
Add 30µl 0.1mM d-Biotin and mix.  
Incubate 15min at 4° C.
  - 15 Add above complex to 60ml SuperBlock.
4. Add filters to SA-P/biotinylated peptide probe complex and incubate 2hrs at RT with agitation.
5. Wash Plaque lifts in PBS/Tr 5x 10min at Room Temperature (RT) with agitation.
- 20 6. Place each filter in a petri dish and add 5ml Biotinyl Tyramide reagent prepared as follows;  
Mix equal volumes of 2X amplification diluent and deionized water.  
Add 40µl Biotinyl Tyramide reagent /5 ml  
25 amplification diluent and mix.
7. Incubate Biotinyl Tyramide reagent on filters for 10min at RT. Exposure time and concentration of Biotinyl Tyramide reagent of filters may have to be determined empirically.
- 30 8. Wash filters thoroughly for:  
4x10min in 15ml PBS/tr + 20% DMSO.  
3x5min in 15ml PBS/tr.  
2x3min in 10ml SuperBlock.
9. Add filters to SA-AP diluted in SuperBlock (0.33µl 1mg/ml stock per 20ml SuperBlock). Exposure time and concentration of SA-AP to filters may have to be determined empirically. Use about 10ml per filter.
- 35

10. Incubate 30min at RT.

11. Wash filters thoroughly for:

4x5min in 15ml PBS/tr.

3x5min in PBS.

5 12. Develop filters using SIGMA FAST™BCIP/NBT Buffered Substrate Tablets. Use 60ml for 10 filters.

Dissolve 1 tablet in 10ml deionized water.

Allow development to proceed for 5-30min at RT with agitation until desired signal to noise levels are visually obtained.

10

Rinse filters in water and air dry.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described  
15 herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of  
20 which are incorporated by reference in their entireties.

25

30

35



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: Pirozzi, Gregorio  
Kay, Brian K.  
Fowlkes, Dana M.
- (ii) TITLE OF INVENTION: IDENTIFICATION AND ISOLATION OF NOVEL  
POLYPEPTIDES HAVING WW DOMAINS AND METHODS OF USING SAME
- (iii) NUMBER OF SEQUENCES: 230
- 10 (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Pennie & Edmonds  
(B) STREET: 1155 Avenue of the Americas  
(C) CITY: New York  
(D) STATE: New York  
(E) COUNTRY: United States  
(F) ZIP: 10036-2711
- 15 (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE: 03-APR-1997  
(C) CLASSIFICATION:
- 20 (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: MISROCK, S. LESLIE  
(B) REGISTRATION NO: 18,872  
(C) REFERENCE/DOCKET NO:1101-208
- (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: (212) 790-9090  
(B) TELEFAX: (212) 896-8864/9741
- 25 (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown
- 30 (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:  
Pro Gly Thr Pro Pro Leu Asn Tyr Asp Ser Leu Arg Leu  
1 5 10
- 35 (2) INFORMATION FOR SEQ ID NO:2:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 amino acids  
(B) TYPE: amino acid

- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

5

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 10
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Lys or Arg."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 12
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Tyr or Phe."

10

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 13
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Tyr or Phe."

(ix) FEATURE:

15

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 15
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Asn or Asp."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 18
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Thr or Ser."

20

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 19
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Lys or Arg."

(ix) FEATURE:

25

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 21
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Thr or Ser."

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION: 22
- (C) OTHER INFORMATION: /note= "Xaa May Be Either Thr, Gln, or Ser."

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Trp Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Trp Xaa Xaa Pro  
20 25

35

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids

(B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Pro Pro Pro Pro Tyr  
 1 5

(2) INFORMATION FOR SEQ ID NO:4:

10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 129 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCCTCGAGTA TCGACATGCC TTAGACTGCT AGCACTATGT ACAACATGCT TCATCGCAAC 60  
 GAGCCAGGTG GGAGGAAGTT GAGCCCGCCC GCCAACGACA TGCCGCCCCG CCTCCTGAAG 120  
 AGGTCTAGA 129

20

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 35 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

25 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Thr Ala Ser Thr Met Tyr Asn Met Leu His Arg Asn Glu Pro Gly Gly  
 1 5 10 15  
 Arg Lys Leu Ser Pro Pro Ala Asn Asp Met Pro Pro Ala Leu Leu Lys  
 20 25 30  
 Arg Ser Arg  
 35

30

(2) INFORMATION FOR SEQ ID NO:6:

35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 13 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5 His Pro Gly Thr Pro Pro Pro Tyr Thr Val Gly Pro  
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

10 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

15 Pro Gly Tyr Pro Tyr Pro Pro Pro Pro Glu Phe Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

20 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

25 Tyr Val Gln Pro Pro Pro Pro Tyr Pro Gly Pro Met  
1 5 10

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

30 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

35 Ser Gly Ser Gly Pro Gly Thr Pro Pro Pro Tyr Thr Val Gly Pro  
1 5 10 15

Gly Tyr

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

5

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

10 Ser Gly Ser Gly Tyr Val Gln Pro Pro Pro Pro Tyr Pro Gly Pro  
 1 5 10 15  
 Met

## (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

15

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

20 Ser Gly Ser Gly Pro Gly Thr Pro Tyr Pro Pro Pro Pro Glu Phe Tyr  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

25

(ii) MOLECULE TYPE: peptide

30

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Val Pro Leu Pro Ala Gly Trp Glu Met Ala Lys Thr Ser Ser Gly Gln  
 1 5 10 15

Arg Tyr Phe Leu Asn His Ile Asp Gln Thr Thr Thr Trp Gln Asp Pro  
 20 25 30

35

Arg Lys Ala Met Leu Ser  
 35

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Val Pro Leu Pro Pro Gly Trp Glu Met Ala Lys Thr Pro Ser Gly Gln  
 1 5 10 15

10 Arg Tyr Phe Leu Asn His Ile Asp Gln Thr Thr Thr Trp Gln Asp Pro  
 20 25 30

Arg Lys Ala Met Leu Ser  
 35

(2) INFORMATION FOR SEQ ID NO:14:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Gly Pro Leu Pro Asp Gly Trp Glu Gln Ala Met Thr Gln Asp Gly Glu  
 1 5 10 15

Ile Tyr Tyr Ile Asn His Lys Asn Lys Thr Thr Ser Trp Leu Asp Pro  
 20 25 30

25 Arg Leu Asp Pro Arg Phe  
 35

(2) INFORMATION FOR SEQ ID NO:15:

- 30 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

35 Val Pro Leu Pro Ala Gly Trp Glu Met Ala Lys Thr Ser Ser Gly Gln  
 1 5 10 15

Arg Tyr Phe Leu Asn His Asn Asp Gln Thr Thr Thr Trp Gln Asp Pro  
 20 25 30

Arg Lys Ala Met Leu Ser  
35

(2) INFORMATION FOR SEQ ID NO:16:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Gly Pro Leu Pro Asp Gly Trp Glu Gln Ala Met Thr Gln Asp Gly Glu  
1 5 10 15  
Val Tyr Tyr Ile Asn His Lys Asn Lys Thr Thr Ser Trp Leu Asp Pro  
20 25 30

15 Arg Leu Asp Pro Arg Phe  
35

(2) INFORMATION FOR SEQ ID NO:17:

- 20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

25 Ser Pro Leu Pro Pro Gly Trp Glu Glu Arg Gln Asp Val Leu Gly Arg  
1 5 10 15  
Thr Tyr Tyr Val Asn His Glu Ser Arg Arg Thr Gln Trp Lys Arg Pro  
20 25 30  
Ser Pro Asp Asp Asp Leu  
35

(2) INFORMATION FOR SEQ ID NO:18:

- 30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Ser Pro Leu Pro Pro Gly Trp Glu Glu Arg Gln Asp Ile Leu Gly Arg  
 1 5 10 15  
 Thr Tyr Tyr Val Asn His Glu Ser Arg Arg Thr Gln Trp Lys Arg Pro  
 20 25 30  
 Thr Arg Gln Asp Asn Leu  
 35

5

## (2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

10

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

15

Gly Arg Leu Pro Pro Gly Trp Glu Arg Arg Thr Asp Asn Phe Gly Arg  
 1 5 10 15  
 Thr Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Lys Arg Pro  
 20 25 30  
 Thr Leu Asp Gln Thr Glu  
 35

## (2) INFORMATION FOR SEQ ID NO:20:

20

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

30

Ser Gly Leu Pro Pro Gly Trp Glu Glu Lys Gln Asp Asp Arg Gly Arg  
 1 5 10 15  
 Ser Tyr Tyr Val Asp His Asn Ser Lys Thr Thr Thr Trp Ser Lys Pro  
 20 25 30  
 Thr Met Gln Asp Asp Pro  
 35

## (2) INFORMATION FOR SEQ ID NO:21:

35

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

5 Ser Gly Leu Pro Pro Gly Trp Glu Glu Lys Gln Asp Glu Arg Gly Arg  
1 5 10 15  
Ser Tyr Tyr Val Asp His Asn Ser Arg Thr Thr Thr Trp Thr Lys Pro  
20 25 30  
Thr Val Gln Ala Thr Val  
35

(2) INFORMATION FOR SEQ ID NO:22:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Gly Glu Leu Pro Ser Gly Trp Glu Gln Arg Phe Thr Pro Glu Gly Arg  
1 5 10 15  
Ala Tyr Phe Val Asp His Asn Thr Arg Thr Thr Thr Trp Val Asp Pro  
20 25 30  
20 Arg Arg Gln Gln Tyr Ile  
35

(2) INFORMATION FOR SEQ ID NO:23:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Gly Phe Leu Pro Lys Gly Trp Glu Val Arg His Ala Pro Asn Gly Arg  
1 5 10 15  
Pro Phe Phe Ile Asp His Asn Thr Lys Thr Thr Thr Trp Glu Asp Pro  
20 25 30  
Arg Leu Lys Ile Pro Ala  
35

35

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids

(B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Gly Pro Leu Pro Pro Gly Trp Glu Glu Arg Thr His Thr Asp Gly Arg  
 1 5 10 15

Val Phe Phe Ile Asn His Asn Ile Lys Lys Thr Gln Trp Glu Asp Pro  
 20 25 30

10

Arg Leu Gln Asn Val Ala  
 35

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

15

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

20

Gly Pro Leu Pro Pro Gly Trp Glu Glu Arg Thr His Thr Asp Gly Arg  
 1 5 10 15

Ile Phe Tyr Ile Asn His Asn Ile Lys Arg Thr Gln Trp Glu Asp Pro  
 20 25 30

Arg Leu Glu Asn Val Ala  
 35

25

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

30

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Gly Pro Leu Pro Ser Gly Trp Glu Met Arg Leu Thr Asn Thr Ala Arg  
 1 5 10 15

Val Tyr Phe Val Asp His Asn Thr Lys Thr Thr Thr Trp Asp Asp Pro  
 20 25 30

Arg Leu Pro Ser Ser Leu

35

35

## (2) INFORMATION FOR SEQ ID NO:27:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

10 Thr Ser Val Gln Gly Pro Trp Glu Arg Ala Ile Ser Pro Asn Lys Val  
 1 5 10 15  
 Pro Tyr Tyr Ile Asn His Glu Thr Gln Thr Thr Cys Trp Asp His Pro  
 20 25 30  
 Lys Met Thr Glu Leu Tyr  
 35

## 15 (2) INFORMATION FOR SEQ ID NO:28:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

20 (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

25 Thr Ser Val Gln Gly Pro Trp Glu Arg Ala Ile Ser Pro Asn Lys Val  
 1 5 10 15  
 Pro Tyr Tyr Met Asn His Gln Thr Gln Thr Thr Cys Trp Asp His Pro  
 20 25 30  
 Lys Met Thr Glu Leu Tyr  
 35

## (2) INFORMATION FOR SEQ ID NO:29:

## 30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Thr Ser Val Gln Leu Pro Trp Gln Arg Ser Ile Ser His Asn Lys Val

```

1           5           10           15
Pro Tyr Tyr Ile Asn His Gln Thr Gln Thr Thr Cys Trp Asp His Pro
                20                25                30
Lys Met Thr Glu Leu Phe
                35

```

5 (2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

10 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Leu Pro Ser Gly Trp Gly Trp Glu Gln Arg Lys Asp Pro His Gly Arg  
1 5 10 15  
Thr Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Glu Arg Pro  
20 25 30  
Gln Pro Leu Pro Pro Gly  
35

(2) INFORMATION FOR SEO ID NO:31:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## 25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Gln Pro Leu Pro Pro Gly Trp Glu Arg Arg Val Asp Asp Arg Arg Arg  
1 5 10 15

Val Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Gln Arg Pro  
20 25 30

## 30

Thr Met Glu Ser Val Pro  
35

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

5 Gly Pro Leu Pro Pro Gly Trp Glu Lys Arg Val Asp Ser Thr Asp Arg  
1 5 10 15  
Val Tyr Phe Val Asn His Asn Thr Lys Thr Thr Gln Trp Glu Asp Pro  
20 25 30  
Arg Thr Gln Gly Leu Gln  
35

(2) INFORMATION FOR SEQ ID NO:33:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Glu Pro Leu Pro Glu Gly Trp Glu Ile Arg Tyr Thr Arg Glu Gly Val  
1 5 10 15  
Arg Tyr Phe Val Asp His Asn Thr Arg Thr Thr Thr Phe Lys Asp Pro  
20 25 30  
20 Arg Asn Gly Lys Ser Ser  
35

(2) INFORMATION FOR SEQ ID NO:34:

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

30 Asp Ala Leu Pro Ala Gly Trp Glu Gln Arg Glu Leu Pro Asn Gly Arg  
1 5 10 15  
Val Tyr Tyr Val Asp His Asn Thr Lys Thr Thr Thr Trp Glu Arg Pro  
20 25 30  
Leu Pro Pro Gly Trp Glu  
35

35 (2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid

(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Arg Pro Leu Pro Pro Gly Trp Glu Lys Arg Thr Asp Pro Arg Gly Arg  
1 5 10 15

Phe Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Gln Arg Pro  
20 25 30

10 Thr Ala Glu Tyr Val Arg  
35

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

15

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

20 Gly Pro Leu Pro Pro Gly Trp Glu Lys Arg Gln Asp Val Asn Gly Arg  
1 5 10 15

Val Tyr Tyr Val Asn His Asn Thr Arg Thr Thr Gln Trp Glu Asp Pro  
20 25 30

Arg Thr Gln Gly Met Ile  
35

25 (2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 38 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Pro Ala Leu Pro Pro Gly Trp Glu Met Lys Tyr Thr Ser Glu Gly Val  
1 5 10 15

35 Arg Tyr Phe Val Asp His Asn Thr Arg Thr Thr Thr Phe Lys Asp Pro  
20 25 30

Arg Pro Gly Phe Glu Ser  
35

## (2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 38 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

5

- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

10 Gly Pro Leu Pro Glu Asn Trp Glu Met Ala Tyr Thr Glu Asn Gly Glu  
 1 5 10 15  
 Val Tyr Phe Ile Asp His Asn Thr Lys Thr Thr Ser Trp Leu Asp Pro  
 20 25 30  
 Arg Cys Leu Asn Lys Gln  
 35

## (2) INFORMATION FOR SEQ ID NO:39:

15

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 33 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

- (ii) MOLECULE TYPE: peptide

20

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 5  
 (C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 12  
 (C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

25

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 13  
 (C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 14  
 (C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

30

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 16  
 (C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 20  
 (C) OTHER INFORMATION: /note= "A Polar Amino Acid."

35

- (ix) FEATURE:  
 (A) NAME/KEY: Modified-site

(B) LOCATION: 25  
(C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 28  
(C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

5

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 31  
(C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

(ix) FEATURE:  
(A) NAME/KEY: Modified-site  
(B) LOCATION: 33  
(C) OTHER INFORMATION: /note= "A Hydrophobic Amino Acid."

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Xaa Xaa Leu Pro Thr Gly Trp Glu Xaa Xaa Xaa Thr Thr Thr Gly Thr  
1 5 10 15

15 Xaa Tyr Tyr His Xaa His Asn Thr Thr Thr Thr Thr Trp Xaa Thr Pro  
20 25 30

Thr

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:  
20 (A) LENGTH: 33 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CTGTGCGGAT CCAAGACCTG AACACCAGAT GGA

33

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:  
30 (A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

CTGTGCGAAT TCCAAAGTCT CGAACAT

27

(2) INFORMATION FOR SEQ ID NO:42:



- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 18 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- 5 (ix) FEATURE:  
    (A) NAME/KEY: Modified-site  
    (B) LOCATION: 2  
    (C) OTHER INFORMATION: /note= "Xaa May Be Either Ser or Arg."
- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
- |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Xaa | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |
- Arg Pro Thr
- 15 (2) INFORMATION FOR SEQ ID NO:43:
- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 5 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
- |     |     |     |     |     |
|-----|-----|-----|-----|-----|
| Xaa | Xaa | Pro | Xaa | Tyr |
| 1   |     |     |     | 5   |
- 25 (2) INFORMATION FOR SEQ ID NO:44:
- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 4 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
- |     |     |     |     |
|-----|-----|-----|-----|
| Pro | Xaa | Xaa | Pro |
| 1   |     |     |     |
- 35 (2) INFORMATION FOR SEQ ID NO:45:
- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 2052 base pairs  
    (B) TYPE: nucleic acid

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

	GACTAATCAT GTACCTACAA GCACTCTAGT CCAAACTCA TGCTGCTCGT ATGTAGTTAA	60
	TGGAGACAAC ACACCTTCAT CTCCGTCTCA GGTGCTGCC AGACCCAAAA ATACACCAGC	120
	TCCAAAACCA CTCGCATCTG AGCCTGCCGA TGACACTGTT AATGGAGAAT CATCCTCATT	180
10	TGCACCAACT GATAATGCGT CTGTCACGGG TACTCCAGTA GTGTCTGAAG AAAATGCCTT	240
	GTCTCCAAAT TGCCTAGTA CTACTGTTGA AGATCCTCCA GTTCAAGAAA TACTGACTTC	300
	CTCAGAAAAC AATGAATGTA TTCCTTCTAC CAGTGCAGAA TTGGAATCTG AAGCTAGAAG	360
	TATATTAGAG CCTGACACCT CTAATTCTAG AAGTAGTTCT GCTTTTGAAG CAGCCAAATC	420
	AAGACAGCCA GATGGGTGTA TGGATCCTGT ACGGCAGCAG TCTGGGAATG CCAACACAGA	480
15	AACCTTGCCA TCAGGGTGGG AACAAAGAAA AGATCCTCAT GGTAGAACCT ATTATGTGGA	540
	TCATAATACT CGAACTACCA CATGGGAGAG ACCACAACCT TTACCTCCAG GTTGGGAAAG	600
	AAGAGTTGAT GATCGTAGAA GAGTTTATTA TGTGGATCAT AACACCAGAA CAACAACGTG	660
	GCAGCGGCCT ACCATGGAAT CTGTCCGAAA TTTTGAACAG TGGCAATCTC AGCGGAACCA	720
20	ATTGCAGGGA GCTATGCAAC AGTTTAACCA ACGATACCTC TATTCGGCTT CAATGTTAGC	780
	TGCAGAAAAT GACCCTTATG GACCTTTGCC ACCAGGCTGG GAAAAAAGAG TGGATTCAAC	840
	AGACAGGGTT TACTTTGTGA ATCATAACAC AAAACAACC CAGTGGGAAG ATCCAAGAAC	900
	TCAAGGCTTA CAGAATGAAG AACCCTTGCC AGAAGGCTGG GAAATTAGAT ATACTCGTGA	960
	AGGTGTAAGG TACTTTGTTG ATCATAACAC AAGAACAACA ACATTCAAAG ATCCTCGCAA	1020
25	TGGGAAGTCA TCTGTAAC TAAGGTGGTCC ACAAATTGCT TATGAACGCG GCTTTAGGTG	1080
	GAAGCTTGCT CACTTCCGTT ATTTGTGCCA GTCTAATGCA CTACCTAGTC ATGTAAAGAT	1140
	CAATGTGTCC CGGCAGACAT TGTTGAAGA TTCCTTCCAA CAGATTATGG CATTAAAACC	1200
	CTATGACTTG AGGAGGCGCT TATATGTAAT ATTTAGAGGA GAAGAAGGAC TTGATTATGG	1260
30	TGGCCTAGCG AGAGAATGGT TTTTCTTGCT TTCACATGAA GTTTTGAACC CAATGTATTG	1320
	CTTATTTGAG TATGCGGGCA AGAACAACTA TTGTCTGCAG ATAAATCCAG CATCAACCAT	1380
	TAATCCAGAC CATCTTTCAT ACTTCTGTTT CATTTGGTCG TTTATTGCCA TGGCACTATT	1440
	TCATGGAAAG TTTATCGATA CTGGTTTCTC TTTACCATT CACAAGCGTA TGTTAAGTAA	1500
	AAAACCTACT ATTAAGGATT TGGAATCTAT TGATACTGAA TTTTATAACT CCCTTATCTG	1560
35	GATAAGAGAT AACAAATTG AAGAATGTGG CTTAGAAATG TACTTTTCTG TTGACATGGA	1620
	GATTTTGGGA AAAGTTACTT CACATGACCT GAAGTTGGGA GGTCCAATA TTCTGGTGAC	1680

TGAGGAGAAC AAAGATGAAT ATATTGGTTT AATGACAGAA TGGCGTTTTT CTCGAGGAGT 1740  
 ACAAGAACAG ACCAAAGCTT TCCTTGATGG TTTTAATGAA GTTGTTCCTC TTCAGTGGCT 1800  
 ACAGTACTTC GATGAAAAAG AATTAGAGGT TATGTTGTGT GGCATGCAGG AGGTTGACTT 1860  
 GGCAGATTGG CAGAGAAATA CTGTTTATCG ACATTATACA AGAAACAGCA AGCAAATCAT 1920  
 5 TTGGTTTTGG CAGTTTGTGA AAGAGACAGA CAATGAAGTA AGAATGCGAC TATTGCAGTT 1980  
 CGTCACTGGA ACCTGCCGTT TACCTCTAGG AGGATTTGCT GAGCTCATGG GAAGTAATGG 2040  
 GCCCCGGAAT TC 2052

(2) INFORMATION FOR SEQ ID NO:46:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 683 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

	Thr	Asn	His	Val	Pro	Thr	Ser	Thr	Leu	Val	Gln	Asn	Ser	Cys	Cys	Ser	1	5	10	15
	Tyr	Val	Val	Asn	Gly	Asp	Asn	Thr	Pro	Ser	Ser	Pro	Ser	Gln	Val	Ala	20	25	30	
20	Ala	Arg	Pro	Lys	Asn	Thr	Pro	Ala	Pro	Lys	Pro	Leu	Ala	Ser	Glu	Pro	35	40	45	
	Ala	Asp	Asp	Thr	Val	Asn	Gly	Glu	Ser	Ser	Ser	Phe	Ala	Pro	Thr	Asp	50	55	60	
	Asn	Ala	Ser	Val	Thr	Gly	Thr	Pro	Val	Val	Ser	Glu	Glu	Asn	Ala	Leu	65	70	75	80
25	Ser	Pro	Asn	Cys	Thr	Ser	Thr	Thr	Val	Glu	Asp	Pro	Pro	Val	Gln	Glu	85	90	95	
	Ile	Leu	Thr	Ser	Ser	Glu	Asn	Asn	Glu	Cys	Ile	Pro	Ser	Thr	Ser	Ala	100	105	110	
	Glu	Leu	Glu	Ser	Glu	Ala	Arg	Ser	Ile	Leu	Glu	Pro	Asp	Thr	Ser	Asn	115	120	125	
30	Ser	Arg	Ser	Ser	Ser	Ala	Phe	Glu	Ala	Ala	Lys	Ser	Arg	Gln	Pro	Asp	130	135	140	
	Gly	Cys	Met	Asp	Pro	Val	Arg	Gln	Gln	Ser	Gly	Asn	Ala	Asn	Thr	Glu	145	150	155	160
	Thr	Leu	Pro	Ser	Gly	Trp	Glu	Gln	Arg	Lys	Asp	Pro	His	Gly	Arg	Thr	165	170	175	
35	Tyr	Tyr	Val	Asp	His	Asn	Thr	Arg	Thr	Thr	Thr	Trp	Glu	Arg	Pro	Gln	180	185	190	
	Pro	Leu	Pro	Pro	Gly	Trp	Glu	Arg	Arg	Val	Asp	Asp	Arg	Arg	Arg	Val				

					195					200								205
			Tyr	Tyr	Val	Asp	His	Asn	Thr	Arg	Thr	Thr	Thr	Trp	Gln	Arg	Pro	Thr
			210						215					220				
			Met	Glu	Ser	Val	Arg	Asn	Phe	Glu	Gln	Trp	Gln	Ser	Gln	Arg	Asn	Gln
			225					230					235					240
5			Leu	Gln	Gly	Ala	Met	Gln	Gln	Phe	Asn	Gln	Arg	Tyr	Leu	Tyr	Ser	Ala
						245						250					255	
			Ser	Met	Leu	Ala	Ala	Glu	Asn	Asp	Pro	Tyr	Gly	Pro	Leu	Pro	Pro	Gly
					260						265					270		
			Trp	Glu	Lys	Arg	Val	Asp	Ser	Thr	Asp	Arg	Val	Tyr	Phe	Val	Asn	His
					275					280					285			
10			Asn	Thr	Lys	Thr	Thr	Gln	Trp	Glu	Asp	Pro	Arg	Thr	Gln	Gly	Leu	Gln
				290					295					300				
			Asn	Glu	Glu	Pro	Leu	Pro	Glu	Gly	Trp	Glu	Ile	Arg	Tyr	Thr	Arg	Glu
				305				310					315					320
			Gly	Val	Arg	Tyr	Phe	Val	Asp	His	Asn	Thr	Arg	Thr	Thr	Thr	Phe	Lys
						325						330					335	
15			Asp	Pro	Arg	Asn	Gly	Lys	Ser	Ser	Val	Thr	Lys	Gly	Gly	Pro	Gln	Ile
						340					345					350		
			Ala	Tyr	Glu	Arg	Gly	Phe	Arg	Trp	Lys	Leu	Ala	His	Phe	Arg	Tyr	Leu
					355					360					365			
			Cys	Gln	Ser	Asn	Ala	Leu	Pro	Ser	His	Val	Lys	Ile	Asn	Val	Ser	Arg
				370					375					380				
20			Gln	Thr	Leu	Phe	Glu	Asp	Ser	Phe	Gln	Gln	Ile	Met	Ala	Leu	Lys	Pro
				385				390					395					400
			Tyr	Asp	Leu	Arg	Arg	Arg	Leu	Tyr	Val	Ile	Phe	Arg	Gly	Glu	Glu	Gly
							405					410					415	
			Leu	Asp	Tyr	Gly	Gly	Leu	Ala	Arg	Glu	Trp	Phe	Phe	Leu	Leu	Ser	His
						420					425					430		
25			Glu	Val	Leu	Asn	Pro	Met	Tyr	Cys	Leu	Phe	Glu	Tyr	Ala	Gly	Lys	Asn
					435					440					445			
			Asn	Tyr	Cys	Leu	Gln	Ile	Asn	Pro	Ala	Ser	Thr	Ile	Asn	Pro	Asp	His
				450					455					460				
			Leu	Ser	Tyr	Phe	Cys	Phe	Ile	Gly	Arg	Phe	Ile	Ala	Met	Ala	Leu	Phe
				465				470					475					480
30			His	Gly	Lys	Phe	Ile	Asp	Thr	Gly	Phe	Ser	Leu	Pro	Phe	Tyr	Lys	Arg
						485						490					495	
			Met	Leu	Ser	Lys	Lys	Leu	Thr	Ile	Lys	Asp	Leu	Glu	Ser	Ile	Asp	Thr
						500					505					510		
			Glu	Phe	Tyr	Asn	Ser	Leu	Ile	Trp	Ile	Arg	Asp	Asn	Asn	Ile	Glu	Glu
					515					520					525			
35			Cys	Gly	Leu	Glu	Met	Tyr	Phe	Ser	Val	Asp	Met	Glu	Ile	Leu	Gly	Lys
				530					535					540				
			Val	Thr	Ser	His	Asp	Leu	Lys	Leu	Gly	Gly	Ser	Asn	Ile	Leu	Val	Thr

545                      550                      555                      560  
 Glu Glu Asn Lys Asp Glu Tyr Ile Gly Leu Met Thr Glu Trp Arg Phe  
                                  565                      570                      575  
 Ser Arg Gly Val Gln Glu Gln Thr Lys Ala Phe Leu Asp Gly Phe Asn  
                                  580                      585                      590  
 5    Glu Val Val Pro Leu Gln Trp Leu Gln Tyr Phe Asp Glu Lys Glu Leu  
                                  595                      600                      605  
 Glu Val Met Leu Cys Gly Met Gln Glu Val Asp Leu Ala Asp Trp Gln  
                                  610                      615                      620  
 Arg Asn Thr Val Tyr Arg His Tyr Thr Arg Asn Ser Lys Gln Ile Ile  
                                  625                      630                      635                      640  
 10    Trp Phe Trp Gln Phe Val Lys Glu Thr Asp Asn Glu Val Arg Met Arg  
                                  645                      650                      655  
 Leu Leu Gln Phe Val Thr Gly Thr Cys Arg Leu Pro Leu Gly Gly Phe  
                                  660                      665                      670  
 Ala Glu Leu Met Gly Ser Asn Gly Pro Arg Asn  
                                  675                      680

- 15    (2) INFORMATION FOR SEQ ID NO:47:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 3476 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 20    (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

GAATTCGCGG CCGCGTCCAC CGCTTCTGTG GCCACGGCAG ATGAAACAGA AAGGCTAAAG                      60  
 25 AGGGCTGGAG TCAGGGGACT TCTCTTCCAC CAGCTTCACG GTGATGATAT GGCATCTGCC                      120  
 AGCTCTAGCC GGGCAGGAGT GGCCCTGCCT TTTGAGAAGT CTCAGCTCAC TTTGAAAGTG                      180  
 GTGTCCGCAA AGCCCAAGGT GCATAATCGT CAACCTCGAA TTAACCTCCTA CGTGGAGGTG                      240  
 GCGGTGGATG GACTCCCCAG TGAGACCAAG AAGACTGGGA AGCGCATTGG GAGCTCTGAG                      300  
 CTTCTCTGGA ATGAGATCAT CATTTTGAAT GTCACGGCAC AGAGTCATTT AGATTTAAAG                      360  
 30 GTCTGGAGCT GCCATACCTT GAGAAATGAA CTGCTAGGCA CCGCATCTGT CAACCTCTCC                      420  
 AACGTCTTGA AGAACAATGG GGGCAAAATG GAGAACATGC AGCTGACCCT GAACCTGCAG                      480  
 ACGGAGAACA AAGGCAGCGT TGTCTCAGGC GGAAAACTGA CAATTTTCCT GGACGGGCCA                      540  
 ACTGTTGATC TGGGAAATGT GCCTAATGGC AGTGCCCTGA CAGATGGATC ACAGCTGCCT                      600  
 35 TCGAGAGACT CCAGTGGAAC AGCAGTAGCT CCAGAGAACC GGCACCAGCC CCCCAGCACA                      660  
 AACTGCTTTG GTGGAAGATC CCGGACGCAC AGACATTCGG GTGCTTCAGC CAGAACAACC                      720  
 CCAGCAACCG GCGAGCAAAG CCCCGGTGCT CGGAGCCGGC ACCGCCAGCC CGTCAAGAAC                      780

	TCAGGCCACA	GTGGCTTGGC	CAATGGCACA	GTGAATGATG	AACCCACAAC	AGCCACTGAT	840
	CCCGAAGAAC	CTTCCGTTGT	TGGTGTGACG	TCCCCACCTG	CTGCACCCTT	GAGTGTGACC	900
	CCGAATCCCA	ACACGACTTC	TCTCCCTGCC	CCAGCCACAC	CGGCTGAAGG	AGAGGAACCC	960
	AGCACTTCGG	GTACACAGCA	GCTCCCAGCG	GCTGCCCAGG	CCCCCGACGC	TCTGCCTGCT	1020
5	GGATGGGAAC	AGCGAGAGCT	GCCCCAACGGA	CGTGTCTATT	ATGTTGACCA	CAATACCAAG	1080
	ACCACCACCT	GGGAGCGGCC	CCTTCCTCCA	GGCTGGGAAA	AACGCACAGA	TCCCCGAGGC	1140
	AGGTTTTACT	ATGTGGATCA	CAATACTCGG	ACCACCACCT	GGCAGCGTCC	GACCGCGGAG	1200
	TACGTGCGCA	ACTATGAGCA	GTGGCAGTCG	CAGCGGAATC	AGCTCCAGGG	GGCCATGCAG	1260
10	CACTTCAGCC	AAAGATTCTT	ATACCAAGTT	TGGAGTGCTT	CGACTGACCA	TGATCCCCTG	1320
	GGCCCCCTCC	CTCCTGGTTG	GGAGAAAAGA	CAGGACAATG	GACGGGTGTA	TTACGTGAAC	1380
	CATAACACTC	GCACGACCCA	GTGGGAGGAT	CCCCGGACCC	AGGGGATGAT	CCAGGAACCA	1440
	GCTTTGCCCC	CAGGATGGGA	GATGAAATAC	ACCAGCGAGG	GGGTGCGATA	CTTTGTGGAC	1500
	CACAATACCC	GCACCACCAC	CTTTAAGGAT	CCTCGCCCGG	GGTTTGAGTC	GGGGACGAAG	1560
15	CAAGGTTCCC	CTGGTGCTTA	TGACCGCAGT	TTTCGGTGGA	AGTATCACCA	GTTCCGTTTC	1620
	CTCTGCCATT	CAAATGCCCT	ACCTAGCCAC	GTGAAGATCA	GCGTTTGCAG	GCAGACGCTT	1680
	ACCTAGCCAC	GTGAAGATCA	GCGTTTCCAG	GCAGACGCTT	ATGACCTGCG	CCGCCGGCTT	1740
	TACATCATCA	TGCGTGCCGA	GGAGGGCCTG	GACTATGGGG	GCATCGCCAG	AGAGTGGTTC	1800
20	TTCCTCCTGT	CTCAGGAGGT	GCTCAACCCT	ATGTATTGTT	TATTTGAATA	TGCCGGAAAG	1860
	AACAATTACT	GCCTGCAGAT	CAACCCCGCC	TCCTCCATCA	ACCCGGACCA	CCTCACCTAC	1920
	TTTCGCTTTA	TAGGCAGATT	CATCGCCATG	GCGCTGTACC	ATGGAAAGTT	CATCGACACG	1980
	GGCTTCACCC	TCCCTTTCTA	CAAGCGGATG	CTCAATAAGA	GACCAACCCT	GAAAGACCTG	2040
	GAGTCCATTG	ACCCTGAGTT	CTACAACTCC	ATTGTCTGGA	TCAAAGAGAA	CAACCTGGAA	2100
25	GAATGTGGCC	TGGAGCTGTA	CTTCATCCAG	GACATGGAGA	TACTGGGCAA	GGTCACCACC	2160
	CACGAGCTGA	AGGAGGGCGG	CGAGAGCATC	CGGGTCACGG	AGGAGAACAA	GGAAGAGTAC	2220
	ATCATGCTGC	TGACTGACTG	GCGTTTCACC	CGAGGCGTGG	AAGAGCAGAC	CAAAGCCTTC	2280
	CTGGATGGCT	TCAACGAGGT	GGCCCCGCTG	GAGTGGCTGC	GCTACTTTGA	CGAGAAAGAG	2340
30	CTGGAGCTGA	TGCTGTGCGG	CATGCAGGAG	ATAGACATGA	GCGACTGGCA	GAAGAGCACC	2400
	ATCTACCGGC	ACTACACCAA	GAACAGCAAG	CAGATCCAGT	GTTCTGGCA	GGTGGTGAAG	2460
	GAGATGGACA	ACGAGAAGAG	GATCCGGCTG	CTGCAGTTTG	TCACCGGTAC	CTGCCGCCTG	2520
	CCCGTCGGGG	GATTTGCCGA	ACTCATCGGT	AGCAACGGAC	CACAGAAGTT	TTGCATTGAC	2580
	AAAGTTGGCA	AGGAAACCTG	GCTGCCCAGA	AGCCACACCT	GCTTCAACCG	TCTGGATCTT	2640
35	CCACCCTACA	AGAGCTACGA	ACAGCTGAGA	GAGAAGCTGC	TGTATGCCAT	TGAGGAGACC	2700
	GAGGGCTTTG	GACAGGAGTA	ACCGAGGCCG	CCCCTCCCAC	GCCCCCAGC	GCACATGTAG	2760

TCCTGAGTCC TCCCTGCCTG AGAGGCCACT GGCCCCGCAG CCCTTGGGAG GCCCCCGTGG 2820  
 ATGTGGCCCT GTGTGGGACC AACTGTTCAT CTCGCTGCTG GCAGAAAAGC CTGATCCCAG 2880  
 GAGGCCCTGC AGTTCCCCCG ACCCGCGGAT GGCAGTCTGG AATAAAGCCC CCTAGTTGCC 2940  
 TTTGGCCCCA CCTTTGCAAA GTTCCAGAGG GCTGACCCTC TCTGCAAAAC TCTCCCCTGT 3000  
 5 CCTCTAGACC CCACCCTGGG TGTATGTGAG TGTGCAAGGG AAGGTGTTGC ATCCCCAGGG 3060  
 GCTGCCGCAG AGGCCGGAGA CCTCCTGGAC TAGTTCGGCG AGGAGACTGG CCACTGGGGG 3120  
 TGGCTGTTCTG GGAAGTGAAG CGCCAAGGGT CTTTGCCAGC AAAGGAGGTT CTGCCTGTAA 3180  
 TTGAGCCTCT CTGATGATGG AGATGAAGTG AAGGTCTGAG GGACGGGCCC TGGGGCTAGG 3240  
 10 CCATCTCTGC CTGCCTCCCT AGCAGGCGCC AGCGGTGGAG GCTGAGTCGC AGGACACATG 3300  
 CCGGCCAGTT AATTCATTCT CAGCAAATGA AGGTTTGTCT AAGCTGCCTG GGTATCCACG 3360  
 GGACAAAAC AGCAAACTCC CTCCAGACTT TGTCCATGTT ATAAACTTCA AAGTTGGTTG 3420  
 TTGTTTGTTA NGGTTTGCCA GGTTTTTTTG TTTACGCCTG CTGTCACTTT CCTGTC 3476

(2) INFORMATION FOR SEQ ID NO:48:

15

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 906 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Glu Phe Ala Ala Ala Ser Thr Ala Ser Val Ala Thr Ala Asp Glu Thr  
 1 5 10 15  
 25 Glu Arg Leu Lys Arg Ala Gly Val Arg Gly Leu Leu Phe His Gln Leu  
 20 25 30  
 His Gly Asp Asp Met Ala Ser Ala Ser Ser Ser Arg Ala Gly Val Ala  
 35 40 45  
 Leu Pro Phe Glu Lys Ser Gln Leu Thr Leu Lys Val Val Ser Ala Lys  
 50 55 60  
 30 Pro Lys Val His Asn Arg Gln Pro Arg Ile Asn Ser Tyr Val Glu Val  
 65 70 75 80  
 Ala Val Asp Gly Leu Pro Ser Glu Thr Lys Lys Thr Gly Lys Arg Ile  
 85 90 95  
 Gly Ser Ser Glu Leu Leu Trp Asn Glu Ile Ile Ile Leu Asn Val Thr  
 100 105 110  
 35 Ala Gln Ser His Leu Asp Leu Lys Val Trp Ser Cys His Thr Leu Arg  
 115 120 125  
 Asn Glu Leu Leu Gly Thr Ala Ser Val Asn Leu Ser Asn Val Leu Lys  
 130 135 140

	Asn	Asn	Gly	Gly	Lys	Met	Glu	Asn	Met	Gln	Leu	Thr	Leu	Asn	Leu	Gln	
	145					150					155					160	
	Thr	Glu	Asn	Lys	Gly	Ser	Val	Val	Ser	Gly	Gly	Lys	Leu	Thr	Ile	Phe	
					165					170					175		
5	Leu	Asp	Gly	Pro	Thr	Val	Asp	Leu	Gly	Asn	Val	Pro	Asn	Gly	Ser	Ala	
				180					185					190			
	Leu	Thr	Asp	Gly	Ser	Gln	Leu	Pro	Ser	Arg	Asp	Ser	Ser	Gly	Thr	Ala	
			195					200					205				
	Val	Ala	Pro	Glu	Asn	Arg	His	Gln	Pro	Pro	Ser	Thr	Asn	Cys	Phe	Gly	
		210					215					220					
10	Gly	Arg	Ser	Arg	Thr	His	Arg	His	Ser	Gly	Ala	Ser	Ala	Arg	Thr	Thr	
	225					230					235					240	
	Pro	Ala	Thr	Gly	Glu	Gln	Ser	Pro	Gly	Ala	Arg	Ser	Arg	His	Arg	Gln	
					245					250					255		
	Pro	Val	Lys	Asn	Ser	Gly	His	Ser	Gly	Leu	Ala	Asn	Gly	Thr	Val	Asn	
				260					265					270			
15	Asp	Glu	Pro	Thr	Thr	Ala	Thr	Asp	Pro	Glu	Glu	Pro	Ser	Val	Val	Gly	
			275					280					285				
	Val	Thr	Ser	Pro	Pro	Ala	Ala	Pro	Leu	Ser	Val	Thr	Pro	Asn	Pro	Asn	
		290					295					300					
	Thr	Thr	Ser	Leu	Pro	Ala	Pro	Ala	Thr	Pro	Ala	Glu	Gly	Glu	Glu	Pro	
	305					310					315					320	
20	Ser	Thr	Ser	Gly	Thr	Gln	Gln	Leu	Pro	Ala	Ala	Ala	Gln	Ala	Pro	Asp	
					325					330					335		
	Ala	Leu	Pro	Ala	Gly	Trp	Glu	Gln	Arg	Glu	Leu	Pro	Asn	Gly	Arg	Val	
				340					345					350			
	Tyr	Tyr	Val	Asp	His	Asn	Thr	Lys	Thr	Thr	Thr	Trp	Glu	Arg	Pro	Leu	
			355					360					365				
25	Pro	Pro	Gly	Trp	Glu	Lys	Arg	Thr	Asp	Pro	Arg	Gly	Arg	Phe	Tyr	Tyr	
			370				375					380					
	Val	Asp	His	Asn	Thr	Arg	Thr	Thr	Thr	Trp	Gln	Arg	Pro	Thr	Ala	Glu	
	385					390					395					400	
	Tyr	Val	Arg	Asn	Tyr	Glu	Gln	Trp	Gln	Ser	Gln	Arg	Asn	Gln	Leu	Gln	
				405						410					415		
30	Gly	Ala	Met	Gln	His	Phe	Ser	Gln	Arg	Phe	Leu	Tyr	Gln	Phe	Trp	Ser	
				420					425					430			
	Ala	Ser	Thr	Asp	His	Asp	Pro	Leu	Gly	Pro	Leu	Pro	Pro	Gly	Trp	Glu	
				435				440					445				
	Lys	Arg	Gln	Asp	Asn	Gly	Arg	Val	Tyr	Tyr	Val	Asn	His	Asn	Thr	Arg	
		450					455					460					
35	Thr	Thr	Gln	Trp	Glu	Asp	Pro	Arg	Thr	Gln	Gly	Met	Ile	Gln	Glu	Pro	
	465					470					475					480	
	Ala	Leu	Pro	Pro	Gly	Trp	Glu	Met	Lys	Tyr	Thr	Ser	Glu	Gly	Val	Arg	
					485					490					495		



	Tyr	Phe	Val	Asp	His	Asn	Thr	Arg	Thr	Thr	Thr	Phe	Lys	Asp	Pro	Arg	
				500					505					510			
	Pro	Gly	Phe	Glu	Ser	Gly	Thr	Lys	Gln	Gly	Ser	Pro	Gly	Ala	Tyr	Asp	
			515					520					525				
5	Arg	Ser	Phe	Arg	Trp	Lys	Tyr	His	Gln	Phe	Arg	Phe	Leu	Cys	His	Ser	
			530				535					540					
	Asn	Ala	Leu	Pro	Ser	His	Val	Lys	Ile	Ser	Val	Ser	Arg	Gln	Thr	Leu	
			545			550					555					560	
	Phe	Glu	Asp	Ser	Phe	Gln	Gln	Ile	Met	Asn	Met	Lys	Pro	Tyr	Asp	Leu	
					565					570					575		
10	Arg	Arg	Arg	Leu	Tyr	Ile	Ile	Met	Arg	Gly	Glu	Glu	Gly	Leu	Asp	Tyr	
				580					585					590			
	Gly	Gly	Ile	Ala	Arg	Glu	Trp	Phe	Phe	Leu	Leu	Ser	His	Glu	Val	Leu	
			595					600					605				
	Asn	Pro	Met	Tyr	Cys	Leu	Phe	Glu	Tyr	Ala	Gly	Lys	Asn	Asn	Tyr	Cys	
			610				615					620					
15	Leu	Gln	Ile	Asn	Pro	Ala	Ser	Ser	Ile	Asn	Pro	Asp	His	Leu	Thr	Tyr	
			625			630					635					640	
	Phe	Arg	Phe	Ile	Gly	Arg	Phe	Ile	Ala	Met	Ala	Leu	Tyr	His	Gly	Lys	
				645						650					655		
	Phe	Ile	Asp	Thr	Gly	Phe	Thr	Leu	Pro	Phe	Tyr	Lys	Arg	Met	Leu	Asn	
				660					665					670			
20	Lys	Arg	Pro	Thr	Leu	Lys	Asp	Leu	Glu	Ser	Ile	Asp	Pro	Glu	Phe	Tyr	
				675				680					685				
	Asn	Ser	Ile	Val	Trp	Ile	Lys	Glu	Asn	Asn	Leu	Glu	Glu	Cys	Gly	Leu	
				690			695					700					
	Glu	Leu	Tyr	Phe	Ile	Gln	Asp	Met	Glu	Ile	Leu	Gly	Lys	Val	Thr	Thr	
					710						715					720	
25	His	Glu	Leu	Lys	Glu	Gly	Gly	Glu	Ser	Ile	Arg	Val	Thr	Glu	Glu	Asn	
					725					730					735		
	Lys	Glu	Glu	Tyr	Ile	Met	Leu	Leu	Thr	Asp	Trp	Arg	Phe	Thr	Arg	Gly	
				740					745					750			
	Val	Glu	Glu	Gln	Thr	Lys	Ala	Phe	Leu	Asp	Gly	Phe	Asn	Glu	Val	Ala	
				755				760					765				
30	Pro	Leu	Glu	Trp	Leu	Arg	Tyr	Phe	Asp	Glu	Lys	Glu	Leu	Glu	Leu	Met	
				770			775					780					
	Leu	Cys	Gly	Met	Gln	Glu	Ile	Asp	Met	Ser	Asp	Trp	Gln	Lys	Ser	Thr	
					790						795					800	
	Ile	Tyr	Arg	His	Tyr	Thr	Lys	Asn	Ser	Lys	Gln	Ile	Gln	Trp	Phe	Trp	
					805					810					815		
35	Gln	Val	Val	Lys	Glu	Met	Asp	Asn	Glu	Lys	Arg	Ile	Arg	Leu	Leu	Gln	
				820					825					830			
	Phe	Val	Thr	Gly	Thr	Cys	Arg	Leu	Pro	Val	Gly	Gly	Phe	Ala	Glu	Leu	
				835				840					845				

Ile Gly Ser Asn Gly Pro Gln Lys Phe Cys Ile Asp Lys Val Gly Lys  
 850 855 860  
 Glu Thr Trp Leu Pro Arg Ser His Thr Cys Phe Asn Arg Leu Asp Leu  
 865 870 875 880  
 Pro Pro Tyr Lys Ser Tyr Glu Gln Leu Arg Glu Lys Leu Leu Tyr Ala  
 885 890 895  
 Ile Glu Glu Thr Glu Gly Phe Gly Gln Glu  
 900 905

## (2) INFORMATION FOR SEQ ID NO:49:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 673 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

GGAGAAGTGC CTGGCGTGGA CTATAACTTT CTGACTGTGA AGGAGTTCTT GGACCTCGAG 60  
 CAGAGTGGGA CTCTTCTGGA AGTCGGCACC TATGAAGGAA ACTATTATGG GACACCCAAG 120  
 CCTCCTAGCC AGCCAGTCAG TGGGAAAGTG ATCACGACGG ATGCCTTGCA CAGCCTTCAG 180  
 TCTGGCTCTA AGCAGTCGAC CCCGAAGCGA ACCAAGTCCT ACAATGATAT GCAAAATGCT 240  
 20 GGCATAGTCC ACGCGGAGAA TGAGGAGGAG GATGACGTTT CTGAAATGAA CAGCAGCTTT 300  
 ACAGCCGATT CTGGTGAACA AGAGGAGCAC ACTCTCCAAG AAACAGCATT ACCACCTGTG 360  
 AATAGTAGCA TCATCGCTGC TCCCATCACG GACCCTTCTC AGAAGTTCCC TCAATACCTA 420  
 CCTCTTTCTG CAGAGGATAA TTTAGGTCCT CTACCTGAAA ACTGGGAGAT GGCCTATACT 480  
 25 GAAAATGGAG AAGTCTATTT TATAGACCAT AACACGAAAA CAACATCTTG GTTAGACCCT 540  
 CGGTGCCTAA ACAAGCAGCA GAAGCCACTG GAAGAGTGTG AAGATGATGA AGGGGTACAC 600  
 ACCGAGGAGC TGGACAGTGA ACTAGAACTG CCTGCTGGTT GGGAAAAGAT TGAAGACCCA 660  
 TCCCCCGGAA TTC 673

## (2) INFORMATION FOR SEQ ID NO:50:

30

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 224 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

35

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Gly Glu Val Pro Gly Val Asp Tyr Asn Phe Leu Thr Val Lys Glu Phe  
 1 5 10 15  
 Leu Asp Leu Glu Gln Ser Gly Thr Leu Leu Glu Val Gly Thr Tyr Glu  
 20 25 30  
 Gly Asn Tyr Tyr Gly Thr Pro Lys Pro Pro Ser Gln Pro Val Ser Gly  
 35 40 45  
 Lys Val Ile Thr Thr Asp Ala Leu His Ser Leu Gln Ser Gly Ser Lys  
 50 55 60  
 Gln Ser Thr Pro Lys Arg Thr Lys Ser Tyr Asn Asp Met Gln Asn Ala  
 65 70 75 80  
 Gly Ile Val His Ala Glu Asn Glu Glu Glu Asp Asp Val Pro Glu Met  
 85 90 95  
 Asn Ser Ser Phe Thr Ala Asp Ser Gly Glu Gln Glu Glu His Thr Leu  
 100 105 110  
 Gln Glu Thr Ala Leu Pro Pro Val Asn Ser Ser Ile Ile Ala Ala Pro  
 115 120 125  
 Ile Thr Asp Pro Ser Gln Lys Phe Pro Gln Tyr Leu Pro Leu Ser Ala  
 130 135 140  
 Glu Asp Asn Leu Gly Pro Leu Pro Glu Asn Trp Glu Met Ala Tyr Thr  
 145 150 155 160  
 Glu Asn Gly Glu Val Tyr Phe Ile Asp His Asn Thr Lys Thr Thr Ser  
 165 170 175  
 Trp Leu Asp Pro Arg Cys Leu Asn Lys Gln Gln Lys Pro Leu Glu Glu  
 180 185 190  
 Cys Glu Asp Asp Glu Gly Val His Thr Glu Glu Leu Asp Ser Glu Leu  
 195 200 205  
 Glu Leu Pro Ala Gly Trp Glu Lys Ile Glu Asp Pro Ser Pro Gly Ile  
 210 215 220

25 (2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

30 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Ser Ser Ile Asp Met Pro  
 1 5

35 (2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 12 amino acids
  - (B) TYPE: amino acid

- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Pro Gly Thr Pro Tyr Pro Pro Pro Pro Glu Phe Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:53:

10

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Pro Gly Thr Ala Pro Pro Pro Tyr Thr Val Gly Pro Gly Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:54:

20

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Pro Gly Thr Pro Pro Pro Ala Tyr Thr Val Gly Pro Gly Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:55:

30

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Pro Gly Thr Pro Pro Pro Pro Pro Tyr Thr Val Gly Pro Gly Tyr  
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 14 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

Glu Tyr Pro Pro Tyr Pro Pro Pro Pro Tyr Pro Ser Gly Glu  
1 5 10

[illegible]

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20 Ser Lys Thr Thr Ser Pro Pro Pro Pro Tyr Ser Leu Gly Pro Leu Lys  
1 5 10 15

20	1				5					10								
----	---	--	--	--	---	--	--	--	--	----	--	--	--	--	--	--	--	--

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30 His Ser Pro Pro Leu Pro Pro Tyr Thr Pro Pro Thr Leu  
1 5 10

	His	Ser	Phe	Phe	Leu	Phe	Phe	Tyr	Thr	Pro	Pro	Thr	Leu
30	1				5					10			

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 13 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Pro Gly Thr Pro Pro Pro Asn Tyr Asp Ser Leu Arg Leu  
1 5 10

(2) INFORMATION FOR SEQ ID NO:60:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Pro Gly Thr Pro Pro Pro Lys Tyr Asn Thr Leu Arg Leu  
1 5 10

(2) INFORMATION FOR SEQ ID NO:61:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Pro Pro Pro Ala Leu Pro Pro Pro Pro Arg Pro Val Ala Asp Lys  
1 5 10

(2) INFORMATION FOR SEQ ID NO:62:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

Gly Ile Leu Ala Pro Pro Val Pro Pro Arg Asn Thr Arg  
1 5 10

(2) INFORMATION FOR SEQ ID NO:63:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

(2) INFORMATION FOR SEQ ID NO:64:

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

(2) INFORMATION FOR SEQ ID NO:65:

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65;

(2) INFORMATION FOR SEQ ID NO:66:

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 13 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Ser Ile Trp Glu Met Gly Xaa Asp Trp Trp Ala Arg Pro  
1                    5                    10

10 (2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 13 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Arg Met Ser Trp Trp Glu Glu Trp Glu Phe Gly Leu Gly  
1                    5                    10

20 (2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 13 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Ser Trp Gly Leu Asp Gly Trp Leu Val Asp Gly Trp Ser  
1                    5                    10

30 (2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 53 amino acids  
    (B) TYPE: amino acid  
    (C) STRANDEDNESS:  
    (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:



Phe Asn Asp Glu Ser Ser Glu Gly Pro Asp Lys Leu Lys Phe Lys Arg  
 1 5 10 15  
 Trp Phe Trp Ser Ile Val Glu Lys Met Asn Ile Met Glu Arg Gln His  
 20 25 30  
 Leu Val Tyr Phe Trp Thr Gly Ser Pro Ala Leu Pro Ala Ser Glu Glu  
 35 40 45  
 Gly Phe Gln Pro Leu  
 50

## (2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 52 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Tyr Lys Asn Gly Tyr Ser Met Asn His Gln Val Ile His Asp Phe Ile  
 1 5 10 15  
 Ser Ile Ile Ser Ala Phe Gly Lys His Glu Arg Arg Leu Phe Leu Gln  
 20 25 30  
 Phe Leu Thr Gly Ser Pro Arg Leu Pro Ile Gly Gly Phe Lys Ser Leu  
 35 40 45  
 Asn Pro Lys Phe  
 50

## (2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 48 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Tyr Val Gly Gly Phe Ser Asp Asp Ser Arg Ala Val Cys Trp Phe Trp  
 1 5 10 15  
 Glu Ile Ile Glu Ser Trp Asp Tyr Pro Leu Gln Arg Lys Leu Leu Gln  
 20 25 30  
 Phe Val Thr Ala Ser Asp Arg Ile Pro Ala Thr Gly Ile Ser Thr Ile  
 35 40 45

## (2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 51 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Tyr His Lys Tyr Gln Ser Asn Ser Ile Gln Ile Gln Trp Phe Trp Arg  
 1 5 10 15  
 10 Ala Leu Arg Ser Phe Asp Gln Ala Asp Arg Ala Lys Phe Leu Gln Phe  
 20 25 30  
 Val Thr Gly Thr Ser Arg Val Pro Leu Gln Gly Phe Ala Ala Leu Glu  
 35 40 45  
 Gly Met Asn  
 50

15 (2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 54 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Gly Pro Arg Arg Phe Thr Ile Glu Lys Ala Gly Glu Val Gln Gln Leu  
 1 5 10 15  
 25 Pro Lys Ser His Thr Cys Phe Asn Arg Val Asp Leu Pro Gln Tyr Val  
 20 25 30  
 Asp Tyr Asp Ser Met Arg Gln Arg Leu Thr Leu Ala Val Glu Glu Thr  
 35 40 45  
 Ile Gly Phe Gly Gln Glu  
 50

30 (2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 55 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Gly Pro Gln Ser Phe Thr Val Glu Gln Trp Gly Thr Pro Asp Arg Leu  
 1 5 10 15  
 Pro Arg Ala His Thr Cys Phe Asn Arg Leu Asp Leu Pro Pro Tyr Glu  
 20 25 30  
 Ser Phe Asp Glu Leu Trp Asp Arg Leu Gln Met Ala Ile Glu Asn Thr  
 35 40 45  
 Gln Gly Phe Asp His Val Asp  
 50 55

## (2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 52 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Lys Met Ile Ile Ala Lys Asn Gly Pro Asp Thr Glu Arg Leu Pro Thr  
 1 5 10 15  
 Ser His Thr Cys Phe Asn Val Leu Leu Leu Pro Glu Tyr Ser Ser Lys  
 20 25 30  
 Glu Lys Leu Arg Glu Arg Leu Leu Lys Ala Ile Thr Tyr Ala Arg Gly  
 35 40 45  
 Phe Gly Met Leu  
 50

## (2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 50 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Pro Ser Ile Thr Ile Arg Pro Pro Asp Asp Gln His Leu Pro Thr Ala  
 1 5 10 15  
 Asn Thr Cys Ile Ser Arg Leu Tyr Val Pro Leu Tyr Ser Ser Arg Gln  
 20 25 30  
 Ile Leu Arg Gln Arg Leu Leu Leu Ala Ile Lys Thr Arg Asn Phe Gly  
 35 40 45  
 Phe Val  
 50

## (2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 52 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

5

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

10 Ala Phe Cys Ile His Asn Gly Gly Ser Asp Leu Glu Arg Leu Pro Thr  
 1 5 10 15  
 Ala Ser Thr Cys Met Asn Leu Leu Lys Leu Pro Glu Phe Tyr Asp Glu  
 20 25 30  
 Thr Leu Leu Arg Ser Arg Leu Leu Tyr Ala Ile Glu Cys Ala Ala Gly  
 35 40 45  
 Phe Glu Leu Ser  
 15 50

## (2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 53 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

20

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

25 Pro Ser Ile Thr Ile Gln Ser Thr Ala Ser Gly Glu Glu Tyr Leu Pro  
 1 5 10 15  
 Val Ala His Thr Cys Tyr Asn Leu Leu Asp Leu Pro Lys Tyr Ser Ser  
 20 25 30  
 Arg Glu Ile Leu Ser Ala Arg Leu Thr Gln Ala Leu Asp Asn Tyr Glu  
 35 40 45  
 Gly Phe Ser Leu Ala  
 30 50

## (2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 53 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

35

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Gln Ile Val Ile Glu Ser Thr Glu Asn Pro Asp Asp Phe Leu Pro Ser  
1 5 10 15  
Val Met Thr Cys Val Asn Tyr Leu Lys Leu Pro Asp Tyr Ser Ser Ile  
20 25 30  
5 Glu Ile Met Arg Glu Arg Leu Leu Ile Ala Ala Arg Glu Gly Gln Gln  
35 40 45  
Ser Phe His Leu His  
50

(2) INFORMATION FOR SEQ ID NO:81:

- 10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 52 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Pro Ser Val Thr Ile Arg Pro Ala Asp Asp Ser His Leu Pro Thr Ala  
1 5 10 15  
Asn Thr Cys Ile Ser Arg Leu Tyr Ile Pro Leu Tyr Ser Ser Arg Ser  
20 25 30  
20 Ile Leu Arg Ser Lys Asn Leu Met Ala Ile Lys Xaa Xaa Ser Arg Asn  
35 40 45  
Phe Gly Phe Val  
50

(2) INFORMATION FOR SEQ ID NO:82:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 56 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Thr Ile Val Arg Lys Thr Phe Glu Asp Gly Leu Thr Ala Asp Glu Tyr  
1 5 10 15  
Leu Pro Ser Val Met Thr Cys Ala Asn Tyr Leu Lys Leu Pro Lys Tyr  
20 25 30  
35 Thr Ser Arg Asp Ile Met Arg Ser Arg Leu Cys Gln Ala Ile Glu Glu  
35 40 45  
Gly Ala Gly Ala Phe Leu Leu Ser

50

55

## (2) INFORMATION FOR SEQ ID NO:83:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 53 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

5

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

10

Pro Phe Lys Ile Ser Leu Leu Gly Ser His Asp Ser Asp Asp Leu Pro  
 1 5 10 15

Leu Ala His Thr Cys Phe Asn Glu Ile Cys Leu Trp Asn Tyr Ser Ser  
 20 25 30

Arg Lys Arg Leu Glu Leu Arg Leu Leu Trp Ala Ile Asn Glu Ser Glu  
 35 40 45

15

Gly Tyr Gly Phe Arg  
 50

## (2) INFORMATION FOR SEQ ID NO:84:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

20

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

25

Gly Ile Gln Lys Phe Gln Ile His Arg Asp Asp Arg Ser Thr Asp Arg  
 1 5 10 15

Leu Pro Ser Ala His Thr Cys Phe Asn Gln Leu Asp Leu Pro Ala Tyr  
 20 25 30

Glu Ser Phe Glu Lys Leu Arg His Met Leu Leu Leu Ala Ile Gln Glu  
 35 40 45

30

Cys Ser Glu Gly Phe Gly Leu Ala Asn Lys  
 50 55

## (2) INFORMATION FOR SEQ ID NO:85:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

35

## (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Pro Gly Thr Pro Pro Pro Pro Tyr Thr Val Gly Pro Gly Tyr  
1 5 10

5 (2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

His Gly Pro Thr Pro Pro Pro Pro Tyr Thr Val Gly Pro  
1 5 10

15 (2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Tyr Val Gln Pro Pro Pro Pro Pro Tyr Pro Gly Pro Met  
1 5 10

25 (2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Pro Gly Tyr Pro Tyr Pro Pro Pro Pro Glu Phe Tyr  
1 5 10

35 (2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid

- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Pro Gly Thr Pro Ala Pro Pro Tyr Thr Val Gly Pro Gly Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:90:

- 10 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Pro Gly Thr Pro Pro Ala Pro Tyr Thr Val Gly Pro Gly Tyr  
1 5 10

(2) INFORMATION FOR SEQ ID NO:91:

- 20 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Asp Ser Gly Val Arg Pro Leu Pro Pro Leu Pro Asp Pro Gly Val  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:92:

- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 22 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Val Arg Pro Leu Pro Pro Leu Pro Glu Glu Leu Pro Arg Pro Arg Arg  
1 5 10 15



Arg Pro Pro Pro Glu Asp  
20

(2) INFORMATION FOR SEQ ID NO:93:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Pro Pro Pro Ala Leu Pro Pro Pro Pro Arg Pro Val Ala Asp Lys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:94:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Ala Pro Ala Pro Pro Pro Gly Pro Pro Arg Pro Ala Ala Ala Ala  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:95:

- 25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Gly Gly Gly Phe Pro Pro Leu Pro Pro Pro Pro Tyr Leu Pro Pro Leu  
1 5 10 15

Gly

(2) INFORMATION FOR SEQ ID NO:96:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Ser Ile Ser Pro Arg Pro Arg Pro Pro Gly Arg Pro Val Ser Gly  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:97:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 17 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Pro Pro Pro Glu His Ile Pro Pro Pro Pro Arg Pro Lys Arg Ile Leu  
1 5 10 15

Glu

(2) INFORMATION FOR SEQ ID NO:98:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Lys Glu Gly Glu Arg Ala Leu Pro Ser Ile Pro Lys Leu Ala Asn  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:99:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Ser Arg Leu Lys Pro Ala Pro Pro Pro Pro Ala Ala Ser Ala Gly

1

5

10

15

## (2) INFORMATION FOR SEQ ID NO:100:

- 5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Gln Ala Ser Leu Pro Pro Val Pro Pro Arg Asp Leu Leu Leu Pro  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:101:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Pro Val Pro Pro Thr Leu Arg Asp Leu Pro Pro Pro Pro Pro Pro Asp  
 1 5 10 15  
 Arg Pro Tyr Ser  
 20

## (2) INFORMATION FOR SEQ ID NO:102:

- 25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 15 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Ser Asp Gln Gly Arg Asn Leu Pro Gly Thr Pro Val Pro Ala Ser  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:103:

- 35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 18 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Arg His Ser Arg Arg Gln Leu Pro Pro Val Pro Pro Lys Pro Arg Pro  
1 5 10 15  
Leu Leu

(2) INFORMATION FOR SEQ ID NO:104:

10

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Glu Lys Val Gly Phe Pro Val Thr Pro Gln Val Pro Leu Arg Pro Met  
1 5 10 15  
Thr Tyr

20

(2) INFORMATION FOR SEQ ID NO:105:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

25

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Pro Gln Pro His Arg Val Leu Pro Thr Ser Pro Ser Asp Ile Ala  
1 5 10 15

30

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 19 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

35

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Ala Asp Phe Gln Pro Pro Tyr Phe Pro Pro Tyr Gln Pro Ile Tyr  
1 5 10 15  
Pro Gln Ser

5

(2) INFORMATION FOR SEQ ID NO:107:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

10

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Ser Ser Ala Ala Pro Pro Pro Pro Pro Arg Arg Ala Thr Pro Glu Lys  
1 5 10 15

15

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

20

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Ser Lys Lys Gly Val Met Thr Ala Pro Pro Pro Pro Pro Pro Val  
1 5 10 15  
Tyr Glu Pro Gly Gly  
20

25

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

30

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Glu Ala Phe Gln Pro Gln Glu Pro Asp Phe Pro Pro Pro Pro Asp  
1 5 10 15

Leu Glu

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 24 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Asp Glu Leu Ala Pro Pro Leu Pro Pro Leu Pro Glu Gly Glu Val Pro  
1 5 10 15  
Pro Pro Arg Pro Pro Pro Pro Glu  
20

(2) INFORMATION FOR SEQ ID NO:111:

15

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Pro Gln Arg Arg Ala Pro Ala Val Pro Pro Ala Arg Pro Gly Ser Arg  
1 5 10 15

25 (2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Leu Gly Gly Ala Pro Pro Val Pro Ser Arg Pro Gly Ala Ser Pro Asp  
1 5 10 15

35

Gly

(2) INFORMATION FOR SEQ ID NO:113:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 62 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

GGCTCGAGNN NSNNSNNSNN SNNSNNSNNS NNSNNSNNSN NSNNSTCTAG AAGGATCGGG 60  
CC 62

10

(2) INFORMATION FOR SEQ ID NO:114:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 17 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: unknown

15

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

GGCCCCGATCC TTCTAGA 17

20 (2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 51 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS:
  - (D) TOPOLOGY: unknown

25

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Tyr Arg His Tyr Thr Arg Asn Ser Lys Gln Ile Ile Trp Phe Trp Gln  
1 5 10 15  
30 Phe Val Lys Glu Thr Asp Asn Glu Val Arg Met Arg Leu Leu Gln Phe  
20 25 30  
Val Thr Gly Thr Cys Arg Leu Pro Leu Gly Gly Phe Ala Glu Leu Met  
35 40 45  
Gly Ser Asn  
50

35 (2) INFORMATION FOR SEQ ID NO:116:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 51 amino acids
  - (B) TYPE: amino acid

(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Tyr Arg His Tyr Thr Lys Asn Ser Lys Gln Ile Gln Trp Phe Trp Gln  
1 5 10 15

Val Val Lys Glu Met Asp Asn Glu Lys Arg Ile Arg Leu Leu Gln Phe  
20 25 30

10 Val Thr Gly Thr Cys Arg Leu Pro Val Gly Gly Phe Ala Glu Leu Ile  
35 40 45

Gly Ser Asn  
50

(2) INFORMATION FOR SEQ ID NO:117:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 51 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Tyr Arg Gly Tyr Gln Glu Ser Asp Glu Val Ile Gln Trp Phe Trp Lys  
1 5 10 15

Cys Val Ser Glu Trp Asp Asn Glu Gln Arg Ala Arg Leu Leu Gln Phe  
20 25 30

25 Thr Thr Gly Thr Ser Arg Ile Pro Val Asn Gly Phe Lys Asp Leu Gln  
35 40 45

Gly Ser Asp  
50

(2) INFORMATION FOR SEQ ID NO:118:

30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 54 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Phe Asn Asp Glu Ser Gly Glu Asn Ala Glu Lys Leu Leu Ile His Trp  
1 5 10 15



Phe Trp Lys Ala Val Trp Met Met Asp Ser Glu Lys Arg Ile Arg Leu  
 20 25 30

Leu Gln Phe Val Thr Gly Thr Ser Arg Val Pro Met Asn Gly Phe Ala  
 35 40 45

Glu Leu Tyr Gly Ser Asn  
 50

5

## (2) INFORMATION FOR SEQ ID NO:119:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

10

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

15

Tyr Asp Gly Gly Tyr Thr Arg Asp Ser Val Leu Ile Arg Glu Phe Trp  
 1 5 10 15

Glu Ile Val His Ser Phe Thr Asp Glu Gln Arg Arg Leu Phe Leu Gln  
 20 25 30

Phe Thr Thr Gly Thr Asp Arg Ala Pro Val Gly Gly Leu Gly Arg Leu  
 35 40 45

## (2) INFORMATION FOR SEQ ID NO:120:

20

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 52 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

25

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Tyr Lys Gly Asp Tyr Ser Ala Thr His Pro Thr Gln Phe Lys Arg Trp  
 1 5 10 15

30

Phe Trp Ser Ile Val Glu Arg Met Ser Met Thr Glu Arg Gln Asp Leu  
 20 25 30

Val Tyr Phe Trp Thr Ser Ser Pro Ser Leu Pro Ala Ser Glu Glu Gly  
 35 40 45

Phe Gln Pro Met  
 50

## (2) INFORMATION FOR SEQ ID NO:121:

35

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Tyr Ser Gly Gly Tyr Ser Ala Asp His Pro Val Ile Arg Val Phe Trp  
1 5 10 15

Arg Val Val Glu Gly Phe Thr Asp Glu Glu Lys Arg Lys Leu Leu Lys  
20 25 30

10 Phe Val Thr Ser Cys Ser Arg Pro Pro Leu Leu Gly Phe Lys Glu Leu  
35 40 45

Tyr Pro  
50

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 50 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Pro Asp His Gly Tyr Thr His Asp Ser Arg Ala Val Lys Val Arg Leu  
1 5 10 15

Phe Trp Glu Thr Phe His Glu Phe Pro Leu Glu Lys Lys Arg Lys Phe  
20 25 30

25 Leu Leu Phe Leu Thr Gly Ser Asp Arg Ile Pro Ile Tyr Gly Met Ala  
35 40 45

Ser Leu  
50

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 50 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Ala Glu His Gly Tyr Thr Met Asp Ser Ser Ile Phe Leu Phe Glu Ile  
1 5 10 15

Leu Ser Ser Phe Asp Asn Glu Gln Gln Arg Leu Phe Leu Gln Phe Val  
20 25 30

Thr Gly Ser Pro Arg Leu Pro Val Gly Gly Phe Arg Ser Leu Asn Pro  
35 40 45

Pro Leu  
50

5

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 54 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

10

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

15

Gly Pro Gln Lys Phe Cys Ile Asp Lys Val Gly Lys Glu Thr Trp Leu  
1 5 10 15

Pro Arg Ser His Thr Cys Phe Asn Arg Leu Asp Leu Pro Pro Tyr Lys  
20 25 30

Ser Tyr Glu Gln Leu Arg Glu Lys Leu Leu Tyr Ala Ile Glu Glu Thr  
35 40 45

20

Glu Gly Phe Gly Gln Glu  
50

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2232 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

	TCGGCGGATT	CGTCGACCCA	CGCGTCCGGC	CCGAGCCCTC	GGAGGGCGGG	GATGTCCCCG	60
	AGCCTTGGA	GACCATTTCA	GAGGAAGTGA	ATATCGCTGG	AGACTCTCTC	GGTCTGGCTC	120
	TGCCCCCACC	ACCGGCCTCC	CCAGGATCTC	GGACCAGCCC	TCAGGAGCTG	TCAGAGGAAC	180
30	TAAGCAGAAG	GCTTCAGATC	ACTCCAGACT	CCAATGGGGA	ACAGTTCAGC	TCTTTGATTC	240
	AAAGAGAACC	CTCCTCAAGG	TTGAGGTCAT	GCAGTGTAC	CGACGCAGTT	GCAGAACAGG	300
	GCCATCTACC	ACCGCCCAGT	GCCCCAGCTG	GGAGAGCGCG	TTCATCAACT	GTCACGGGTG	360
	GTGAGGAACC	AACGCCATCA	GTGGCCTATG	TACATACCAC	GCCGGGTCTG	CCTTCAGGCT	420
	GGGAAGAAAG	AAAAGATGCT	AAGGGGCGCA	CATACTATGT	CAATCATAAC	AATCGAACCA	480
	CAACTTGGAC	TCGACCTATC	ATGCAGCTTG	CAGAAGATGG	TGCGTCCGGA	TCAGCCACAA	540
	ACAGTAACAA	CCATCTAATC	GAGCCTCAGA	TCCGCCGGCC	TCGTAGCCTC	AGCTCGCCAA	600
	CAGTAACTTT	ATCTGCCCCG	CTGGAGGGTG	CCAAGGACTC	ACCCGTACGT	CGGGCTGTGA	660
	AAGACACCCT	TTCCAACCCA	CAGTCCCCAC	AGCCATCACC	TTACAACTCC	CCCAAACCAC	720
35	AACACAAAGT	CACACAGAGC	TTCTTGCCAC	CCGGCTGGGA	AATGAGGATA	GCGCAAACG	780
	GCCGGCCCTT	CTTCATTGAT	CATAACACAA	AGACTACAAC	CTGGGAAGAT	CCACGTTTGA	840
	AATTTCCAGT	ACATATGCGG	TCAAAGACAT	CTTTAAACCC	CAATGACCTT	GGCCCCCTTC	900
	CTCCTGGCTG	GGAAGAAAGA	ATTCACTTGG	ATGGCCGAAC	GTTTTATATT	GATCATAATA	960
	GCAAAATTAC	TCAGTGGGAA	GACCCAAGAC	TGCAGAACCC	AGCTATTACT	GGTCCGGCTG	1020

	TCCCTTACTC	CAGAGAATTT	AAGCAGAAAT	ATGACTACTT	CAGGAAGAAA	TTAAAGAAAC	1080
	CTGCTGATAT	CCCCAATAGG	TTTGAAATGA	AACCTTCACAG	AAATAACATA	TTTGAAGAGT	1140
	CCTATCGGAG	AATTATGTCC	GTGAAAAGAC	CAGATGTCCT	AAAAGCTAGA	CTGTGGATTG	1200
	AGTTTGAATC	AGAGAAAGGT	CTTGACTATG	GGGGTGTGGC	CAGAGAATGG	TTCTTCTTAC	1260
	TGTCCAAAGA	GATGTTCAAC	CCCTACTACG	GCCTCTTTGA	GTACTCTGCC	ACGGACAAC	1320
	ACACCCTTCA	GATCAACCCT	AATTCAGGCC	TCTGTAATGA	GGATCATTG	TCCTACTTCA	1380
	CTTTTATTGG	AAAAGTTGCT	GGTCTGGCCG	TATTTTCATGG	GAAGCTCTTA	GATGGTTTCT	1440
5	TCATTAGACC	ATTTTACAAG	ATGATGTTGG	GAAAGCAGAT	AACCCTGAAT	GACATGGAAT	1500
	CTGTGGATAG	TGAATATTAC	AACCTCTTTGA	AATGGATCCT	GGAGAATGAC	CCTACTGAGC	1560
	TGGACCTCAT	GTTCTGCATA	GACGAAGAAA	ACTTTGGACA	GACATATCAA	GTGGATTTGA	1620
	AGCCCAATGG	GTCAGAAATA	ATGGTCACAA	ATGAAAACAA	AAGGGAATAT	ATCGACTTAG	1680
	TCATCCAGTG	GAGATTTGTG	AACAGGGTCC	AGAAGCAGAT	GAACGCCTTC	TTGGAGGGAT	1740
	TCACAGAACT	ACTTCCTATT	GATTTGATTA	AAATTTTGA	TGAAAATGAG	CTGGAGTTGC	1800
	TCATGTGCGG	CCTCGGTGAT	GTGGATGTGA	ATGACTGGAG	ACAGCATCTCT	ATTTACAAGA	1860
	ACGGCTACTG	CCCAAACCAC	CCCGTCATTC	AGTGGTTCTG	GAAGGCTGTG	CTACTCATGG	1920
	ACGCCGAAAA	GCGTATCCGG	TTACTGCAGT	TTGTCACAGG	GACATCGCGA	GTACCTATGA	1980
10	ATGGATTTGC	CGAACTTTAT	GGTTCCAATG	GTCCTCAGCT	GTTTACAATA	GAGCAATGGG	2040
	GCAGTCCTGA	GAAACTGCCC	AAAGCTCACA	CATGCTTTAA	TCGCCTTGAC	TTACCTCCAT	2100
	ATGAAACCTT	TGAAGATTGA	CAAGAGAAAC	TTCTCATGGC	CGTGGAATAAT	GCTCAAGGAT	2160
	TTGAAGGGGT	GGATTAAGCA	CCCTGTGCCT	CGGGGGTGGT	TGTTCTTCAA	GCAATTTCTG	2220
	CTTGCACTTT	TG					2232

## (2) INFORMATION FOR SEQ ID NO:126:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 726 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

20	Ser	Ala	Glu	Phe	Val	Asp	Pro	Arg	Val	Arg	Pro	Glu	Pro	Ser	Glu	Gly
	1				5					10					15	
	Gly	Asp	Val	Pro	Glu	Pro	Trp	Glu	Thr	Ile	Ser	Glu	Glu	Val	Asn	Ile
				20					25					30		
	Ala	Gly	Asp	Ser	Leu	Gly	Leu	Ala	Leu	Pro	Pro	Pro	Pro	Ala	Ser	Pro
				35				40					45			
	Gly	Ser	Arg	Thr	Ser	Pro	Gln	Glu	Leu	Ser	Glu	Glu	Leu	Ser	Arg	Arg
		50				55					60					
	Leu	Gln	Ile	Thr	Pro	Asp	Ser	Asn	Gly	Glu	Gln	Phe	Ser	Ser	Leu	Ile
25		65				70				75					80	
	Gln	Arg	Glu	Pro	Ser	Ser	Arg	Leu	Arg	Ser	Cys	Ser	Val	Thr	Asp	Ala
				85					90					95		
	Val	Ala	Glu	Gln	Gly	His	Leu	Pro	Pro	Ser	Ala	Pro	Ala	Gly	Arg	
				100				105						110		
	Ala	Arg	Ser	Ser	Thr	Val	Thr	Gly	Gly	Glu	Glu	Pro	Thr	Pro	Ser	Val
				115				120					125			
	Ala	Tyr	Val	His	Thr	Thr	Pro	Gly	Leu	Pro	Ser	Gly	Trp	Glu	Glu	Arg
		130				135						140				
30	Lys	Asp	Ala	Lys	Gly	Arg	Thr	Tyr	Tyr	Val	Asn	His	Asn	Asn	Arg	Thr
		145				150				155					160	
	Thr	Thr	Trp	Thr	Arg	Pro	Ile	Met	Gln	Leu	Ala	Glu	Asp	Gly	Ala	Ser
				165					170					175		
	Gly	Ser	Ala	Thr	Asn	Ser	Asn	Asn	His	Leu	Ile	Glu	Pro	Gln	Ile	Arg
				180				185						190		
	Arg	Pro	Arg	Ser	Leu	Ser	Ser	Pro	Thr	Val	Thr	Leu	Ser	Ala	Pro	Leu
				195				200					205			
	Glu	Gly	Ala	Lys	Asp	Ser	Pro	Val	Arg	Arg	Ala	Val	Lys	Asp	Thr	Leu
		210				215						220				
35	Ser	Asn	Pro	Gln	Ser	Pro	Gln	Pro	Ser	Pro	Tyr	Asn	Ser	Pro	Lys	Pro
		225				230					235				240	
	Gln	His	Lys	Val	Thr	Gln	Ser	Phe	Leu	Pro	Pro	Gly	Trp	Glu	Met	Arg
				245					250						255	

Ile Ala Pro Asn Gly Arg Pro Phe Phe Ile Asp His Asn Thr Lys Thr  
 260 265 270  
 Thr Thr Trp Glu Asp Pro Arg Leu Lys Phe Pro Val His Met Arg Ser  
 275 280 285  
 Lys Thr Ser Leu Asn Pro Asn Asp Leu Gly Pro Leu Pro Gly Trp  
 290 295 300  
 5 Glu Glu Arg Ile His Leu Asp Gly Arg Thr Phe Tyr Ile Asp His Asn  
 305 310 315 320  
 Ser Lys Ile Thr Gln Trp Glu Asp Pro Arg Leu Gln Asn Pro Ala Ile  
 325 330 335  
 Thr Gly Pro Ala Val Pro Tyr Ser Arg Glu Phe Lys Gln Lys Tyr Asp  
 340 345 350  
 Tyr Phe Arg Lys Lys Leu Lys Lys Pro Ala Asp Ile Pro Asn Arg Phe  
 355 360 365  
 Glu Met Lys Leu His Arg Asn Asn Ile Phe Glu Glu Ser Tyr Arg Arg  
 370 375 380  
 10 Ile Met Ser Val Lys Arg Pro Asp Val Leu Lys Ala Arg Leu Trp Ile  
 385 390 395 400  
 Glu Phe Glu Ser Glu Lys Gly Leu Asp Tyr Gly Gly Val Ala Arg Glu  
 405 410 415  
 Trp Phe Phe Leu Leu Ser Lys Glu Met Phe Asn Pro Tyr Tyr Gly Leu  
 420 425 430  
 Phe Glu Tyr Ser Ala Thr Asp Asn Tyr Thr Leu Gln Ile Asn Pro Asn  
 435 440 445  
 15 Ser Gly Leu Cys Asn Glu Asp His Leu Ser Tyr Phe Thr Phe Ile Gly  
 450 455 460  
 Lys Val Ala Gly Leu Ala Val Phe His Gly Lys Leu Leu Asp Gly Phe  
 465 470 475 480  
 Phe Ile Arg Pro Phe Tyr Lys Met Met Leu Gly Lys Gln Ile Thr Leu  
 485 490 495  
 Asn Asp Met Glu Ser Val Asp Ser Glu Tyr Tyr Asn Ser Leu Lys Trp  
 500 505 510  
 Ile Leu Glu Asn Asp Pro Thr Glu Leu Asp Leu Met Phe Cys Ile Asp  
 515 520 525  
 20 Glu Glu Asn Phe Gly Gln Thr Tyr Gln Val Asp Leu Lys Pro Asn Gly  
 530 535 540  
 Ser Glu Ile Met Val Thr Asn Glu Asn Lys Arg Glu Tyr Ile Asp Leu  
 545 550 555 560  
 Val Ile Gln Trp Arg Phe Val Asn Arg Val Gln Lys Gln Met Asn Ala  
 565 570 575  
 Phe Leu Glu Gly Phe Thr Glu Leu Leu Pro Ile Asp Leu Ile Lys Ile  
 580 585 590  
 Phe Asp Glu Asn Glu Leu Glu Leu Met Cys Gly Leu Gly Asp Val  
 595 600 605  
 25 Asp Val Asn Asp Trp Arg Gln His Ser Ile Tyr Lys Asn Gly Tyr Cys  
 610 615 620  
 Pro Asn His Pro Val Ile Gln Trp Phe Trp Lys Ala Val Leu Leu Met  
 625 630 635 640  
 Asp Ala Glu Lys Arg Ile Arg Leu Leu Gln Phe Val Thr Gly Thr Ser  
 645 650 655  
 Arg Val Pro Met Asn Gly Phe Ala Glu Leu Tyr Gly Ser Asn Gly Pro  
 660 665 670  
 30 Gln Leu Phe Thr Ile Glu Gln Trp Gly Ser Pro Glu Lys Leu Pro Lys  
 675 680 685  
 Ala His Thr Cys Phe Asn Arg Leu Asp Leu Pro Pro Tyr Glu Thr Phe  
 690 695 700  
 Glu Asp Leu Gln Glu Lys Leu Leu Met Ala Val Glu Asn Ala Gln Gly  
 705 710 715 720  
 Phe Glu Gly Val Asp  
 725

35 (2) INFORMATION FOR SEQ ID NO:127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

5 Trp Glu Glu Arg Lys Asp Ala Lys Gly Arg Thr Tyr Tyr Val Asn His  
1 5 10 15  
Asn Asn Arg Thr Thr Thr Trp Thr Arg Pro  
20 25

(2) INFORMATION FOR SEQ ID NO:128:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

15 Trp Glu Met Arg Ile Ala Pro Asn Gly Arg Pro Phe Phe Ile Asp His  
1 5 10 15  
Asn Thr Lys Thr Thr Thr Trp Glu Asp Pro  
20 25

(2) INFORMATION FOR SEQ ID NO:129:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

25 Trp Glu Glu Arg Ile His Leu Asp Gly Arg Thr Phe Tyr Ile Asp His  
1 5 10 15  
Asn Ser Lys Ile Thr Gln Trp Glu Asp Pro  
20 25

(2) INFORMATION FOR SEQ ID NO:130:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 107 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

35 Tyr Lys Asn Gly Tyr Cys Pro Asn His Pro Val Ile Gln Trp Phe Trp  
1 5 10 15  
Lys Ala Val Leu Met Asp Ala Glu Lys Arg Ile Arg Leu Leu Gln  
20 25 30  
Phe Val Thr Gly Thr Ser Arg Val Pro Met Asn Gly Phe Ala Glu Leu  
35 40 45  
Tyr Gly Ser Asn Gly Pro Gln Leu Phe Thr Ile Glu Gln Trp Gly Ser  
50 55 60

Pro Glu Lys Leu Pro Lys Ala His Thr Cys Phe Asn Arg Leu Asp Leu  
 65 70 75 80  
 Pro Pro Tyr Glu Thr Phe Glu Asp Leu Gln Glu Lys Leu Leu Met Ala  
 85 90 95  
 Val Glu Asn Ala Gln Gly Phe Glu Gly Val Asp  
 100 105

5 (2) INFORMATION FOR SEQ ID NO:131:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Gln Pro Leu Pro Pro Gly Trp Glu Arg Arg Val Asp Asp Arg Arg Arg  
 1 5 10 15  
 Val Tyr Tyr Val Asp His Asn Thr Arg Thr Thr Thr Trp Gln Arg Pro  
 20 25 30  
 Thr Met Glu Ser Val Arg  
 35

15

(2) INFORMATION FOR SEQ ID NO:132:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Pro Gly Leu Pro Ser Gly Trp Glu Glu Arg Lys Asp Ala Lys Gly Arg  
 1 5 10 15  
 Thr Tyr Tyr Val Asn His Asn Asn Arg Thr Thr Thr Trp Thr Arg Pro  
 20 25 30  
 Ile Met Gln Leu Ala Glu  
 35

25

(2) INFORMATION FOR SEQ ID NO:133:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

30

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Ser Phe Leu Pro Pro Gly Trp Glu Met Arg Ile Ala Pro Asn Gly Arg  
 1 5 10 15  
 Pro Phe Phe Ile Asp His Asn Thr Lys Thr Thr Thr Trp Glu Asp Pro  
 20 25 30  
 Arg Leu Lys Phe Pro Val  
 35

35

(2) INFORMATION FOR SEQ ID NO:134:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Gly Pro Leu Pro Pro Gly Trp Glu Glu Arg Ile His Leu Asp Gly Arg  
 1 5 10 15  
 Thr Phe Tyr Ile Asp His Asn Ser Lys Ile Thr Gln Trp Glu Asp Pro  
 20 25 30  
 Arg Leu Gln Asn Pro Ala  
 35

10

## (2) INFORMATION FOR SEQ ID NO:135:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

15

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Thr Ser Gln Pro Pro Pro Pro Tyr Tyr Pro Pro  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:136:

20

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

25

Tyr Val Gln Ala Pro Pro Pro Tyr Pro Gly Pro Met  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:137:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

30

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Tyr Val Gln Pro Ala Pro Pro Pro Tyr Pro Gly Pro Met  
 1 5 10

35

## (2) INFORMATION FOR SEQ ID NO:138:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids



(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

5 Tyr Val Gln Pro Pro Ala Pro Pro Tyr Pro Gly Pro Met  
1 5 10

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

Tyr Val Gln Pro Pro Pro Ala Pro Tyr Pro Gly Pro Met  
1 5 10

15 (2) INFORMATION FOR SEQ ID NO:140:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

20 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

Tyr Val Gln Pro Pro Pro Pro Ala Tyr Pro Pro Gly Pro Met  
1 5 10

(2) INFORMATION FOR SEQ ID NO:141:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

30 Ala Pro Pro Thr Pro Pro Pro Leu Pro Pro  
1 5 10

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 17 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Gln His Ser Pro Tyr Trp Ala Pro Pro Cys Tyr Thr Leu Lys Pro Glu  
 1 5 10 15  
 Thr

5 (2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Arg Asp Gly Asp Arg Asn Arg Pro Pro Val Tyr Gln Asp Leu Leu Pro  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

20 Glu Lys Ala Pro Leu Pro Pro Pro Glu Tyr Pro Asn Gln Ser  
 1 5 10

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Met Thr Pro Tyr Arg Ser Pro Pro Pro Tyr Val Pro Pro  
 1 5 10

30

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Gly Val Ile Met Tyr Ile Leu Leu Cys Gly Tyr Pro Pro Phe Tyr Ser  
 1 5 10 15

Asn His Gly Leu Ala  
20

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

10 Gly Val Leu Ile Tyr Glu Met Ala Val Gly Phe Pro Pro Phe Tyr Ala  
1 5 10 15  
Asp Gln Pro Ile Gln  
20

(2) INFORMATION FOR SEQ ID NO:148:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

20 Phe Arg Met Gln Ala Gln Pro Pro Gly Tyr Arg His Val Ala Asp  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:149:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

25 Pro Asp Ser Asp Pro Gln Ile Pro Pro Pro Tyr Val Glu Pro Thr Ala  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:150:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

35 Thr Ala Thr Ala Ser Ala Pro Pro Pro Pro Tyr Val Gly Ser Gly Leu  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:151:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:
- His Leu Tyr Ser Pro Pro Pro Pro Pro Pro Tyr Ser Gly Cys Ala  
1 5 10 15
- (2) INFORMATION FOR SEQ ID NO:152:
- 10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:
- 15 Pro His Pro Gln Pro Pro Pro Tyr Gly His Cys Val  
1 5 10
- (2) INFORMATION FOR SEQ ID NO:153:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
20 (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:
- Pro Arg Arg Gly Pro Pro Thr Tyr Arg Ala Asp Asp  
1 5 10
- 25 (2) INFORMATION FOR SEQ ID NO:154:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:
- Pro Leu Glu Pro Pro Pro Leu Tyr Leu Met Glu Asp  
1 5 10
- (2) INFORMATION FOR SEQ ID NO:155:
- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

Pro Pro Pro Ala Pro Pro Gln Tyr Pro Asp Phe Ser  
1 5 10

5 (2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

Pro Asn Ser Asp Pro Pro Arg Tyr Gln Phe Leu Trp  
1 5 10

(2) INFORMATION FOR SEQ ID NO:157:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

20 Pro His Ser Leu Pro Pro Thr Tyr Tyr Asp Asn Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO:158:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

Ile Ala Pro Pro Pro Pro Pro Tyr Asn Asn Glu Thr  
1 5 10

30 (2) INFORMATION FOR SEQ ID NO:159:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

Ser Arg Gly Met Pro Ser Tyr Glu Glu Ala Val Met Ala  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:160:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

5

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

Pro Gly Thr Pro Pro Pro Pro Asn His Asp Ser Leu Arg Leu  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:161:

10

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

15

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

Pro Gly Thr Ala Pro Pro Asn Tyr Asp Ser Leu Arg Leu  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:162:

## (i) SEQUENCE CHARACTERISTICS:

20

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

Pro Gly Thr Pro Ala Pro Asn Tyr Asp Ser Leu Arg Leu  
25 1 5 10

## (2) INFORMATION FOR SEQ ID NO:163:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

30

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

Pro Gly Thr Pro Pro Pro Asn Ala Asp Ser Leu Arg Leu  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:164:

35

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:



Leu Thr Ala Pro Pro Pro Ala Tyr Ala Thr Leu Gly Pro  
 1 5 10

(2) INFORMATION FOR SEQ ID NO:169:

- 5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 13 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

10 Leu Thr Ala Pro Pro Pro Ala Ala Ala Thr Leu Gly Pro  
 1 5 10

(2) INFORMATION FOR SEQ ID NO:170:

- 15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

Pro Pro Leu Ala Leu Thr Ala Pro Pro Pro Ala Tyr Ala Thr Leu Gly  
 1 5 10 15  
 Pro

20 (2) INFORMATION FOR SEQ ID NO:171:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

25 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

Pro Ser Pro Ala Leu Thr Ala Pro Pro Pro Ala Tyr Ala Thr Leu Gly  
 1 5 10 15  
 Pro

30 (2) INFORMATION FOR SEQ ID NO:172:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Pro Ser Pro Ala Leu Thr Ala Pro Pro Pro Ala Ala Ala Thr Leu Gly  
 1 5 10 15



Pro

## (2) INFORMATION FOR SEQ ID NO:173:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 12 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

10 Pro Ser Pro Ala Leu Thr Ala Pro Pro Pro Ala Tyr  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:174:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 17 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

Gln His Ser Pro Tyr Trp Ala Pro Pro Cys Tyr Thr Leu Lys Pro Glu  
 1 5 10 15  
 Thr

20

## (2) INFORMATION FOR SEQ ID NO:175:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

Met Thr Pro Tyr Arg Ser Pro Pro Pro Tyr Val Pro Pro  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO:176:

## (i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

35 Pro Asp Ser Asp Pro Gln Ile Pro Pro Pro Tyr Val Glu Pro Thr Ala  
 1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:177:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

Thr Ala Thr Ala Ser Ala Pro Pro Pro Pro Tyr Val Gly Ser Gly Leu  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:178:

## (i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 10 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

Ala Pro Pro Thr Pro Pro Pro Leu Pro Pro  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:179:

## (i) SEQUENCE CHARACTERISTICS:

20

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

Asn Arg Leu Asp Leu Pro Pro Tyr Lys Ser Tyr Glu Gln  
1 5 10

25

## (2) INFORMATION FOR SEQ ID NO:180:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

30

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

Asn Arg Leu Asp Leu Pro Pro Ala Lys Ser Tyr Glu Gln  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:181:

## (i) SEQUENCE CHARACTERISTICS:

35

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

Asn Arg Leu Asp Leu Pro Pro Tyr Glu Thr Phe Glu Asp  
1 5 10

5 (2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 13 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

Asn Arg Leu Asp Leu Pro Pro Ala Glu Thr Phe Glu Asp  
1 5 10

(2) INFORMATION FOR SEQ ID NO:183:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

20 Gly Leu Pro Pro Pro Tyr Asp Leu Thr Trp Val Asn  
1 5 10

(2) INFORMATION FOR SEQ ID NO:184:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

Gly Asp Val Arg Phe Trp Gly Ala Pro Pro Pro Tyr  
1 5 10

30 (2) INFORMATION FOR SEQ ID NO:185:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

Leu Lys Leu Pro Asp Tyr Trp Glu Ser Ser Ala Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:186:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

5

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

Leu Lys Leu Pro Glu Tyr Trp Glu Ser Ser Ala Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:187:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

10

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

Arg Ser Glu Arg Gly Val Pro Pro Thr Tyr Ala Glu Phe Phe Pro Met  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:188:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

20

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

Asn Trp Pro His Val Met Pro Pro Pro Tyr Ala Gln Tyr Arg  
1 5 10

25

## (2) INFORMATION FOR SEQ ID NO:189:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

30

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

Gly Ala His Asp Ser Pro Pro Pro Tyr Ser Arg Tyr Trp Pro  
1 5 10

35

## (2) INFORMATION FOR SEQ ID NO:190:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

5 Gly Pro Ser Glu Gln Pro Pro Pro Tyr Glu Tyr Thr Val Lys  
1 5 10

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

10

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

Ser Arg Ile Lys Gly Asp Pro Pro Gly Tyr Glu Glu Val Met Gly Leu  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:192:

15

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

Gln Thr Asp Tyr Tyr Pro Pro Pro Gly Tyr Pro Trp Trp Glu Ser Arg  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

25

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

30 Gly Val Glu Phe Gly Pro Pro Pro Asp Tyr Glu Ala Leu Phe Lys Pro  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:194:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: unknown

35

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

Met Leu Pro Glu Tyr Thr Glu Tyr Gly Phe Ser Met  
1 5 10

(2) INFORMATION FOR SEQ ID NO:195:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

10 Thr Leu Leu Pro Gly Tyr Leu Ser Asp Glu Tyr Trp  
1 5 10

(2) INFORMATION FOR SEQ ID NO:196:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

Leu Lys Leu Pro Asp Tyr Trp Glu Ser Ser Ala Ser  
1 5 10

(2) INFORMATION FOR SEQ ID NO:197:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

25 Leu Leu Pro Asn Tyr Gly Glu Trp Trp Arg Gly Gly  
1 5 10

(2) INFORMATION FOR SEQ ID NO:198:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

35 Ser Leu Leu Pro Thr Tyr Gly His Glu Leu Phe Trp  
1 5 10

(2) INFORMATION FOR SEQ ID NO:199:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

Ser Leu Leu Pro Glu Tyr Asn Met Pro Leu Tyr His  
1 5 10

(2) INFORMATION FOR SEQ ID NO:200:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

15 Leu Met Leu Pro Ala Tyr Asn Glu Ala Val Thr Trp  
1 5 10

(2) INFORMATION FOR SEQ ID NO:201:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

20 Leu Met Leu Pro His Tyr Gly Asp Met Gln Phe Ala  
1 5 10

(2) INFORMATION FOR SEQ ID NO:202:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

Leu Leu Pro Met Tyr Gly Glu Ala Glu Ala Trp Phe  
1 5 10

(2) INFORMATION FOR SEQ ID NO:203:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

Gln Leu Pro Ile Ser Pro Pro Pro Tyr Ser Glu Met Gly Leu  
1 5 10

(2) INFORMATION FOR SEQ ID NO:204:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

10 Gly Trp Thr Leu Gly Asp Pro Pro Pro Tyr His Ile Ala Gly  
1 5 10

(2) INFORMATION FOR SEQ ID NO:205:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- 15 (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

Arg Gly Gly Val Trp Leu Pro Pro Tyr Ser Ser Ile Asp Asn  
1 5 10

20 (2) INFORMATION FOR SEQ ID NO:206:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

25 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

His Lys Pro Leu Thr Pro Pro Pro Tyr Asp Ala His Asp Phe  
1 5 10

(2) INFORMATION FOR SEQ ID NO:207:

30 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

35 Leu Phe Trp Gln Val Gly Pro Pro Ser Tyr Glu Glu Ala Ile  
1 5 10

(2) INFORMATION FOR SEQ ID NO:208:



- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

Pro Ser Met Leu Thr Pro Pro Tyr Phe Glu His Lys Gln Asp Glu  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:209:

- 10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

15 Trp Ser Met Lys Thr Ser Pro Pro Ser Tyr Glu Ser Ile Phe Gly Leu  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:210:

- 20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

Ala Val His Ser Leu Thr Leu Pro Ala Tyr Glu Ala Thr Glu Tyr Met  
1 5 10 15

25 (2) INFORMATION FOR SEQ ID NO:211:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

Gly Arg Val Val Ser His Pro Pro Ala Tyr Cys Glu Leu Phe Lys Cys  
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:212:

- 35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

Ser Gly Arg Met Gln Gly Pro Pro Glu Tyr Gly Asp Met Glu Tyr Val  
1 5 10 15

5 (2) INFORMATION FOR SEQ ID NO:213:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

Gly Met Leu Pro Ser Tyr Glu Glu Ala Val Met Ala  
1 5 10

(2) INFORMATION FOR SEQ ID NO:214:

(i) SEQUENCE CHARACTERISTICS:

15

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

20 Pro Ile Ala Pro Pro Thr Tyr Trp Glu Trp Ala Leu  
1 5 10

(2) INFORMATION FOR SEQ ID NO:215:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

Arg Leu Pro Ala Tyr Lys Glu Pro Ala Ala Thr Phe  
1 5 10

30 (2) INFORMATION FOR SEQ ID NO:216:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

Leu Pro Ser Tyr Ser Glu Trp Val Ala Glu Thr Arg  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:217:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

5

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

Leu Pro Thr Tyr Asn Glu Tyr Leu Thr Arg Ala Ala  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:218:

10

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

15

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

Arg Val Tyr Arg Asp Leu Pro Pro Pro Tyr Pro Gln Gly Thr  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:219:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

20

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

His Arg Ser Glu Leu Pro Pro Pro Tyr Ser Glu Ala Val Lys  
1 5 10

25

## (2) INFORMATION FOR SEQ ID NO:220:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: unknown

30

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

Gly Gly Trp Arg Ala Val Pro Pro Pro Tyr Pro Gly Ser Pro  
1 5 10

35

## (2) INFORMATION FOR SEQ ID NO:221:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:



Gly Ser Trp Glu Thr Pro Pro Pro Ser Tyr Glu Glu Trp Leu Arg Lys  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:226:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

Ala His Met Tyr Arg Pro Pro Pro Pro Tyr Arg Gly Ser Ser Asp Gly  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:227:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

Gly Arg Phe Leu Arg Glu Pro Pro Pro Tyr Pro Asn Arg Asp Val Ala  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

Val Ala Met Arg Asp Pro Pro Pro Pro Tyr Asn Tyr Val Asp Ala Pro  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:229:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS:  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

Val Ala Thr Leu Arg Pro Pro Pro Ala Tyr Gly Val Glu Tyr Ser Arg  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:230:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

Met	Leu	Lys	Asp	Val	Ala	Pro	Pro	Ala	Tyr	Glu	Glu	Ala	Val	Arg	Arg
1				5					10					15	

10

15

20

25

30

35

## WHAT IS CLAIMED IS:

1. A method of identifying a polypeptide comprising a WW domain comprising:
  - (a) contacting a multivalent recognition unit  
5 complex with a plurality of polypeptides, in which the recognition unit of the complex has a selective binding affinity for a WW domain; and
  - (b) identifying a polypeptide having a selective binding affinity for said recognition unit complex.
- 10 2. The method of claim 1 in which said plurality of polypeptides is from a polypeptide expression library.
3. The method of claim 1 in which said plurality of polypeptides is obtained from a virus.
4. The method of claim 2 in which said expression  
15 library is a cDNA expression library.
5. The method of claim 2 in which said expression library is a genomic DNA library.
6. The method of claim 2 in which said expression library is a recombinant bacteriophage library.
- 20 7. The method of claim 6 in which said recombinant bacteriophage library is a recombinant M13 library.
8. The method of claim 2 in which said expression library is a recombinant plasmid or cosmid library.
9. The method of claim 1 in which the recognition unit  
25 is a peptide.
10. The method of claim 1 in which said recognition unit is a peptide having less than about 140 amino acid residues.
11. The method of claim 1 in which said recognition unit is a peptide having less than about 100 amino acid residues.
- 30 12. The method of claim 1 in which said recognition unit is a peptide having less than about 70 amino acid residues.
13. The method of claim 1 in which said recognition unit is a peptide having about 6 to 60 amino acid residues.
14. The method of claim 1 in which said recognition unit  
35 is a peptide having 20 to 50 amino acid residues.
15. The method of claim 1 in which the valency of the recognition unit in the complex is at least two.

16. The method of claim 9 in which the valency of the recognition unit in the complex is at least two.

17. The method of claim 1 in which the valency of the recognition unit in the complex is at least four.

5 18. The method of claim 9 in which the valency of the recognition unit in the complex is at least four.

19. The method of claim 17 in which the recognition unit complex is a complex comprising (a) avidin or streptavidin, and (b) biotinylated recognition units.

10 20. The method of claim 18 in which the recognition unit complex is a complex comprising (a) avidin or streptavidin, and (b) the biotinylated peptides.

21. The method of claim 2 in which said identifying step comprises selecting a positive clone, which harbors a DNA  
15 construct encoding a polypeptide having a selective affinity for said recognition unit and which polypeptide includes a WW domain of interest or a functional equivalent thereof.

22. The method of claim 21 which further comprises determining the coding sequence of said DNA construct.

20 23. The method of claim 22 which further comprises deducing an amino acid sequence from said coding sequence.

24. The method of claim 1 in which said contacting step comprises immobilizing said recognition unit complex on a solid support and bringing a solution containing said  
25 plurality of polypeptides in contact with said immobilized recognition unit complex.

25. The method of claim 1 in which said contacting step comprises separating said plurality of polypeptides and bringing a solution of said recognition unit complex in  
30 contact with said separated polypeptides.

26. The method of claim 1 in which said identifying step includes selecting a polypeptide, among said plurality of polypeptides, having a selective affinity for said recognition unit and determining the amino acid sequence of said  
35 polypeptide.

27. The method of claim 1 in which said plurality of polypeptides is immobilized on a solid support.



28. The method of claim 27 in which said contacting step comprises contacting said solid support with a solution containing said recognition unit complex.

29. The method of claim 28 which further comprises  
5 washing away any unbound recognition unit complex.

30. The method of claim 29 which further comprises detecting any recognition unit complex that remains bound to said solid support.

31. The method of claim 1 in which said selective  
10 binding affinity is on the order of about 1 nM to about 1 mM.

32. The method of claim 1 in which said selective binding affinity is on the order of about 10 nM to about 100  $\mu$ M.

33. The method of claim 1 in which said selective  
15 binding affinity is on the order of about 100 nm to about 10  $\mu$ M.

34. The method of claim 1 in which said selective binding affinity is on the order of about 100 nm to about 1  $\mu$ M.

20 35. The method of claim 9 in which said peptide is chosen from a random peptide library.

36. A method of identifying a polypeptide comprising a WW domain comprising:

(a) contacting a multivalent recognition unit  
25 complex, which complex comprises (i) avidin or streptavidin, and (ii) biotinylated recognition units, with a plurality of polypeptides from a cDNA expression library, in which the recognition unit is a peptide having in the range of 6 to 60 amino acid residues that has a selective binding affinity for  
30 a WW domain; and

(b) identifying a polypeptide having a selective binding affinity for said recognition unit complex.

37. The method of claim 36 in which the cDNA expression library is a human cDNA expression library.

35 38. The method of claim 36 in which the peptide is previously identified by a method comprising screening a random peptide library to identify a peptide having selective

binding affinity for a WW domain of interest or a functional equivalent thereof.

39. A method of identifying a polypeptide comprising a WW domain of interest or a functional equivalent thereof

5 comprising:

(a) screening a random peptide library to identify a peptide that selectively binds a WW domain of interest; and

(b) screening a cDNA or genomic expression library with said peptide or a binding portion thereof to identify a  
10 polypeptide that selectively binds said peptide.

40. The method of claim 39 in which the screening step (b) is carried out by use of said peptide in a multivalent peptide complex.

41. The method of claim 40 in which the screening step  
15 (b) is carried out by use of said peptide in a complex comprising streptavidin and biotinylated peptide.

42. The method of claim 40 in which the screening step (b) is carried out by use of said peptide in the form of multiple antigen peptides (MAP).

20 43. The method of claim 40 in which the screening step (b) is carried out by use of said peptide cross-linked to bovine serum albumin or keyhole limpet hemocyanin.

44. A method of identifying a polypeptide comprising a WW domain of interest or a functional equivalent thereof  
25 comprising:

(a) screening a random peptide library to identify a plurality of peptides that selectively bind a WW domain of interest;

(b) determining at least part of the amino acid  
30 sequences of said peptides;

(c) determining a consensus sequence based upon the determined amino acid sequences of said peptides; and

(d) screening a cDNA or genomic expression library with a peptide comprising the consensus sequence to identify a  
35 polypeptide that selectively binds said peptide.

45. The method of claim 44 in which the screening step (d) is carried out by use of said peptide in a multivalent peptide complex.

46. A method of identifying a polypeptide comprising a WW domain of interest or a functional equivalent thereof comprising:

(a) screening a random peptide library to identify a first peptide that selectively binds a WW domain of interest;

10 (b) determining at least part of the amino acid sequence of said first peptide;

(c) searching a database containing the amino acid sequences of a plurality of expressed natural proteins to identify a protein containing an amino acid sequence  
15 homologous to the amino acid sequence of said first peptide; and

(d) screening a cDNA or genomic expression library with a second peptide comprising the sequence of said protein that is homologous to the amino acid sequence of said first  
20 peptide.

47. An assay kit comprising in one or more containers:

(a) a purified polypeptide comprising a WW domain; and

(b) a purified recognition unit having a selective  
25 binding affinity for said WW domain in said polypeptide.

48. The assay kit of claim 47 in which said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 46, 48, 50, and 126.

49. The assay kit of claim 47 in which said polypeptide  
30 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 30-38 and 127-129.

50. The assay kit of claim 47 in which said recognition unit is a peptide.

51. The assay kit of claim 47 in which said polypeptide  
35 or recognition unit is labeled.

52. The assay kit of claim 51 in which said polypeptide or recognition unit is labeled with an enzyme.

53. The assay kit of claim 51 in which said polypeptide or recognition unit is labeled with an epitope.

54. The assay kit of claim 51 in which said polypeptide or recognition unit is labeled with a chromogen.

5 55. The assay kit of claim 51 in which said polypeptide or recognition unit is labeled with biotin.

56. The assay kit of claim 47 in which said polypeptide or recognition unit is immobilized on a solid support.

57. An assay kit comprising in one or more containers:

10 (a) a plurality of purified different polypeptides, each polypeptide in a separate container and each polypeptide containing a WW domain; and

(b) at least one peptide having a selective affinity for the WW domain in each of said plurality of  
15 polypeptides.

58. A kit comprising a plurality of purified polypeptides comprising a WW domain, each polypeptide in a separate container, and each polypeptide having a WW domain of a different sequence but capable of displaying the same  
20 binding specificity.

59. The kit of claim 58 in which the polypeptides have an amino acid sequence selected from the group consisting of: SEQ ID NO: 46, 48, 50, and 126.

60. The kit of claim 58 in which the WW domains consist  
25 of an amino acid sequence selected from the group consisting of: SEQ ID NO: 30-38 and 127-129.

61. A method for screening a potential drug candidate comprising:

(a) allowing at least one polypeptide comprising a  
30 WW domain to come into contact with at least one recognition unit having a selective affinity for said WW domain in said polypeptide, in the presence of an amount of a potential drug candidate, such that said polypeptide and said recognition unit are capable of interacting when brought into contact with  
35 one another in the absence of said drug candidate; and

(b) determining the effect, if any, of the presence of the amount of said drug candidate on the interaction of said polypeptide with said recognition unit.

62. The method of claim 61 in which the effect of the  
5 drug candidate upon multiple, different interacting polypeptide-recognition unit pairs is determined in which at least some of said polypeptides have a WW domain that differs in sequence but is capable of displaying the same binding specificity as the WW domain in another of said polypeptides.
- 10 63. The method of claim 61 in which at least one of said at least one polypeptide or recognition unit contains a consensus WW domain and consensus recognition unit, respectively.
64. The method of claim 61 in which the polypeptide is a  
15 polypeptide identified by the method of claim 1.
65. The method of claim 61 in which the drug candidate is an inhibitor of the polypeptide-recognition unit interaction that is identified by detecting a decrease in the binding of polypeptide to recognition unit in the presence of  
20 such inhibitor.
66. A purified polypeptide comprising a WW domain, said WW domain consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 30-38 and 127-129.
67. A purified polypeptide comprising a WW domain, said  
25 polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46, 48, 50, and 126.
68. A purified DNA encoding a WW domain, said DNA comprising a sequence selected from the group consisting of SEQ ID NOs: 45, 47, 49, and 125.
- 30 69. A purified DNA encoding a polypeptide consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 46, 48, 50, and 126.
70. A purified DNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: SEQ  
35 ID NOs: 30-38 and 127-129.

71. A purified molecule comprising a WW domain of a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 46, 48, 50, or 126.

72. A fusion protein comprising (a) an amino acid sequence comprising a WW domain of a polypeptide having the amino acid sequence of SEQ ID NO: 46, 48, 50 or 126, joined via a peptide bond to (b) an amino acid sequence of at least six amino acids from a different polypeptide.

73. A purified DNA encoding the fusion protein of claim 72.

74. A nucleic acid vector comprising the DNA of claim 73 operably linked to a non-native promoter.

75. A nucleic acid vector comprising the DNA of claim 68 operably linked to a non-native promoter.

76. A nucleic acid vector comprising the DNA of claim 70 operably linked to a non-native promoter.

77. A recombinant cell containing the nucleic acid vector of claim 74, 75, or 76.

78. A purified nucleic acid hybridizable to a nucleic acid having a sequence selected from the group consisting of: SEQ ID NOS: 45, 47, 49, and 125.

79. A method of producing the fusion protein of claim 72 comprising culturing a recombinant cell containing a nucleic acid vector encoding said fusion protein such that said fusion protein is expressed, and recovering the expressed fusion protein.

80. A method of producing the fusion protein of claim 68 comprising culturing a recombinant cell containing a nucleic acid vector encoding said polypeptide such that said polypeptide is expressed, and recovering the expressed polypeptide.

81. The method of claim 61 in which said polypeptide is a polypeptide containing a WW domain produced by a method comprising:

(i) screening a peptide library with a WW domain to obtain one or more peptides that bind the WW domain;

(ii) using one of the peptides from step (i) to screen a source of polypeptides to identify one or more polypeptides containing a WW domain;

(iii) determining the amino acid sequence of the  
5 polypeptides identified in step (ii); and

(iv) producing the one or more novel polypeptides containing a WW domain.

82. The method of claim 61 in which said polypeptide is a polypeptide containing a WW domain produced by a method  
10 comprising:

(i) screening a peptide library with a WW domain to obtain a plurality of peptides that bind the WW domain;

(ii) determining a consensus sequence for the peptides obtained in step (i);

15 (iii) producing a peptide comprising the consensus sequence;

(iv) using the peptide comprising the consensus sequence to screen a source of polypeptides to identify one or more polypeptides containing a WW domain;

20 (v) determining the amino acid sequence of the polypeptides identified in step (iv); and

(vi) producing the one or more polypeptides containing a WW domain.

83. A method of determining the potential  
25 pharmacological activities of a molecule comprising:

(a) contacting the molecule with a compound comprising a WW domain under conditions conducive to binding;

(b) detecting or measuring any specific binding that occurs; and

30 (c) repeating steps (a) and (b) with a plurality of different compounds, each compound comprising a WW domain of different sequence but capable of displaying the same binding specificity.

84. A method of identifying a compound that affects the  
35 binding of a molecule comprising a WW domain to a recognition unit that selectively binds to the WW domain comprising:

(a) contacting the molecule comprising the WW domain and the recognition unit under conditions conducive to binding in the presence of a candidate compound and measuring the amount of binding between the molecule and the recognition unit in which the WW domain has an amino acid sequence selected from the group consisting of: SEQ ID NOS: 30-38 and 127-129;

(b) comparing the amount of binding in step (a) with the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound, where a difference in the amount of binding between step (a) and the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound indicates that the candidate compound is a compound that affects the binding of the molecule comprising a WW domain and the recognition unit.

85. The method of claim 20 in which the recognition unit complex is a complex comprising (a) streptavidin conjugated to alkaline phosphatase; and (b) the biotinylated peptides.

86. A method of identifying a polypeptide having a WW domain of interest comprising:

(a) contacting a recognition unit that is a peptide having 140 amino acids or fewer with a plurality of polypeptides from a cDNA or genomic expression library, said recognition unit having selective binding affinity for a WW domain; and

(b) identifying a polypeptide having a selective binding affinity for said recognition unit complex.

87. An antibody to a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 30-38 and 127-129.

88. An antibody to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 46, 48, 50, and 126.



89. A method of identifying a compound that affects the binding of a molecule comprising a WW domain and a recognition unit that selectively binds to the WW domain comprising:

- (a) contacting the molecule comprising the WW domain and the recognition unit under conditions conducive to binding in the presence of a candidate compound and measuring the amount of binding between the molecule and the recognition unit;
- (b) comparing the amount of binding in step (a) with the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound, where a difference in the amount of binding between step (a) and the amount of binding known or determined to occur between the molecule and the recognition unit in the absence of the candidate compound indicates that the candidate compound is a compound that affects the binding of the molecule comprising a WW domain and the recognition unit;

where the compound is not a peptide.

90. A purified polypeptide comprising a HECT domain, said HECT domain having an amino acid sequence selected from the group consisting of: SEQ ID NOS: 115, 116, 124, and 130.

91. A method of identifying a polypeptide comprising a HECT domain comprising:

- (a) contacting a multivalent recognition unit complex with a plurality of polypeptides, in which the recognition unit of the complex has a selective binding affinity for a HECT domain; and
- (b) identifying a polypeptide having a selective binding affinity for said recognition unit complex.

92. A purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 183-230, as depicted in Figure 27.

93. The purified polypeptide of claim 92 in which said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 183-193.

94. The purified polypeptide of claim 92 in which said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 194-212.

95. The purified polypeptide of claim 92 in which said  
5 polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 213-230.

96. A purified DNA encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 183-230, as depicted in Figure 27.

10 97. The purified DNA of claim 96 in which said encoded polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 183-193.

98. The purified DNA of claim 96 in which said encoded polypeptide comprises an amino acid sequence selected from the  
15 group consisting of SEQ ID NOs: 194-212.

99. The purified DNA of claim 96 in which said encoded polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 213-230.

100. A purified molecule comprising an amino acid  
20 sequence selected from the group consisting of SEQ ID NOs: 183-230, as depicted in Figure 27.

101. A purified polypeptide consisting essentially of a WW domain, said WW domain having an amino acid sequence selected from the group consisting of: SEQ ID NOs: 30-38 and  
25 127-129.

102. A purified polypeptide, the amino acid sequence of which is selected from the group consisting of SEQ ID NOs: 46, 48, 50, and 126.

103. A purified DNA encoding a polypeptide, the amino  
30 acid sequence of which polypeptide consists essentially of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 30-38 and 127-129.

104. A purified molecule consisting essentially of a WW domain of a polypeptide, the amino acid sequence of the WW  
35 domain being selected from the group consisting of: SEQ ID NO: 46, 48, 50, and 126.

105. A fusion protein consisting essentially of (a) an amino acid sequence selected from the group consisting of SEQ ID NOS: 46, 48, 50, and 126, joined via a peptide bond to (b) an amino acid sequence of at least six amino acids from a  
5 different polypeptide.

106. A purified DNA encoding the fusion protein of claim 105 operably linked to a non-native promoter.

107. A nucleic acid vector comprising the DNA of claim 106 operably linked to a non-native promoter.

10 108. A nucleic acid vector comprising the DNA of claim 96 operably linked to a non-native promoter.

109. A nucleic acid vector comprising the DNA of claim 103 operably linked to a non-native promoter.

15 110. A recombinant cell containing the nucleic acid vector of claim 107, 108, or 109.

111. The purified polypeptide of claim 92 in which the amino acid sequence of said polypeptide is selected from the group consisting of SEQ ID NOS: 183-230.

20

25

30

35

1/34




FIG.1

2/34




FIG.2

3/34




FIG.3

4/34



FIG.4

5/34

SEQ. ID NO.

GENE/SPECIES	POS.	WWW DOMAIN SEQUENCES	ACC. NO.	
WWP1-1	?	LPSGWCWEQRKDPHGRTYYVDHNTRTTTWERPQPLPPG		30
WWP1-2	?	QPLPPGWERRVDDRRRVYYVDHNTRTTTWQRPTMESVR		131
WWP1-3	?	GPLPPGWEKRV DSTDRVYFVNHNKTTQWEDPRTQGLQ		32
WWP1-4	?	EPLPEGWEIRYTRGVRYFVDHNTRTTTFKDPRNGKSS		33
WWP2-1	?	DALPAGWEQREL PNGRVYYVDHNKTTTWERPLPPGWE		34
WWP2-2	?	RPLPPGWEKRTDPRGRFYVDHNTRTTTWQRPTAEYVR		35
WWP2-3	?	GPLPPGWEKRQD .NGRVYYVNHNTRTTQWEDPRTQGM I		36
WWP2-4	?	PALPPGWE MKYTSEGVR YFVDHNTRTTTFKDPRPGFES		37
WWP3	?	GPLPENWEMAYTENGEVYFIDHNKTTSWLDPRCLNKO		38
WWP4-1	?	PGLPSGWEERKDAKGRTYVNHNNRTTTWTRPIMQLAE		132
WWP4-2	?	SFLPPGWEMRIAPNGRPFFIDHNKTTTWEDPRLKFPV		133
WWP4-3	?	GPLPPGWEERIHL DGRTFYIDHNSKITQWEDPRLQNP A		134
Yap/HUMAN	171	VPLPAGWEMAKTSSGQRYFLNHIDQTTTWQDPRKAMLS	X80507	12
Yap/MOUSE-1	151	VPLPAGWEMAKTSSGQRYFLNHNDQTTTWQDPRKAMLS	X80508	15
Yap/CHICK-1	169	VPLPPGWEMAKTPSGQRYFLNHIDQTTTWQDPRKAMLS	X76483	13
Yap/CHICK-2	229	GPLPDGWEQAMTQDGEIYYINHKNTTSWLDPRLDPRF	X76483	14
Yap/MOUSE-2	218	GPLPDGWEQAMTQDGEVYYINHKNTTSWLDPRLDPRF	X80508	16
Ned4/HUMAN-1	218	SPLPPGWEERQDILGRTYVNHESRRTQWKRPTQDNL	D42055	17
Ned4/MOUSE-1	?	SPLPPGWEERQDVLGRTYVNHESRRTQWKRPSDDDL	D10714	18
Rsp5/YEAST-1	228	GRLPPGWERRTDNFGRTYYVDHNTRTTTWKRPTLDQTE	L11119	19
Ned4/HUMAN-2	375	SGLPPGWEEKQDERGRSYYVDHNSRTTTWTKPTVQATV	D42055	21
Ned4/MOUSE-2	?	SGLPPGWEEKQDDRGRSYYVDHNSKTTTWSKPTMQDDP	D10714	20
Rsp5/YEAST-2	331	GELPSGWEQRF TPEGRAYFVDHNTRTTTWVDP RRQYI	L11119	22
Ned4/HUMAN-3	448	GFLPKGWEVRHAPNGRPFFIDHNKTTTWEDPRLKIPA	D42055	23
NED4/MOUSE-3	?	GPLPPGWEERTHTDGRVFFINHN I KKTQWEDPRLQNV A	D10714	24
Rsp5/YEAST-3	387	GPLPSGWE MRLTNTARVYFVDHNKTTTWDDPRLPSSL	L11119	26
Ned4/HUMAN-4	500	GPLPPGWEERTHTDGRIFYINHN I KRTQWEDPRL ENVA	D42055	25
Dmd_HUMAN	3052	TSVQGPWERAISP NKVPYYINHETQTTCWDHPKMTELY	P11532	27
Dmd/Torco	253	TSVQGPWERAISP NKVPYYMNHQTQTTCWDHPKMTELY	M37645	28
Utro/HUMAN	2813	TSVQLPWQRSISHNKVPYYINHQTQTTCWDHPKMTELF	X69086	29
* * *				
CONSENSUS		LPLGWEXXXtltGtXYyXHNtltTTtWXtPl		

FIG.5



6/34




FIG.6A




FIG.6B

7/34

## WW DOMAIN CLONES

PEPTIDE	NAME	SEQUENCE	SEQ. ID NO.	WWP1	WWP2	WWR3	
SH3001	WBP-1	PGTPPPPYTVGPGY	85	+++	+++	+++	-
TPPY	WBP-1	HGTPPPPYTVGP	86	+++	++	++	-
QPPY	WBP-2	YVQPPPPYPGPM	87	+++	+++	+++	++
YPPE	WBP-2	PGYPYPPPEFY	88	-	-	-	-
WW005	WBP-1	PGTPAPPYTVGPGY	89	+++	+++	+++	-
WW006	WBP-1	PGTPPAPYTVGPGY	90	-	-	-	-
bSH3002	K <sup>+</sup> CHANNEL	DSGVRPLPLPDPCV	91	-	-	-	-
bSH3003	K <sup>+</sup> CHANNEL	VRPLPLPEELPRRRPPED	92	-	-	-	-
bSH3004	M4 AChr	PPPALPPPRPVADK	93	-	-	-	-
bSH3005	β1 ADRENERGIC	APAPPPGPPRPAAAA	94	-	-	-	-
bSH3006	RasGap	GGGPPPLPPPYLPPLG	95	++	++	++	-
bSH3007	MEK	SISPRRPPGRPVSG	96	-	-	-	-
bSH3008	P Tyr PHOSP.	PPPEHPPPPPKRILE	97	-	-	-	-
bSH3009	Fok	KEGERALPSIPKLAN	98	-	-	-	-
bSH3010	c-Abl	SRLKPAPPPPAASAG	99	-	-	-	-
bSH3011	c-Cbl	QASLPPVPPRDLLLP	100	-	-	-	-
bSH3012	c-Cbl	PVPPTLRDLPPPPPPDRPYS	101	-	-	-	-
bSH3013	Ca <sup>2+</sup> CHANNEL	SDQGRNLPGTPVPAS	102	-	-	-	-
bSH3014	Ca <sup>2+</sup> CHANNEL	RHSRRQLPPVPPKPRPLL	103	-	-	-	-
bSH3015	Nef	EKVGFPVTPQVPLRPMY	104	-	-	-	-
bSH3016	Mus CADHERIN	PQPHRVLPTSPDIA	105	-	-	-	-
bSH3017	AP2	ADFQPPYFPPPYQPTYQS	106	++	++	++	-
bSH3018	ACTIN BINDING	SSAAPPPPPRRATPEK	107	-	-	-	-
bSH3019	EZRIN	SKKGVMTAPPPPPPVYEPGG	108	-	-	-	-
bSH3020	VINCULIN	EAFQPEPDFPPPPPDLE	109	-	-	-	-
bSH3021	VINCULIN	DELAPPKPLPEGEVPPRRPPPE	110	-	-	-	-
bSH3022	DYNAMIN	PQRRAPAVPPARPGSR	111	-	-	-	-
bSH3023	DYNAMIN	LGGAPPVPSRPGASPDG	112	-	-	-	-
NUMBER OF DOMAINS ENCODED BY CLONE				4	4	4	1

FIG.7

8/34




FIG.8

9/34




FIG.9

10/34




FIG.10

11/34




FIG.11

12/34




FIG.12

13/34

SPECIFICITY CONTINUUM




FIG.13



SEQ ID NO.

GENE	HECT DOMAIN SEQUENCE	
	*-100	
WMP1:	YR-HYTRNSKQ---I I W F W Q F V K E T D N E V R M R L L Q F V T G T C R L P L G G F A E L M G S N	115
WMP2:	YR-HYTKNSKQ---I Q W F W Q V V K E M D N E K R I R L L Q F V T G T C R L P V G G F A E L I G S N	116
RSP5:	YR-GYQESDEV---I Q W F W K C V S E W D N E Q R A R L L Q F T T G T S R I P V N G F K D L Q G S D	117
NEDD-4:	F N D E S G E N A E K L L - I H W F W K A V W M D S E K R I R L L Q F V T G T S R V P M N G F A E L Y G S N	118
EG-AP:	Y D G G Y T R D S V L --- I R E F W E I V H S F T D E Q R R L F L Q F T T G T D R A P V G G L G R L ---	119
RAT p100:	Y K G D Y S A T H P T - Q F K R W F W S I V E R M S M T E R O D L V Y F W T S S P S L P A S E E G F Q P M ---	120
D13635:	Y S G G Y S A D H P V --- I R V E W R V V F G F T D E E K R K L L K F V T S C S R P P L L G F K E L Y P ---	121
D25215:	P D H G Y T H D S R A V K - V R L F W E T F H E F P L E K K R K F L L F L T G S D R I P I Y G M A S L ---	122
D28476:	A E H G Y T M D S S I --- F L F - E I L S S F D N E Q Q R L F L Q F V T G S P R L P V G G F R S L N P P L	123
DROS. HYD:	F N D E S S E G P D K L K F K R W F W S I V E K M N I M E R Q H L V Y F W T G S P A L P A S E E G F Q P L ---	70
YKL162:	Y K N G Y S M N H Q V --- I H D F I S I S A F G K H E R R L F L Q F T G S P R L P I G G F K S L N P K F	71
ScORF	Y V G G F S D D S R A --- V C W F W E I I E S W D Y P L Q R K L L Q F V T A S D R I P A I G I S T I ---	72
UreB1:	Y - H K Y Q S N S I Q --- I Q W F W R A L R S F D Q A D R A K F L Q F V T G T S R V P L Q G F A A L E G M N	73
	-50	
WMP2:	G P Q K F C I D - K V G K E T W L P R S H T C F N R L D L P P Y K S Y E Q L R E K L L Y A I - E E T E C F G G E	124
RSP5:	G P R R F T I E - K A G E V Q Q L P K S H T C F N R V D L P Q Y V D Y D S M R Q R L T L A V - E E T I G F G G E	74
NEDD-4:	G P Q S F T V E - Q W G T P D R L P R A H T C F N R L D L P P Y E S F D E L W D R L Q M A I - E N T Q G F D H V D	75
E6-AP:	--- K M I I A K N G P D T E R L P T S H T C F N V L L L P E Y S S K E K L R E R L L K A I T - Y A R G F G M L	76
RAT p100:	--- P S I T I R P P D D Q H L P T A N T C I S R L Y V P L Y S S R Q I L R Q R L L A I K --- T R N F G F V	77
D13635:	--- A F C I H N G G S D L E R L P T A S T C M N L L K L P E F Y D E T L L R S R L L Y A I - E C A A G E E L S	78
D25215:	--- P S I T I Q S T A S G E E Y L P V A H T C Y N L L D L P K Y S S R E I L S A R L I Q A L - D N Y E G E S L A	79
D28476:	--- Q I V I E S T E N P D D F L P S V M T C V N Y L K L P D Y S S I E I M R E R L L I A A R E G Q Q S F H L S	80
Dros. HYD:	--- P S V I I --- R P A D D S H L P T A N T C I S R L Y I P L Y S S R S I L R S K N L M A I K --- S R N F G F V	81
YKL162	T I V R K T F E D G L T A D E Y L P S V M T C A N Y L K L P K Y T S R D I M R S R L C G A I E E G A G A F L L S	82
ScORF:	--- P F K I S L L G S H D S D L P L A H T C F N E I C L W N Y S S R K R L E L R L L W A I - N E S E G Y G F R	83
UreB1:	G I Q K F Q I H R D D R S T D R L P S A H T C F N Q L D L P A Y E S F E K L R H M L L L A I Q E C S E G F G L A N K	84

FIG.14

$$((+)=1.0-2.0 \quad (++)=2.0-3.0 \quad (++++)=>3.0$$

PEPTIDE	SEQUENCE	SEQ.
WBP-1	PGTPPPPYTVGPGY	85
WBP-2A	YVQPPPPPYPGPM	8
WBP-2B	PGYPYPPPPPEFY	7
WBP-2C	TSQPPPPPYYP	135
WBP-1-Pro1	PGTAPPPTYTVGPGY	53
WBP-1-Pro2	PGTPPAPYTVGPGY	89
WBP-1-Pro3	PGTPPAPYTVGPGY	90
WBP-1-Pro4	PGTTPPAYTVGPGY	54
WBP-2A-Pro1	YVQAPPPPYPGPM	136
WBP-2A-Pro2	YVQAPPPPYPGPM	137
WBP-2A-Pro3	YVQPPAPPYPGPM	138
WBP-2A-Pro4	YVQPPAPPYPGPM	139
WBP-2A-Pro5	YVQPPPPAYPGPM	140
pWBP-1	PGTPPPPPYTVGPGY	55
RasGap	GGGFPLPPPPYLPPLG	95
AP-2	ADFQPPYFPYPYQPIYPQS	106
p53BP-2	EYPPYPPPPYPSGE	56
IL-6R $\alpha$	SKTTSPPPPYSLGPLK	57
CLCN5	HSPPLPPYTPPTL	58
ENaC $\beta$	PGTPPPNYDSLRL	59
ENaC $\beta$ -P616L	PGTPPLNYDSLRL	1
ENaC $\gamma$	PGTPPPKYNTLRL	60
FORMIN	APPTPPPLPP	141
M4 A Chr	PPPALPPPPRPVADK	61
c-Ab1	SRLKPAPPPPPAASAG	99
Src	GILAPPVPPRNTIR	62
Crk	SVPAAPPLPPKSGG	63

0.0 UNITS SCALE (-) = 0 - 0.5 (+) = 0.5 - 1.0

**FIG. 15A**

16/34

SEQ. ID NO.		GST FUSION PROTEINS			
PEPTIDE	SEQUENCE		WMP4.1	WMP4.2	WMP4.3
WBP-1	PGT <u>PPPPY</u> TVGPGY	85	+++	++	+
WBP-2A	YVQ <u>PPPPY</u> PGPM	8	+++	+++	+++
WBP-2B	PGY <u>PPPP</u> PEFY	7	-	-	-
WBP-2C	TSQ <u>PPPPY</u> YPP	135	+++	+++	-
WBP-1-Pro1	PGT <u>APPPY</u> TVGPGY	53	+++	+++	+
WBP-1-Pro2	PGT <u>PPAPY</u> TVGPGY	89	-	-	-
WBP-1-Pro3	PGT <u>PPAPY</u> TVGPGY	90	-	-	-
WBP-1-Pro4	PGT <u>PPPAY</u> TVGPGY	54	+++	++	-
WBP-2A-Pro1	YVQ <u>APPPY</u> PGPM	136	+++	+++	+++
WBP-2A-Pro2	YVQ <u>APPPY</u> PGPM	137	+++	+++	+++
WBP-2A-Pro3	YVQ <u>PPAPPY</u> PGPM	138	+	++	+
WBP-2A-Pro4	YVQ <u>PPAPY</u> PGPM	139	-	-	-
WBP-2A-Pro5	YVQ <u>PPPPAY</u> PGPM	140	+++	+++	+++
pWBP-1	PGT <u>PPPPpY</u> TVGPGY	55	-	-	-
RasGap	GGG <u>FPLPPPPY</u> LPLG	95	++	++	+
AP-2	ADFQ <u>PPYFPPPY</u> QPIYPQS	106	++	++	-
p53BP-2	EYPPY <u>PPPPY</u> PSGE	56	+++	+++	++
IL-6R $\alpha$	SKTT <u>SPPPPY</u> SLGPLK	57	-	-	+
CLCN5	HSP <u>LPPYTP</u> PTL	58	-	-	-
FORMIN	AP <u>TPPPLP</u> P	141	-	-	-
M4 A ChR	PPP <u>ALPPPPR</u> PVADK	61	-	-	-
c-Abl	SRLK <u>PAPPPPA</u> ASAG	99	-	-	-
Src	GIL <u>APPVPPR</u> NTR	62	-	-	-
Crk	SVP <u>APPPLPPK</u> SGG	63	-	-	-

FIG.15B

17/34

SEQ. ID NO.		GST FUSION PROTEINS			
PEPTIDE	SEQUENCE		WMP4.1	WMP4.2	WMP4.3
IL-2R Hum	QHSPYWAPPCYTLKPET	142	++	-	-
IL-7R	RDGDRNRPPVYQDLLP	143	-	+++	++
Dystcon-1	EKAPLPPPEYPNQS	144	-	+	-
Dystcon-2	MTPYRSPPPYVPP	145	-	+	-
MAPKAP2	GVIMYILLCGYPPFYSNHGLA	146	-	-	-
PRKACG	GVL IYEMAVGFPPFYADQPIQ	147	-	+	-
LAP Hum	FRMQAQPPGYRHVAD	148	-	-	-
HTLV-1	PDSDPQIPPPYVEPTA	149	-	++	-
RSV-1	TATASAPPPPYVGSGL	150	+	++	-
EGR2	HLYSPPPPPPPYSGCA	151	+++	+++	+++
FIBNECT	PHPQPPPYGHCV	152	+++	+++	++
LAMININ	PRRGPTTYRADD	153	-	-	-
NTPHIN-3	PLEPPPLYLMED	154	-	-	-
CDX BOX	PPPAPPQYPDFS	155	-	-	-
MEL. AG	PNSDPPTYQFLW	156	+++	+++	+++
FU TARZAZU	PHSLPPTYDNS	157	-	-	-
INSCUTEABLE	IAPPPPPPYNNET	158	-	+	-
WMP3.CW3	SRGMPSYEEAVMA	159	-	++	++

FIG.15C

18/34

SEQ. ID NO.	PEPTIDE	SEQUENCE	WW DOMAIN/GST FUSION PROTEINS										SH3 DOMAINS	
			WWP1.1	WWP1.2	WWP1.3	WWP1.4	WWP2.1	WWP2.2	WWP2.3	WWP2.4	WWP3	Fyn	Lyn	
95	Ras-Gap	GGGFPPLPPPPYLPLG	++++	-	+++	-	+++	-	+++	-	-	-	-	
106	AP-2	ADFQPPYFPPPYQPIYPQS	+++	+	-	-	-	-	-	-	-	-	-	
56	p53BP-2	EYPPYPPPPYPSGE	++++	+++	+++	-	+++	+++	+++	-	+	-	-	
58	CLCN5	HSPPLPPYTPPTL	++	-	+	++	++	-	-	+++	-	-	-	
174	IL-2R $\gamma$	QHSPYWAPPCYTILKPET	+	-	-	-	-	-	++	-	-	-	-	
57	IL-6R $\alpha$	SKTTSPPPPYSLGPLK	+++	+	+++	-	+++	++	+++	-	+++	-	-	
175	$\beta$ -DYSTROGLYCAN	MTYRSPPPYVPP	+	-	+	-	-	-	+++	+	+++	-	-	
176	HIV-1 Gag	PDSDPQIPPPYVEPTA	+	-	-	-	++	-	-	-	-	-	-	
177	RSV-1 Gag	TATASAPPPPYVCSGL	++++	-	+++	-	+++	+	++	-	+++	-	-	
178	FORMIN	APPTPPPLPP	-	-	-	-	-	-	-	-	-	-	-	

FIG.15D

19/34

GACTAATCATGTACCTACAAGCACTCTAGTCCAAAACCTCA 40  
TGCTGCTCGTATGTAGTTAATGGAGACAACACACCTTCAT 80  
CTCCGTCTCAGGTTGCTGCCAGACCCAAAAATACACCAGC 120  
TCCAAAACCACTCGCATCTGAGCCTGCCGATGACACTGTT 160  
AATGGAGAATCATCCTCATTTCACCAACTGATAATGCGT 200  
CTGTCACGGGTACTCCAGTAGTGTCTGAAGAAAATGCCTT 240  
GTCTCCAAATTGCACTAGTACTACTGTTGAAGATCCTCCA 280  
GTTCAAGAAATACTGACTTCCTCAGAAAACAATGAATGTA 320  
TTCCTTCTACCAGTGCAGAATTGGAATCTGAAGCTAGAAG 360  
TATATTAGAGCCTGACACCTCTAATTCTAGAAGTAGTTCT 400  
GCTTTTGAAGCAGCCAAATCAAGACAGCCAGATGGGTGTA 440  
TGGATCCTGTACGGCAGCAGTCTGGGAATGCCAACACAGA 480  
AACCTTGCCATCAGGTTGGGAACAAAGAAAAGATCCTCAT 520  
GGTAGAACCTATTATGTGGATCATAATACTCGAACTACCA 560  
CATGGGAGAGACCACAACCTTTACCTCCAGGTTGGGAAAG 600  
AAGAGTTGATGATCGTAGAAGAGTTTATTATGTGGATCAT 640  
AACACCAGAACAACAACGTGGCAGCGGCTACCATGGAAT 680  
CTGTCCGAAATTTTGAACAGTGGCAATCTCAGCGGAACCA 720  
ATTGCAGGGAGCTATGCAACAGTTTAACCAACGATACCTC 760  
TATTTCGGCTTCAATGTTAGCTGCAGAAAATGACCCTTATG 800  
GACCTTTGCCACCAGGCTGGGAAAAAAGAGTGGATTCAAC 840  
AGACAGGGTTTACTTTGTGAATCATAACACAAAAACAACC 880  
CAGTGGGAAGATCCAAGAACTCAAGGCTTACAGAATGAAG 920  
AACCCCTGCCAGAAGGCTGGGAAATTAGATATACTCGTGA 960  
AGGTGTAAGGTACTTTGTTGATCATAACACAAGAACAACA 1000  
ACATTCAAAGATCCTCGCAATGGGAAGTCATCTGTAACCTA 1040  
AAGGTGGTCCACAAATTGCTTATGAACGCGGCTTTAGGTG 1080  
GAAGCTTGCTCACTTCCGTTATTTGTGCCAGTCTAATGCA 1120  
CTACCTAGTCATGTAAAGATCAATGTGTCCCGGCAGACAT 1160  
TGTTTGAAGATTCCCTTCCAACAGATTATGGCATTAAAACC 1200  
CTATGACTTGAGGAGGCGCTTATATGTAATATTTAGAGGA 1240  
GAAGAAGGACTTGATTATGGTGGCCTAGCGAGAGAATGGT 1280  
TTTTCTTGCTTTCACATGAAGTTTGAACCCAATGTATTG 1320  
CTTATTTGAGTATGCGGGCAAGAACAACCTATTGTCTGCAG 1360  
ATAAATCCAGCATCAACCATTAAATCCAGACCATCTTTTCAT 1400  
ACTTCTGTTTTCATTGGTCGTTTTATTGCCATGGCACTATT 1440  
TCATGGAAAGTTTATCGATACTGGTTTCTCTTTACCATTCT 1480  
TACAAGCGTATGTTAAGTAAAAAAGTACTATTAAGGATT 1520  
TGGAATCTATTGATACTGAATTTTATAACTCCCTTATCTG 1560  
GATAAGAGATAACAACATTGAAGAATGTGGCTTAGAAATG 1600  
TACTTTTCTGTTGACATGGAGATTTTGGGAAAAGTTACTT 1640  
CACATGACCTGAAGTTGGGAGGTTCCAATATTCTGGTGAC 1680  
TGAGGAGAACAAAGATGAATATATTGGTTTAAATGACAGAA 1720  
TGGCGTTTTTCTCGAGGAGTACAAGAACAGACCAAAGCTT 1760

FIG. 16A

SUBSTITUTE SHEET (RULE 26)

20/34

TCCTTGATGGTTTTAATGAAGTTGTTCCCTCTTCAGTGGCT 1800  
ACAGTACTTCGATGAAAAAGAATTAGAGGTTATGTTGTGT 1840  
GGCATGCAGGAGGTTGACTTGGCAGATTGGCAGAGAAATA 1880  
CTGTTTATCGACATTATACAAGAAACAGCAAGCAAATCAT 1920  
TTGGTTTTTGGCAGTTTGTGAAAGAGACAGACAATGAAGTA 1960  
AGAATGCGACTATTGCAGTTCGTCAGTGGAAACCTGCCGTT 2000  
TACCTCTAGGAGGATTTGCTGAGCTCATGGGAAGTAATGG 2040  
GCCCCGGAATTC 2052 (SEQ ID NO: 45)

FIG.16B

21/34

TNHVPTSTLVQNSCCSYVVNGDNTSPSSPSQVAARPKNTPA 40  
PKPLASEPADDTVNGESSFAPT DNASVTGTPVVSEENAL 80  
SPNCTSTTVEDPPVQEILTSSENNECIPSTSAELESEARS 120  
ILEPDTSNSRSSSAFEAAKSRQPDGCM DPVRQQSGNANTE 160  
TLPSGWEQRKDPHGRTYYVDHNTRTTTWERPQPLPPGWER 200  
RVDDRRRVYYVDHNTRTTTWQRPTMESVRNFEQWQSQRNQ 240  
LQGAMQQFNQRYLYSASMLAAENDPYG PLPPGWEKRVDST 280  
DRVYFVNHNTKTTQWEDPRTQGLQNEEPLPEGWEIRYTRE 320  
GVRYFVDHNTRTTTFKDPRNGKSSVTKGGPQIAYERGRW 360  
KLAHFRYLCQSNALPSHVKINVSRTLFEDSFQQIMALKP 400  
YDLRRRLYVIFRGEGLDYGGLAREWFFLLSHEVLNPMYC 440  
LFEYAGKNNYCLQINPASTINPDHLSYFCFIGRFIAMALF 480  
HGKFIDTGFSLPFYKRMLSKKLTIKDLESIDTEFYNSLIW 520  
IRDNNIEECGLEMYFSVDMEILGKVTSHDLKLGGSNILVT 560  
EENKDEYIGLMTWRF SRGVQEQT KAF LDGFNEVVPLQWL 600  
QYFDEKELEVMLCGMQEVDLADWQRNTVYRHYTRNSKQII 640  
WFWQFVKETDNEVRMRL LQFVTGTCRLPLGGFAELMGSNG 680  
PRN 683 (SEQ ID NO: 46)

FIG.17



22/34

GAATTCGCGGCCGCGTCCGACCGCTTCTGTGGCCACGGCAG 40  
ATGAAACAGAAAGGCTAAAGAGGGCTGGAGTCAGGGGACT 80  
TCTCTTCCACCAGCTTCACGGTGATGATATGGCATCTGCC 120  
AGCTCTAGCCGGGCAGGAGTGGCCCTGCCTTTTGAGAAGT 160  
CTCAGCTCACTTTGAAAGTGGTGTCCGCAAAGCCCAAGGT 200  
GCATAATCGTCAACCTCGAATTAACCTACGTGGAGGTG 240  
GCGGTGGATGGACTCCCCAGTGAGACCAAGAAGACTGGGA 280  
AGCGCATTGGGAGCTCTGAGCTTCTCTGGAATGAGATCAT 320  
CATTTTGAATGTCACGGCACAGAGTCATTTAGATTTAAAG 360  
GTCTGGAGCTGCCATACCTTGAGAAATGAACTGCTAGGCA 400  
CCGCATCTGTCAACCTCTCCAACGTCTTGAAGAACAATGG 440  
GGGCAAAATGGAGAACATGCAGCTGACCCTGAACCTGCAG 480  
ACGGAGAACAAAGGCAGCGTTGTCTCAGGCGGAAAACCTGA 520  
CAATTTTCCTGGACGGGCCAACTGTTGATCTGGGAAATGT 560  
GCCTAATGGCAGTGCCCTGACAGATGGATCACAGCTGCCT 600  
TCGAGAGACTCCAGTGGAACAGCAGTAGCTCCAGAGAACC 640  
GGCACCAGCCCCCAGCACAACTGCTTTGGTGGGAAGATC 680  
CCGGACGCACAGACATTCGGGTGCTTCAGCCAGAACAACC 720  
CCAGCAACCGGCGAGCAAAGCCCCGGTGCTCGGAGCCGGC 760  
ACCGCCAGCCCGTCAAGAACTCAGGCCACAGTGGCTTGGC 800  
CAATGGCACAGTGAATGATGAACCCACAACAGCCACTGAT 840  
CCCGAAGAACCCTTCGGTTGTTGGTGTGACGTCCCCACCTG 880  
CTGCACCCTTGAGTGTGACCCCGAATCCCAACACGACTTC 920  
TCTCCCTGCCCCAGCCACACCGGCTGAAGGAGAGGAACCC 960  
AGCACTTCGGGTACACAGCAGCTCCCAGCGGCTGCCCAGG 1000  
CCCCCGACGCTCTGCCTGCTGGATGGGAACAGCGAGAGCT 1040  
GCCCAACGGACGTGTCTATTATGTTGACCACAATACCAAG 1080  
ACCACCACCTGGGAGCGGCCCTTCCTCCAGGCTGGGAAA 1120  
AACGCACAGATCCCCGAGGCAGGTTTACTATGTGGATCA 1160  
CAATACTCGGACCACCACCTGGCAGCGTCCGACCGCGGAG 1200  
TACGTGCGCAACTATGAGCAGTGGCAGTCGCAGCGGAATC 1240  
AGCTCCAGGGGGCCATGCAGCACTTCAGCCAAAGATTCTT 1280  
ATACCAGTTTTGGAGTGCTTCGACTGACCATGATCCCCTG 1320  
GGCCCCCTCCCTCCTGGTTGGGAGAAAAGACAGGACAATG 1360  
GACGGGTGTATTACGTGAACCATAAACAACCTCGCACGACCCA 1400  
GTGGGAGGATCCCCGGACCCAGGGGATGATCCAGGAACCA 1440  
GCTTTGCCCCCAGGATGGGAGATGAAATACACCAGCGAGG 1480  
GGGTGCGATACTTTGTGGACCACAATACCCGCACCACCAC 1520  
CTTTAAGGATCCTCGCCCGGGGTTTGAGTCGGGGACGAAG 1560  
CAAGGTTCCCCTGGTGCTTATGACCGCAGTTTTCGGTGGA 1600  
AGTATCACCAGTTCCGTTTTCCTCTGCCATTCAAATGCCCT 1640  
ACCTAGCCACGTGAAGATCAGCGTTTCCAGGCAGACGCTT 1680  
TTCGAAGATTCCCTTCCAACAGATCATGAACATGAAACCCT 1720  
ATGACCTGCGCCGCCGGCTTTACATCATCATGCGTGGCGA 1760  
GGAGGGCCTGGACTATGGGGGCATCGCCAGAGAGTGGTTT 1800

FIG. 18A

SUBSTITUTE SHEET (RULE 26)

23/34

TTCTCCTGTCTCACGAGGTGCTCAACCCTATGTATTGTT 1840  
TATTTGAATATGCCGGAAGAACAATTACTGCCTGCAGAT 1880  
CAACCCCGCCTCCTCCATCAACCCGGACCACCTCACCTAC 1920  
TTTCGCTTTATAGGCAGATTTCATCGCCATGGCGCTGTACC 1960  
ATGGAAAGTTCATCGACACGGGCTTCACCCTCCCTTTCTA 2000  
CAAGCGGATGCTCAATAAGAGACCAACCCTGAAAGACCTG 2040  
GAGTCCATTGACCCTGAGTTCTACAACCTCCATTGTCTGGA 2080  
TCAAAGAGAACAACCTGGAAGAATGTGGCCTGGAGCTGTA 2120  
CTTCATCCAGGACATGGAGATACTGGGCAAGGTGACGACC 2160  
CACGAGCTGAAGGAGGGCGGCGAGAGCATCCGGGTCACGG 2200  
AGGAGAACAAGGAAGAGTACATCATGCTGCTGACTGACTG 2240  
GCGTTTCACCCGAGGCGTGGAAGAGCAGACCAAAGCCTTC 2280  
CTGGATGGCTTCAACGAGGTGGCCCCGCTGGAGTGGCTGC 2320  
GCTACTTTGACGAGAAAGAGCTGGAGCTGATGCTGTGCGG 2360  
CATGCAGGAGATAGACATGAGCGACTGGCAGAAGAGCACC 2400  
ATCTACCGGCACTACACCAAGAAGCAAGCAGATCCAGT 2440  
GGTTCTGGCAGGTGGTGAAGGAGATGGACAACGAGAAGAG 2480  
GATCCGGCTGCTGCAGTTTGTACCGGTACCTGCCGCCTG 2520  
CCCGTCGGGGGATTTGCCGAACCTCATCGGTAGCAACGGAC 2560  
CACAGAAGTTTTCATTGACAAAGTTGGCAAGGAAACCTG 2600  
GCTGCCCAGAAGCCACACCTGCTTCAACCGTCTGGATCTT 2640  
CCACCCTACAAGAGCTACGAACAGCTGAGAGAGAAGCTGC 2680  
TGATGCCATTGAGGAGACCGAGGGCTTTGGACAGGAGTA 2720  
ACCGAGGCCGCCCCCTCCCACGCCCCCAGCGCACATGTAG 2760  
TCCTGAGTCCTCCCTGCCTGAGAGGCCACTGGCCCCGCAG 2800  
CCCTTGGGAGGCCCCCGTGATGTGGCCCTGTGTGGGACC 2840  
ACACTGTCATCTCGCTGCTGGCAGAAAAGCCTGATCCCAG 2880  
GAGGCCCTGCAGTTCCCCCGACCCGCGGATGGCAGTCTGG 2920  
AATAAAGCCCCCTAGTTGCCTTTGGCCCCACCTTTGCAAA 2960  
GTTCCAGAGGGCTGACCCTCTCTGCAAACTCTCCCCTGT 3000  
CCTCTAGACCCACCCCTGGGTGTATGTGAGTGTGCAAGGG 3040  
AAGGTGTTGCATCCCCAGGGGCTGCCGCAGAGGCCGGAGA 3080  
CCTCCTGGACTAGTTCCGCGAGGAGACTGGCCACTGGGGG 3120  
TGGCTGTTCCGGACTGAGAGCGCCAAGGGTCTTTGCCAGC 3160  
AAAGGAGGTTCTGCCTGTAATTGAGCCTCTCTGATGATGG 3200  
AGATGAAGTGAAGGTCTGAGGGACGGGCCCTGGGGCTAGG 3240  
CCATCTCTGCCTGCCTCCCTAGCAGGCCCGAGCGGTGGAG 3280  
GCTGAGTCGCAGGACACATGCCGGCCAGTTAATTCATTCT 3320  
CAGCAAATGAAGGTTTGTCTAAGCTGCCTGGGTATCCACG 3360  
GGACAAAAACAGCAAACTCCCTCCAGACTTTGTCCATGTT 3400  
ATAAACTTGAAAGTTGGTTGTTGTTTGTAXGGTTTGCCA 3440  
GGTTTTTTTGTTTACGCCTGCTGTCACTTTCCCTGTC 3476 (SEQ ID NO:47)

FIG.18B

SUBSTITUTE SHEET (RULE 26)

24/34

EF AASTASVATADETERLKRAGVRGLLFHQLHGDDMASA 40  
SSSRAGVALPFEKSQLTLKVVSAPKPVHNROPRINSYVEV 80  
AVDGLPSETKKTGKRIGSSELLWNEIIILNVTAQSHLDLK 120  
VWSCHTLRNE LLGTASVNL SNVLKNNGGKMENMQLTLNLQ 160  
TENKGSVVSGGKLTIFLDGPTVDLGNVPNGSALTDGSQLP 200  
SRDSSGTAVAPENRHQPPSTNCFGGRSRTHRHSGASARTT 240  
PATGEQSPGARSRRHQPVKNSGHSGLANGTVNDEPTTATD 280  
PEEPSVVGVTSPPAAPLSVTPNPNTTSLPAPATPAEGEEP 320  
STSGTQQLPAAAQAPDALPAGWEQRELPNGRVYYVDHNTK 360  
TTTWERPLPPGWEKRTDPRGRFYVDHNTRTTTWQRPTAE 400  
YVRNYEQWQSQRNQLQGAMQHF SQRFLYQFWSASTDHDPL 440  
GPLPPGWEKRDNGRVYYVNHNTTRTTQWEDPRTQGM IQEP 480  
ALPPGWEMKYTSEGVRYFVDHNTRTTTFKDPRPGFESGTK 520  
QGSPGAYDRSFRWKYHQFRFLCHSNALPSHVKISVSRQTL 560  
FEDSFQQIMNMKPYDLRRRLYIIMRGEGLDYGGIAREWF 600  
FLLSHEVLNPMYCLFEYAGKNNYCLQINPASSINPDHLTY 640  
FRF IGRFIAMALYHGKFIDTGF TLPFYKRMLNKRPTLKDL 680  
ESIDPEFYNSIWWIKENNLEECGLELYFIQDMEILGKVTT 720  
HELKEGGESIRVTEENKEEYIMLLTDWRFTRGVEEQTKAF 760  
LDGFNEVAPLEWLRYFDEKELELMLCGMQEIDMSDWQKST 800  
IYRHYTKNSKQIQVVFQWKEMDNEKRIRLLQFVTGTCRL 840  
PVGGFAELIGSNGPQKFCIDKVGKETWLPRSHTCFNRDL 880  
PPYKSYEQLREKLLYAIEETEGFGQE 906 (SEQ ID NO:48)

FIG.19

25/34

GGAGAAGTGCCTGGCGTGGACTATAACTTTCTGACTGTGA 40  
AGGAGTTCTTGGACCTCGAGCAGAGTGGGACTCTTCTGGA 80  
AGTCGGCACCTATGAAGGAACTATTATGGGACACCCAAG 120  
CCTCCTAGCCAGCCAGTCAGTGGGAAAGTGATCACCACGG 160  
ATGCCTTGCACAGCCTTCAGTCTGGCTCTAAGCAGTCGAC 200  
CCCGAAGCGAACCAAGTCCTACAATGATATGCAAATGCT 240  
GGCATAGTCCACGCGGAGAATGAGGAGGAGGATGACGTT 280  
CTGAAATGAACAGCAGCTTTACAGCCGATTCTGGTGAACA 320  
AGAGGAGCACACTCTCCAAGAAACAGCATTACCACCTGTG 360  
AATAGTAGCATCATCGCTGCTCCCATCACGGACCCTTCTC 400  
AGAAGTTCCCTCAATACCTACCTCTTTCTGCAGAGGATAA 440  
TTTAGGTCCTCTACCTGAAAACCTGGGAGATGGCCTATACT 480  
GAAAATGGAGAAGTCTATTTTATAGACCATAACACGAAAA 520  
CAACATCTTGGTTAGACCCTCGGTGCCTAAACAAGCAGCA 560  
GAAGCCACTGGAAGAGTGTGAAGATGATGAAGGGGTACAC 600  
ACCGAGGAGCTGGACAGTGAAGTAGAACTGCCTGCTGGTT 640  
GGGAAAAGATTGAAGACCCATCCCCCGGAATTC 673 (SEQ ID NO:49)

FIG.20

26/34

GEVPGVDYNFLTVKEFLDLEQSGTLLEVGTYESGNYGTPK 40  
PPSQPVSGKVIITDALHSLQSGSKQSTPKRTKSYNDMUNA 80  
GIVHAENEEEDDVPENSSFTADSGEQEEHTLQETALPPV 120  
NSSIIAAPITDPSQKFPQYLPLSAEDNLGPLPENWEMAYT 160  
ENGEVYFIDHNTKTTSWLDPRCLNKQKPLEECEDDEGVH 200  
TEELDSELELPAGWEKIEDPSPGI 224 (SEQ ID NO:50)

FIG.21

27/34

TCGGCGGATTGCTCGACCCACGGCTCCGGCCCCAGCCCTCGGAGGGCGGGGATGTCCCGAGCCTTGGGAGA  
CCATTTTCAGAGGAAGTGAATATCGCTGGAGACTCTCTCGGTCTGGCTCTGCCCCACCACCGCCCTCCCCAG  
GATCTCGGACCAGCCCTCAGGAGCTGTAGAGGAAGTAAAGCAGAAGGCTTCAGATCACTCCAGACTCCAATG  
GGGAACAGTTAGCTCTTTGATTCAAAGAGAACCCTCCTCAAGTTGAGGTCATGCAGTGTACCGACGCAG  
TTGCAGAACAGGGCCATCTACCACCGCCAGTGCCCCAGCTGGGAGAGCGGTTTCATCAACTGTACGGGTG  
GTGAGGAACCAACGCCATCAGTGGCCTATGTACATACCACGCGGGTCTGCCTTCAGGCTGGGAAGAAAGAA  
AAGATGCTAAGGGGGCCACATACTATGTCAATCATAACAATCGAACCACAACTTGGACTCGACCTATCATGC  
AGCTTGCAGAAGATGGTGGTCCGGATCAGCCACAAACAGTAACAACCATCTAATCGAGCCTCAGATCCGCC  
GGCCTCGTAGCCTCAGCTCGCCAACAGTAACCTTATCTGCCCCGCTGGAGGGTGCCAAGGACTCACCCGTAC  
GTCCGGCTGTGAAAGACACCTTTCCAACCCACAGTCCCCACAGCCATCACCTTACAACCCCCAAACCAC  
AACACAAAGTCACACAGAGCTTCTGCCACCCGGCTGGGAAATGAGGATAGCGCCAAACGGCCGGCCCTTCT  
TCATTGATCATAACACAAAGACTACAACCTGGGAAGATCCACGTTTGAATTTCCAGTACATATGCGGTCAA  
AGACATCTTTAAACCCCAATGACCTTGGCCCCCTTCCTCCTGGCTGGGAAGAAAGAATTCAGTTGGATGGCC  
GAACGTTTTATATTGATCATAATAGCAAAATTACTCAGTGGGAAGACCCAAGACTGCAGAACCACGCTATTA  
CTGGTCCGGCTGTCCCTTACTCCAGAGAATTTAAGCAGAAATATGACTACTTCAGGAAGAAATTAAGAAAC  
CTGCTGATATCCCAATAGGTTTGAATGAAACTTCACAGPAATAACATATTTGAAGAGTCTATCGGAGAA  
TTATGTCCGTGAAAAGACCAGATGTCTAAAAGCTAGACTGTGGATTGAGTTTGAATCAGAGAAAGGCTTG  
ACTATGGGGGTGTGGCCAGAGAATGGTTCTTCTTACTGTCCAAGAGATGTTCAACCCCTACTACGGCCTCT  
TTGAGTACTCTGCCACGGACAACCTACACCTTCAGATCAACCCTAATTCAGGCCTCTGTAATGAGGATCATT  
TGTCTTACTTCACTTTTATTGGAAAAGTTGCTGGTCTGGCCGTATTTTCATGGGAAGCTCTTAGATGGTTTCT  
TCATTAGACCATTTTACAAGATGATGTGGGPAAGCAGATAACCCTGAATGACATGGAATCTGTGGATAGTG  
AATATTACAACCTTTTGAATGGATCCTGGAGAATGACCCTACTGAGCTGGACCTCATGTTCTGCATAGACG  
AAGAAAACCTTTGGACAGACATATCAAGTGGATTGGAAGCCCAATGGGTGAGAAATATGGTCACAAATGAAA  
ACAAAAGGGAATATATCGACTTAGTCATCCAGTGGAGATTTGTGAACAGGTCAGAGAGCAGATGAACGCT  
TCTTGGAGGATTCACAGAACTACTTCTTATTGATTTGATTAATTTTGTATGAAAATGAGCTGGAGTTGC  
TCATGTGGCCCTCGGTGATGTGGATGTGAATGACTGGAGACAGCATTCTATTTACAAGAACGGCTACTGCC  
CAAACCAACCCGTCATTGAGTGTCTGGAAGGCTGTGCTACTCATGGACGCCGAAAAGCGTATCCGGTTAC  
TGCAGTTTGTACAGGGACATCCGAGTACCTATGAATGGATTTGCCGAACCTTATGTTCCAATGGTCCCTC  
AGCTGTTTACAATAGAGCAATGGGCAGTCTGAGAACTGCCCAAAGCTCACACATGCTTTAATCCGCTTG  
ACTTACCTCATATGAAACCTTTGAAGATTTACAAGAGAACTTCTCATGGCCGTGGAATGCTCAAGGAT  
TTGAAGGGGTGGATTAAGCACCTGTGCCTCGGGGTGGTTGTTCTTCAAGCAATTTCTGCTTGCATTTTG  
(SEQ ID NO: 125)

FIG.22

28/34

SAEFVDPVRPEpSEGGOVPEPWETISEEVNIAGDSLGLALPPPPASPGSRTSPQELSEELSRRLQITPDSN  
 GEQFSSLIQREPSSRLRSCSVTDAVAEQGHLPPPSAPAGRARSSTVTGCEPTPSVAYVHTTPGLPSGWEER  
 KDAKGRTYVNHNNRTTWTTRPIMQLAEDGASGSA TSNNNHLIEPQIRRPRLSSPTVTLSAPLEGAKDSPV  
 RR~~AVKDTLSNPQSPQSPYN~~SPK~~PQHKTQSF~~LPPGWE~~MRIAPNGRPFF~~IDHNTKTTITWEDPRLKFPVHMRS  
 KTS~~LNPN~~DLG~~PLPPGWEER~~IHL~~DGR~~TFYIDHNSKI~~TQWEDPRLQNP~~AITGPAVPYSREFKQKYDYFRKKLKK  
 PADIPNRFEMKLHRNNIFEESYRRIMSVKRPDVLKARLWIEFESEKGLDYCGVAREWFFLLSKEMFNYYGL  
 FEYSATDNYTLQINPNSGLCNEDHLSYFTFICKVAGLAVFHGKLLDGFFIRPFYK~~ML~~GKQITLNDMESVDS  
 EYNSL~~Kw~~I~~LENDp~~TELDLMFCIDEENFGQTYQVDLKPNGSEIMVTNENKREYIDLVIQWRFVNRVQKQMNNA  
 FLEGFT~~ELL~~PKIFDENELELLMCGLGDDVDVNDWRQHSIYKNGYCPNHPVIQWFWKAVLLMDAEKRIRL  
 LQFVTGTSRVP~~MNGF~~AELYGSNGPQLFTIEQWGSPEKLPKAHTCFNRDLPPYE~~TFEDLQEKLL~~MAVENAQG  
 FEGVD

(SEQ ID NO: 126)

FIG.23

29/34

		SEQ. ID NO.	WW DOMAIN/GST FUSION PROTEINS										SH3 DOMAINS	
PEPTIDE	SEQUENCE		WWP1.1	WWP1.2	WWP1.3	WWP1.4	WWP2.1	WWP2.2	WWP2.3	WWP2.4	WWP3	F <sub>yn</sub>	L <sub>yn</sub>	
ENaC $\alpha$ -WT	LTAPPAYATLGP	168	+++	-	++	-	+++	-	+++	-	-	-	-	
ENaC $\alpha$	LTAPPPAAATLGP	169	-	-	-	-	-	-	-	-	-	-	-	
ENaC $\beta$ -WT	PGTPPPNYDSLRL	59	++	-	-	-	-	-	++	-	-	-	-	
ENaC $\beta$ -P616L	PGTPPLNYDSLRL	1	-	-	-	-	-	-	-	-	-	-	-	
ENaC $\beta$ -Y618H	PGTPPPNHDSLRL	160	-	-	-	-	-	-	-	-	-	-	-	
ENaC $\beta$	PGTAPPNYDSLRL	161	++	-	-	-	-	-	+	-	-	-	-	
ENaC $\beta$	PGTPAPNYDSLRL	162	-	-	-	-	-	-	-	-	-	-	-	
ENaC $\beta$	PGTPPPNADSLRL	163	-	-	-	-	-	-	-	-	-	-	-	
ENaC $\beta$	PGTPPPNYDALRL	164	+	-	-	-	-	-	+	-	-	-	-	
ENaC $\beta$	PGTPPPNYDSARL	165	+	-	-	-	-	-	-	-	-	-	-	
ENaC $\beta$	PGTPPPNYDSERL	166	-	-	-	-	-	-	-	-	-	-	-	
ENaC $\gamma$ -WT	PGTPPPKYNTLRL	60	++	-	+	-	-	++	-	+	-	+++	-	
ENaC $\gamma$	PGTPPPKANTLRL	167	-	-	-	-	-	-	-	-	-	-	-	

FIG.24A



30/34

PEPTIDE		SEQUENCE	SEQ. ID NO.	GST FUSION PROTEINS					
				WMP4.1	WMP4.2	WMP4.3	YAP-1	YAP-2	FE65
ENaC $\alpha$ -WT		LTAPPPAYATLGP	168	+	++++	++++	-	-	-
ENaC $\alpha$		LTAPPPAAATLGP	169	-	-	-	-	-	-
ENaC $\alpha$		PPLALTAPPPAYATLGP	170	+	++++	++++	-	-	-
ENaC $\alpha$		PSPALTAPPPAYATLGP	171	+	++++	++++	-	-	-
ENaC $\alpha$		PSPALTAPPPAAATLGP	172	-	-	-	-	-	-
ENaC $\alpha$		PSPALTAPPAY	173	-	-	-	-	-	-
ENaC $\beta$ -WT		PGTTPPNYDSLRL	59	-	++++	++++	-	-	-
ENaC $\beta$ -P616L		PGTTPPLNYDSLRL	1	-	-	-	-	-	-
ENaC $\beta$ -Y618H		PGTTPPNHDSLRL	160	-	-	-	-	-	-
ENaC $\beta$		PGTAPPNYDSLRL	161	-	++++	+++	-	-	-
ENaC $\beta$		PGTPAPNYDSLRL	162	-	-	-	-	-	-
ENaC $\beta$		PGTTPPNADSLRL	163	-	-	-	-	-	-
ENaC $\beta$		PGTTPPNYDALRL	164	-	+++	+	-	-	-
ENaC $\beta$		PGTTPPNYDSARL	165	++	+++	++	++	++	+
ENaC $\beta$		PGTTPPNYDSERL	166	-	-	-	-	-	-
ENaC $\gamma$ -WT		PGTTPPKYNTLRL	60	-	++++	+++	-	-	-
ENaC $\gamma$		PGTTPPKANTLRL	167	-	-	-	-	-	-
Src		GILAPPVPPNTR	62	-	-	-	-	-	-
Crk		SVPAPPPLPPKSGG	63	-	-	-	-	-	-

FIG.24B

31/34

PEPTIDE	SEQUENCE	SEQ. ID NO.	WMP1.1	WMP1.2	WMP1.3	WMP1.4	WMP2.1	WMP2.2	WMP2.3	WMP2.4	WMP3	WMP4.1	WMP4.2	WMP4.3	YAP1	YAP2
bWW061	NRLDLPPYKSYEQ	179	-	-	-	+	++	-	-	+	-	-	+	-	-	-
bWW062	NRLDLPPAKSYEQ	180	-	-	-	-	-	-	-	-	-	-	-	-	-	-
bWW059	NRLDLPPYETTFED	181	+	-	-	++	+++	+	-	++	-	+	++	+	-	-
bWW060	NRLDLPPAETTFED	182	-	-	-	-	-	-	-	-	-	-	-	-	-	-
WBP-2A	YVQPPPPPPYCPGM	8	++++	++++	++++	++++	++++	++++	++++	++++	++++	++++	++++	++++	++++	++++

FIG.25




FIG.26A

33/34




FIG. 26B

WWP1 AND WWP2  
Nedd4-LIKE PROTEIN  
INTERACTIONS

DOMAIN	WWP1.1	RELATIVE BINDING AFFINITY	WWP1.4	RELATIVE BINDING AFFINITY	WWP3	RELATIVE BINDING AFFINITY
CW			CW		CW	
1	GLPPPYDLTWVN	**** 183	1	MLPEYTEYGF <sup>SM</sup>	4	GMLPSYEEAVMA 213
1	GQVRFWGAPPY(SRPSR)	**** 124	1	TLLPGYLSDEYW	5	PIAPPTYWE <sup>WAL</sup> 214
4	LKLPDYMESSAS	*	1	LKLPDYMESSAS	1	RLPAYKEPAATF 215
1	LKLPDYMESSAS	186	3	LLPNYGEWWRGG	1	LPSYSEWVAETR 216
			2	SLLPTYGHELFW	2	LPTYNEYLIRAA 217
			1	SLLPEYNMPLYH		
			1	LMLPAYNEAVTW		
			1	LMLPHYGDWQFA		
			1	LLPNYGEAEAWF		
pp	LIBRARY		pp	LIBRARY	pp	LIBRARY
RSERGVPPITYAEFFPM	187		QLPISPPPYSEMGL	*** 203	RVYRDLPPPYPQGT	** 218
NWPHVMPPPYAQYR	*** 188		GWTLGDPPPYHIAG	**** 204	HRSELPPPYSEAVK	*** 219
GAHDSPPPYSRYP	**** 189		RCGVMLPPYSSIDN	** 205	GGWRAVPPPYPGSP	* 220
GPSEQPPPYETVK	**** 190		HKPLTPPPYDAHDF	* 206	LMRRAPPPYPQVA	* 221
			LFWQVGPSPSYEEAI	** 207	RLYTTPPPYASLHK	* 222
					PMHRVGPPPPYPGCL	*** 223
xy	LIBRARY		xy	LIBRARY	xy	LIBRARY
SR1KGDPPGYEEVWGL	*** 191		PSMLTLPYFEHKQDE	**** 208	PWLRGDPPPYMELVSE	224
QTDYPPPPGYPWESR	**** 192		WSMKTSPPSYESIFGL	**** 209	GSWETPPPSYEEWLRK	225
GVEFGPPPDYEALFKP	** 193		AVHSLTLPAYEATEYM	**** 210	AHMYRPPPPYRGSSDG	**** 226
			GRVSHPPPAYCELFKC	**** 211	GRFLREPPYPNRDVA	** 227
			SGRMQGPPEYGDMEYV	* 212	VAMRDPPPPYNYVDAP	** 228
					VATLRPPPAYGVEYSR	** 229
					MLKDVAPPAYEEAVRR	*** 230

34/34

FIG.27

34/34

FIG. 27

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/05547

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : 435/7.21, 7.23; 436/63, 64; 530/328, 352

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.21, 7.23; 436/63, 64; 530/328, 352

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEN. H. I. The WW Domain of Yes-associated Protein Binds a Proline-rich Ligand that Differs from the Consensus Established for Src Homology 3-binding Modules. Proceedings of the National Academy of Science, USA. August 1995, Vol. 92, pages 7819-7823, especially page 7819.	1-60, 66-80, 85, 86, 101-107, 109, 110
X	SUDOL. M. et al Characterization of a Novel Protein-binding Module-the WW Domain. FEBS Letters. August 1995, Vol. 369, No. 1, pages 67-71, especially page 67.	1-60, 66-80, 85, 86, 101-107, 109, 110

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents; such combination being obvious to a person skilled in the art
*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 19 JUNE 1997	Date of mailing of the international search report 14 AUG 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer YVONNE EYLER Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US97/05547

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	SUDOL. M. et al. Characterization of the Mammalian YAP (Yes-associated Protein) Gene and its Role in Defining a Novel Protein Module, the WW Domain. The Journal of Biological Chemistry. 16 June 1995, Vol. 270, No. 24, pages 14733-14741, especially page 14733.	1-90, 107, 109, 110
Y	NUBER. U. et al. Cloning of Human Ubiquitin-Conjugating Enzymes UbcH6 and UbcH7 (E2-F1) and Characterization of their Interaction with E6-AP and RSP5. The Journal of Biological Chemistry. 02 February 1996, Vol. 271, No. 5, pages 2795-2800, especially page 2795.	90-100, 108, 111
Y	HUIBREGTSE. J. M. et al. A Family of Proteins Structurally and Functionally Related to the E6-AP Ubiquitin-Protein Ligase. Proceedings of the National Academy of Science, USA. March 1995, Vol. 92, pages 2563-2567, especially page 2563.	90-100, 108, 111

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US97/05547

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☒ No protest accompanied the payment of additional search fees.



# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US97/05547

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

G01N 33/567, 33/574, 33/48; A61K 38/06, 38/16; C07K 1/00, 5/00, 7/00, 14/00, 16/00, 17/00

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-46, 85 and 86, drawn to a method of identifying peptides with WW domains.

Group II, claim(s) 47-60, 66, 67, 71, 101, 102, 104, and 105, drawn to purified polypeptides containing WW domains and a recognition unit.

Group III, claim(s) 61-65, 81-84 and 89, drawn to a method of determining compounds which interfere with WW domain and recognition unit binding.

Group IV, claim(s) 68-70, 72-80, 103, 106, 107, 109, 110, drawn to DNA, vectors, and host cells encoding WW domains.

Group V, claim(s) 87 and 88, drawn to antibodies which bind WW domains.

Group VI, claim(s) 90-100, 108 and 111, drawn to DNA and polypeptides with HECT domains.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The polypeptides and recognition units of Group II may be used in materially distinct methods from that of Group I, for example to raise antibodies. Likewise, the DNA of Group IV may be used in materially distinct ways, such as hybridization methods. The methods of Groups I and III use completely different method steps and have completely different outcomes. The compounds of Groups II and IV are completely different biochemically with different biological functions. Note that the WW domain of Group II is known in the art (Chen et al., Proceedings of the National Academy of Science, USA, August 1995, Vol. 92, pages 7819-7823) and therefore does not provide a contribution to the art and cannot be considered a special technical feature. Likewise the antibodies of Group V are completely different chemically and functionally from the proteins of Group II and the DNA of Group IV. Finally, the HECT domain proteins are completely different with different motifs from the WW domains of Groups I-V.

